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Abstract 
The overall objective of this body of work is to examine methods of quantifying prescription 
drug misuse in pharmaceutical claims. We approach this by first undertaking a systematic 
review of the global literature measuring the extent of prescription drug misuse in 
pharmaceutical claims. Our review highlights four measures, based on number of 
prescribers, number of dispensing pharmacies, volume of drug dispensed and number of 
early refills, are used frequently to define prescription drug misuse. Despite this 
homogeneity, we found heterogeneity in the thresholds delineating use from misuse and a 
lack of established or validated benchmarks to accurately measure misuse in pharmaceutical 
claims. In our empirical work, we focus on prescription opioid analgesics due to the recent 
and considerable global increase in use and opioid-related harms. We use publically 
available, routinely collected data to document increases in prescription opioid use and 
related harms in Australia over 20-years. Over three chapters we then explore population 
norms of prescription drug access in national dispensing claims and examine how these 
access patterns relate to the metrics defining ‘misuse’ identified in our systematic review. 
We compare prescription drug access in Australia and British Columbia, Canada, for 
prescription opioids and statins, drug classes with high or no known abuse potential, 
respectively. We found access norms are remarkably similar across drug classes and 
healthcare settings. However, extreme access patterns are more common in people 
dispensed opioids, younger age groups or those receiving income assistance. We then 
examine opioid access in Australian adults initiating or reinitiating strong opioid treatment. 
We found the standard metrics defining ‘misuse’, including doctor and pharmacy shopping, 
are non-specific in that they identify misuse, but are also likely to capture high-need patient 
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groups including individuals with a history of cancer treatment. From a translational 
perspective, our findings are particularly important as the US Food and Drug Administration 
recently endorsed using routinely collected data, including pharmaceutical claims, to 
quantify prescription opioid misuse and measure the effectiveness of interventions aimed to 
curb the ‘opioid epidemic’. We recommend using these commonly established metrics with 
caution due to their inability to isolate a population of people misusing opioids. 
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Chapter One: Introduction 
This thesis examines methods of quantifying population prescription drug use and potential 
misuse in pharmaceutical claims, with a specific interest in prescription opioid analgesics. In 
this chapter we provide background information for each research component related to 
our objective. Specifically, we outline the following issues in relation to prescription opioids: 
global rates of use; benefits, risks and harms associated with opioid use; and, real world 
methods of quantifying prescription opioid use in routine clinical care. As the vast majority 
of research in this field to date is set in North America, this aspect of the chapter is largely 
US-centric. However, the latter part of the chapter focuses on prescription opioid use and 
potential misuse in the Australian context and details aspects of the Australian healthcare 
system to provide the context for our research.  
 
In this thesis we use the term prescription drug(s) to refer to substances prescribed by a 
doctor to treat a medical condition. The Australian National Medicines Policy uses the term 
‘prescribed medicines’ to refer to these substances.1 Throughout the thesis chapters we use 
the term ‘prescription drug’ as the majority of our research is published in international 
journals and this term is frequently used. We use the terms ‘extramedical use’ and ‘misuse’ 
interchangeably to refer to ‘any use of a prescription opioid or drug outside a doctor’s 
prescription, not excluding the possibility that the user may have a medically driven reason 
for using the drug’.2,3 We also use the term diversion to refer to ‘the unsanctioned supply of 
                                                     
 The work contained in this thesis was conducted by the PhD candidate in collaboration with PhD supervisors 
and co-authors listed on the papers arising from each empirical chapter in this thesis. 
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regulated pharmaceuticals from legal sources to the illicit drug market, or to persons for 
whom the drug was not intended’.2,4 
 
Formatting note: To increase the readability of viewing this thesis electronically, we provide 
all figures or tables on the page following its first citation in the text. We provide the 
reference list at the end of this chapter. 
 
  
3 
 
1.1 Prescription drug use  
Prescription drugs are used to treat, maintain or prevent a medical disease or condition. 
There are benefits and risks associated with any treatment involving prescription drugs, 
including side effects and adverse events; doctors must assess this risk-benefit profile at the 
time of prescribing. The likelihood of adverse outcomes occurring may increase if 
prescription drugs are taken in larger quantities or a longer time period than medically 
recommended; or when combined with other prescription or illicit drugs, or alcohol. 
Although all prescription drugs have side effects, prescription opioids are the most 
commonly misused drug class.5 The risks associated with these drugs include overdose, 
hospitalisation and/or death. Due to the considerable increase in opioid-related harms, 
prescription opioid misuse is now considered an epidemic in the US.6 Of concern, there is 
emerging Australian evidence documenting increases in opioid use and related harms.7-10 
Due to the increasing prominence of opioid risk and harms, coupled with the emerging 
evidence of increasing opioid use locally, we have chosen to focus on prescription opioids 
for the majority of our research. 
 
1.2 Prescription opioid analgesics 
1.2.1 What is an opioid? 
‘Opioid’ is an umbrella term for natural and synthetic drugs derived from or based on 
opium, which is extracted from the poppy plant Papaver somniferum.11 Prescription opioid 
analgesics are prescribed most commonly to relieve pain. In this thesis, we refer to these 
opioids, as prescription opioid analgesic(s), opioid(s), opioid analgesic(s) and prescription 
opioid(s).  
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Opioid analgesics are a complex drug class to study. They are the most effective 
pharmacological pain relievers,12 but they are also highly addictive and sought for 
recreational purposes. If a person becomes dependent on opioids, they will require 
escalating opioid dosages to function and prevent withdrawal symptoms. Over the past two 
decades, opioid use and related harms have escalated to alarming levels. It has been argued 
that policymakers, legislators, the medical community and patients should unite to reduce 
opioid misuse without restricting opioid access or jeopardising pain treatment.13 
 
1.2.2 Brief history of opium to opioid use 
Opium has been used for millennia. Since 4000 Before Common Era (BCE), people have used 
opium to provide pain relief and induce euphoria.11 From 2000 BCE the Egyptians recorded 
the healing properties of opium in their medical text, Ebers papyrus,5,11,12 and used opium-
soaked sponges to facilitate surgery.14  
 
Morphine, codeine and diamorphine were the first prescription opioids synthesised for 
medical purposes in approximately 1804, 1832 and 1874 respectively.11,14 Opioids were 
prescribed to treat pain, alcohol dependence, menstrual cramps, menopausal disorders, 
opium dependence, and cough (suppression).11,14 However, opioid dependence became a 
major public health concern at this time. Due to various US legislative decisions, doctors 
were legally prosecuted if they prescribed opioids for any substance dependence.11,14 
Consequently, doctors largely stopped prescribing opioids for any medical condition for fear 
of legal ramifications. 
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In the second half of the 20th century clinicians fought to destigmatise opioid treatment. In 
the 1960s, the Hospice Movement in Western countries fought and won the right to 
prescribe opioids for symptom management of cancer pain.15 The medical indication for 
opioids was extended to include palliative care and symptom management for other 
illnesses including human immunodeficiency virus.15 In the 1990s, the indication was again 
expanded to include management of all noncancer pain including chronic pain.15,16 Today, in 
many jurisdictions including US, Canada and Australia, the medical indications for opioid 
treatment include: episodic, chronic, cancer and noncancer pain, including palliative care 
and opiate maintenance therapy. Across these jurisdictions, as the medical indications for 
prescribed opioid widened, opioid use and related harms increased. 
 
Although the medical indications for opioids include both pain and opioid dependence, in 
this thesis we focus exclusively on opioids prescribed for pain. Our overarching aim is to 
quantify population prescription drug and opioid use in national pharmaceutical claims. Our 
Australian pharmaceutical claims data do not record the details of opioids dispensed for the 
indication of opiate maintenance therapy.  
 
1.2.4 Pain 
Pain is “an unpleasant physical sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage”17 and “pain is always 
subjective”.17 These definitions highlight the primary challenges of treating pain, it is 
subjective and intangible; there is a lack of any objective medical tests to quantify pain 
intensity or even its existence. Consequently, every prescription for opioids to provide pain 
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relief involves uncertainty on the behalf of prescribers, as they will never know whether 
their patients actually experience pain. 
 
Opioids are used to treat both acute and chronic pain. Acute pain is defined as ‘the normal, 
predicted physiological response to an adverse chemical, thermal or mechanical stimulus’18 
and generally resolves when the injury heals. The definition of chronic pain varies in the 
literature; however, a common definition is pain persisting for ≥3 consecutive months.19  
 
1.2.5 Prevalence and burden of pain 
Pain is a common medical complaint and contributes to a significant societal economic 
burden. Globally, approximately 1 in 5 adults suffer from pain and another 1 in 10 adults are 
diagnosed with chronic pain annually.20 According to the US Medical Expenditure Panel 
Survey, in 2008 approximately 100 million persons (33% of the US population) experienced 
chronic pain.21 In 2010 in the US, the total cost of pain was US$635 billion.21 The annual cost 
of pain is considerably higher than other common chronic illnesses such as heart disease 
(US$309 billion), cancer (US$243 billion), and diabetes (US$188 billion).22 Coinciding with 
the increase in reported pain prevalence, global opioid consumption is also increasing. 
 
1.2.6 Global opioid consumption 
Global opioid consumption is increasing rapidly.23 The International Narcotics Control Board 
(INCB) reports annual opioid consumption by jurisdiction. The INCB was established by the 
Single Convention on Narcotic Drugs in 1961 and merged two bodies: the Permanent 
Central Narcotics Board, created by the 1925 International Opium Convention; and the Drug 
Supervisory Body, created by the 1931 Convention for Limiting the Manufacture and 
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Regulating the Distribution of Narcotic Drugs.24 The goal of the INCB is to monitor and 
support governments’ compliance with international drug control treaties. 
 
Since 2002, the INCB reports annual total opioid consumption by country according to 
defined daily dose for statistical purposes per one million inhabitants per day (S-
DDD/million inhabitants/day).25 This methodology was derived from the World Health 
Organization’s (WHOs) defined daily dose (DDD) method which aims to standardise the 
reporting of prescription drug consumption to facilitate temporal and cross-jurisdictional 
comparisons. WHO calculates the DDD per drug formulation; one DDD is the average 
amount of drug required to treat one adult for one day for the main indication of the drug.26 
Importantly, the DDD for opioid analgesics were first developed for the indication of cancer 
pain, which requires higher doses than the treatment of noncancer pain. Consequently, 
opioid consumption as reported by DDD generally underestimates total population opioid 
use. 
 
The INCB reported Australia’s 2014 opioid consumption was 17 667 S-DDD/million 
inhabitants/day which ranked Australia eighth behind US, Canada, Germany, Denmark, 
Belgium, Austria and Switzerland respectively.24 Figure 1.1 demonstrates the considerable 
differences in opioid use between US, Canada and Australia.  
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Figure 1.1 Opioid consumption for US, Canada and Australia (2002-2014) 
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Globally, prescription opioid use is more prevalent in specific geographical locations. For 
example, between 2010 and 2012, North America, Western Europe and Oceania (including 
Australia) consumed 92% of the global morphine supply, despite accounting for only 17% of 
the global population.27 This increase in opioid consumption is largely driven by noncancer 
pain treatment.28-30  
 
Paradoxically, despite the considerable increase in global opioid consumption, the 
prevalence and economic burden of pain has continued to increase, particularly in the US.  
 
1.3 Prescription opioid treatment guidelines 
Pain guidelines are an important clinical instrument for prescribers as they are based on 
clinical evidence regarding efficacy and safety of opioids as well as best practice guidelines. 
In addition, they recommend particular treatments for specific pain conditions. Arguably, 
one of the contributory factors to the increase in opioid use is the majority of pain 
guidelines recommending opioids as first-line treatment for all pain relief, regardless of the 
underlying condition. 
 
Pain guidelines are available to standardise and improve the quality of pain treatment and 
provide guidance to clinicians prescribing opioids for pain relief.31 In an effort to educate 
and guide practitioners, a plethora of pain guidelines are available for specific and general 
pain conditions. 
 
One of the most commonly cited pain guidelines are the WHO cancer pain ladder for 
adults.32 This approach is the basis for opioid treatment for cancer and noncancer pain in 
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adults. These guidelines recommend three steps to treat pain.32 The first step is a non-
opioid analgesic (e.g. aspirin or paracetamol), if pain persists, then a mild opioid is 
recommended to treat mild to moderate pain (e.g. codeine). If pain continues then a strong 
opioid to treat moderate to severe pain (e.g. morphine) may be prescribed. From a public 
health perspective, the strengths of the WHO step approach are to match the strength of 
the opioid to pain intensity. It recommends strong opioid use for patients with moderate 
pain that is unresponsive to weaker opioids and who have multiple interactions with their 
doctor. This approach may reduce the amount of strong opioids obtained for extramedical 
purposes. However, from a patient perspective, this strategy may also prolong the 
experience of severe pain by having to trial, and fail, weaker opioids. 
 
To reduce the incidence of opioid dependence, pain guidelines also suggest doctors assess 
each patient’s suitability for opioid treatment based on their pain condition, medical history, 
physical tests and risk of substance abuse, misuse or dependence.33  
 
Although opioids are consistently recommended in pain guidelines for pain relief for all 
conditions, the evidence demonstrating the benefits of opioids is weak, particularly long 
term opioid use for noncancer chronic pain. In the next section we present this evidence as 
well as the overwhelming research documenting the risks and harms associated with opioid 
use. 
 
1.4 Prescription opioids: benefits and risks 
There is copious literature examining the benefits and risks associated with prescription 
opioids. In this section, we report these outcomes for all opioids as a drug class, meaning we 
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do not report differences based on a specific opioid, formulation or route of administration. 
Further, we do not report on opioid treatment for specific pain conditions. In this section we 
focus on evidence provided by Cochrane reviews, meta-analyses, systematic reviews and 
draw on other reviews and observational studies where the evidence is weak or lacking. 
 
1.4.1 Benefits of prescription opioid treatment  
Meta-analyses and systematic reviews report prescription opioids provide a 30-63% 
reduction in cancer and non-cancer pain.34-38 One systematic review demonstrated seven 
out of 18 studies found opioid treatment accounted for at least a 50% pain reduction over at 
least 6 months.35 A Cochrane review and systematic review investigating long-term opioid 
treatment (≥6 months) for chronic noncancer pain found persons experienced pain relief 
(quantified as a standardised mean reduction of 1.5 to 7.5 points in pain score).35,36 The 
variation in reported pain reduction may be due to the heterogeneity in methods 
quantifying pain. Evidence surrounding the efficacy of opioid treatment in the longer term is 
lacking.5 For example, the Cochrane review included 26 studies with a median of 13 months 
follow up (range: 6-48 months). Of note, 11 studies (42%) had an observation period of ≤12 
months and eight studies (31%) had an observation period of at least 3 years. These 
observation periods are relatively short considering persons may use opioids chronically for 
several years. 
 
1.4.1.1 Functioning and quality of life 
The evidence concerning the impact of opioid treatment on functioning and quality of life 
(QOL) are weak and conflicting. A Cochrane review investigating QOL and functional status 
after at least 6 months of opioid treatment noted there was insufficient evidence to make 
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any conclusions.36 A systematic review focusing on older persons found short term opioid 
treatment was associated with better physical functioning but poorer mental health 
functioning.38  
 
Due to the minimal clinical evidence available investigating the long term outcomes of 
opioid treatment, we examined findings from observational studies. Two Danish studies 
found opioid use was associated with negative long term outcomes in chronic pain patients 
(persons experiencing pain for at least 6 months).39,40 One study compared QOL and 
functional capacity by stratifying a chronic pain population by opioid use. After controlling 
for pain level and other factors, opioid use was significantly associated with higher levels of 
reporting moderate to very severe pain; poor self-rated health; unemployment; higher use 
of healthcare services; and lower QOL, compared to persons who did not use opioids.39 The 
other Danish study examined health outcomes in chronic pain patients 10 years post 
treatment at a pain centre and found opioid users had lower health-related QOL compared 
to persons who did not use opioids.40 
 
The evidence demonstrating the benefits of opioid treatment is weak, particularly regarding 
prolonged use and outcomes. In fact, some evidence demonstrates prolonged opioid use 
may be harmful, particularly in the long term. The majority of evidence originates from 
randomised clinical trials (RCTs) which, by their nature, focus on the safety and efficacy of 
opioids over a short time period, rather than investigate long term outcomes including 
analgesia, QOL and functioning. Also, RCTs examining opioid treatment typically have small 
sample sizes, high dropout rates, and compare safety and efficacy between opioids rather 
than a non-pharmacological treatment.41-43 Furthermore, these studies predominantly focus 
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on noncancer pain populations;44 routinely exclude individuals with a history of alcohol or 
drug dependence;45 and are predominantly funded by pharmaceutical companies,5,37 all of 
these study factors introduce varying degrees of bias. Observational studies have the 
capability to examine long term outcomes of opioid treatment and complement the findings 
of RCTs by addressing these methodological shortcomings. 
 
1.4.2 Risks of prescription opioid treatment 
1.4.2.1 Ineffective analgesia and side effects 
Two systematic reviews found 6-12% of persons using opioids do not experience pain 
relief.35,37 A multitude of review articles demonstrate up to 80% of persons on opioid 
treatment experience side effects or adverse events.34-37,43,46-49 Common side effects include 
dry mouth, gastrointestinal effects (including constipation), nausea/vomiting, headache, 
fatigue, sedation, clouded mentation, dizziness and urinary complications.50 A systematic 
review found long-term opioid treatment is associated with increased risk of overdose, 
opioid abuse, fractures, myocardial infarction, and sexual dysfunction.51 
 
1.4.2.2 Opioid tolerance and dependence 
Repeated and prolonged exposure to opioid analgesics result in tolerance, which reduces 
the analgesic efficacy of the drug and is compensated by increasing the opioid dose.52 
Multiple observational studies have demonstrated high opioid dose is associated with an 
increased risk of opioid-related harm including overdose and death; as dose increases so 
does the risk of harm.53-55 In some cases dose escalation may lead to a patient developing 
iatrogenic dependence, i.e. when a patient becomes opioid dependent during opioid 
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treatment for pain. The prevalence of iatrogenic dependence is unknown due to a paucity of 
research examining this issue.56  
 
Estimates of opioid abuse or dependence (hereafter referred to as dependence) vary across 
studies. RCTs and clinical studies report only 0.04-0.4% of patients develop opioid 
dependence.35,36 However, due to the short time period of assessment, pre-market clinical 
trials may not have the capability to identify dependence, as this generally emerges over a 
longer time period than the duration of a trial.45 Studies based on real-world data report the 
rate of opioid dependence ranges between 0.6-14%.35-37,57,58 Review articles report 
considerably higher rates of opioid dependence, ranging between 0-50% in noncancer 
patients57,59-61 and 0-7.7% in cancer patients treated for pain.59,61 The variation in reported 
rates may be due to methodological heterogeneity in the measures quantifying prescription 
opioid dependence. Chapter Two of this thesis provides a more detailed examination of how 
prescription drug misuse, including opioid misuse, is quantified in observational studies 
using pharmaceutical claims data.  
 
1.5 Prescription opioid-related harms 
While opioids are the most effective pharmacological option to treat pain, several North 
American ecological studies demonstrate an increase in opioid use is associated with an 
increase in opioid-related harms.6,62-65 In summary, since the 1990s there have been 
considerable increases in recreational prescription opioid use and related-harms including 
poisonings, emergency department presentations, hospitalisations and deaths. Recent 
evidence suggests these harms are plateauing;66 however, these harms still represent a 
significant public health concern.  
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1.5.1 Recreational opioid use 
In 2014, the US National Survey on Drug Use and Health found 6.5 million Americans 
reported non-medical use of a prescription drug (including opioids, sedatives, stimulants 
and tranquilisers); representing 2.5% of the US population aged ≥12 years.67 This figure is 
largely driven by opioids, as two-thirds of this population (4.3 million persons) misused 
prescription opioids.67  
 
1.5.2 Opioid harms 
Prescription opioids are depressants, they slow down the central nervous system including 
respiration and heart rate.68 An opioid overdose or poisoning occurs when the body cannot 
adequately breakdown the quantity of opioids ingested, consequently, normal functions, 
such as breathing or heart rate, may decrease to dangerous levels or stop completely. 
Depending on the amount of opioids consumed and access to medical treatment, an opioid 
overdose may result in an emergency department (ED) presentation, hospitalisation and/or 
death.68 The risk of opioid harm increases if opioids are taken in conjunction with other 
substances including alcohol, illicit drugs or prescription drugs such as benzodiazepines.69 
 
Multiple studies have demonstrated increases in opioid poisonings in recent years.70-72  
Between 1999 and 2006, opioid poisonings in the US increased 3.5 fold (4 000 to 13 800 
poisonings annually).73 These harms also represent a significant economic burden. In 2009, 
the estimated cost of opioid poisonings was US$20.4 billion.73 The majority of these costs 
are work-related including lost future earnings due to mortality (US$18.2 billion) and 
absenteeism (US$335 million). Direct medical costs totalled US$2.2 billion; inpatient costs 
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accounted for US$1.3 billion and ED presentations accounted for the remaining US$800 
million.73  
 
Multiple studies have demonstrated increases in opioid-related ED visits or 
hospitalisations.74-77 Between 1993 and 2010, the rate of ED presentations for opioid toxicity 
in the US increased almost 3.5 fold, from 19 to 63 per 100 000 population.75 In 2010, 
prescription opioids accounted for 41% of the 731 000 ED presentations for overdoses.75 
 
Rates of hospitalisation due to opioid dependence increased 1.7-fold between 2002 and 
2012 and cost US$15 billion.76 In 2012 alone, these hospitalisations cost US$700 million.76 In 
2008, the total cost of ED/hospital visits for opioid-dependent persons in the US was US$9.5 
billion.78 
  
Multiple studies have documented the increase in opioid-deaths.69,79-86 In 2008, there were 
approximately 36 450 drug overdose deaths; equating to one death every 14.5 minutes.86 In 
2008, there were 20 044 prescription drug overdose deaths, of which, prescription opioids 
accounted for 14 800 (74%) deaths.86 In the US between 2000 and 2014, the rates of opioid-
related deaths increased 200%; with a 14% increase between 2013 and 2014 alone (7.3 to 
9.0/100 000 population).79 
 
1.5.3 Economic impact of opioid misuse 
As well as the increase in opioid-related harms, prescription opioid misuse also represents a 
significant economic burden to the community. At an individual level, several studies have 
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demonstrated that opioid-dependent persons have 1.4 to 8.7 times higher healthcare costs 
than their non-dependent counterparts.87-91  
 
At a societal level, the cost of opioid misuse and dependence increased 6.5 fold between 
2001 and 2007; costing up to US$55.7 billion in 2007 alone.92-94 Workplace (US$25.5 billion, 
46%) and healthcare (US$25 billion, 45%) costs together account for over 90% of total costs; 
the criminal justice system accounts for the remainder (US$5.1 billion).91 As opioid use has 
continued to increase over the past 10 years, these costs are also likely to have increased.  
 
Prescription opioids are a complex and controversial drug class. The WHO lists opioids as an 
essential medicine, meaning opioids should be available at all times in adequate amounts, 
with assured quality and priced affordably for the individual and community.95 However, 
there is weak evidence demonstrating opioids efficacy to treat chronic pain, particularly 
exploring long term outcomes of opioid use. In this section we highlighted the considerable 
increases in US opioid-related harms. Similar trends have emerged from other jurisdictions 
including Canada,64,96,97 Great Britain98 and Australia.8-10,99 Opioid misuse and dependence 
also represent a significant economic burden, both at individual and societal levels. Despite 
this evidence, there is relatively limited scholarship examining real world opioid use and 
access patterns. 
 
1.6 Real world methods of quantifying prescription opioid misuse 
In this section we highlight the major challenges in quantifying prescription opioid misuse. 
As opioid-related harms have increased considerably it is believed that rates of opioid 
misuse are also increasing. However, there is no consensus on the definition of misuse.2,100-
18 
108 In this section we examine the strengths and weaknesses of the dominant methodologies 
to quantify misuse in the real world including structured clinical interviews, questionnaires, 
medical chart review and routinely collected data. 
 
1.6.1 Structured clinical interviews 
The main goal of a structured clinical interview is to determine if a person meets the 
diagnostic criteria of opioid misuse or dependence. Two internationally recognised clinical 
tools to diagnose opioid misuse or dependence are the International Statistical Classification 
of Diseases and Related Health Problems (ICD)109 and the American Psychiatric Association 
Diagnostic and Statistical Manual of Mental Disorders (DSM).110 These clinical tools may also 
be adapted for research purposes to quantify the extent of dependence without any clinical 
implications. Structured clinical interviews are generally conducted by trained clinicians such 
as a psychiatrist. The interview is usually based on a set of pre-determined questions, 
regarding another individual’s opioid use and the impact of opioids on their life. 
 
Two Australian studies compared the prevalence of opioid misuse quantified by the ICD 
(edition 10 and draft of edition 11), the DSM (editions 4 and 5) and “addiction” as defined 
by Pain Medicine as including at least one of the following symptoms: impaired control over 
drug use, compulsive use, continued use despite harm and cravings. Lifetime rates of opioid-
misuse were quite similar across all measures (9-10%), however, the extent over 12-months 
varied from 18-24%.111,112 These differences are due to the unique diagnostic criteria used in 
each measure.  
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From a research perspective, these interviews are time consuming, not necessarily 
representative of the general population, rely on a patient’s recall and have inherent biases 
including social desirability and truth bias. For example, persons may under-report opioid 
use as it may be more socially desirable and they may fear negative judgement from the 
interviewer. 
 
1.6.2 Questionnaires 
Questionnaires may be used to characterise past opioid access and determine the risk of 
future extramedical drug seeking behaviour; in this section we focus on the latter. 
Questionnaires may form part of routine patient intake for pain clinics113 and are usually 
self-report. There are a multitude of validated measures predicting future misuse including 
Screener and Opioid Assessment for Patients with Pain (SOAPP);114 Opioid Risk Tool (ORT)115 
and Current Opioid Misuse Measure (COMM).116  
 
Several studies have compared the psychometric properties of these measures to 
determine their validity in different patient populations.108,113,117,118 The results of these 
studies are mixed. One review found the combination of a clinical interview with the SOAPP 
questionnaire was the most sensitive tool to predict opioid misuse followed by clinical 
interview or SOAPP alone, respectively.113 Another review found that high scores on the 
SOAPP, COMM and ORT were associated with increased likelihood of future extramedical 
drug seeking behaviour, and low scores on each of these measures was associated with a 
decreased risk of such behaviour.108 However, the evidence regarding the validity of these 
questionnaires are weak.108 
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From a research perspective, the strengths of patient self-report questionnaires include a 
relatively short time period to complete the measure and larger sample sizes than RCTs or 
studies using structured clinical interviews.119 Questionnaires have similar weaknesses to 
interviews including samples that are unrepresentative of the general population. For 
example, males may be overrepresented and minority groups underrepresented.118 
Questionnaires also have inherent truth, recall and social desirability bias.113,120 Further, 
there may be a non-response bias, meaning the generalisability of the results is limited due 
to large numbers of persons in the population of interest not completing the 
questionnaire.119 
 
1.6.3 Medical chart review 
A chart review involves examining patient medical records from a healthcare setting such as 
a hospital or general medical practice. In pharmacoepidemiological studies, a researcher 
may audit these health records to examine prescription drug use and/or clinician prescribing 
patterns.  
 
Multiple studies have used a chart review to examine important clinical questions such as 
opioid initiation, switching, tolerability, effectiveness, prevalence of potential misuse and/or 
substances involved in a prescription drug-related death.121-124 
 
The strength of these data is the wealth of patient information available including over-the-
counter drug use, comorbid medical conditions, body mass index, family history, smoking 
status, alcohol use and illicit substance use.125 The limitations of chart reviews include being 
largely descriptive in nature, as outcome data is only included if a patient discloses this 
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information and the doctor records it. Based on the studies above, they have relatively small 
sample (range: 61-617 people); consequently, results may be biased to persons seeking 
treatment for the condition of interest, which may not be representative of the entire 
population. Furthermore, the information may vary in completeness due to a patient 
receiving treatment from multiple facilities and the quality and legibility of doctor’s notes.121  
 
1.6.4 Routinely collected data  
Routinely collected data are information collected for a purpose other than research. These 
data are collected by governments, healthcare providers and insurers.126 In section ‘1.5 
Prescription opioid-related harms’ we document the considerable increases in opioid-
related harms; the majority of these findings were based on routinely collected data, 
particularly those examining trends of opioid-related ED visits, hospitalisations and deaths.  
 
In this section we focus on pharmaceutical claims that record real world prescription drug 
dispensings, which provides researchers with the opportunity to examine whole-of-
population patterns of opioid use. Pharmacoepidemiological studies perform an important 
role in examining drug safety and effectiveness in the real world.121,127 As pharmaceutical 
claims are based on community access patterns, studies generally have large sample sizes 
which provides the opportunity to detect rare or uncommon adverse events, examine drug 
safety and patterns of use.128,129 Researchers can assess these factors in diverse populations 
who are not typically represented in RCTs including the elderly, pregnant women and 
children.120,127,128,130 This method can provide insights into clinical questions quicker and at a 
lower cost than other study designs, including RCTs.129,131-133 Generally, researchers are able 
to access these data due to privacy legislation including a section concerning waiver of 
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consent. Consequently, studies are not typically prone to selection bias as per other data 
sources that require informed consent.129 
 
Internationally, pharmaceutical claims have been used extensively to examine prescription 
opioid use;7,29,134-138 evaluate new opioid access policies;55,63,139,140 quantify potential 
misuse,141-144 and examine adherence to pain guidelines.145 Several studies have linked 
pharmaceutical claims with other electronic health outcome datasets to examine the 
association between opioid use and harms including overdose and death.54,54,146-149 
 
Perhaps the most significant limitation to pharmacoepidemiological research using 
pharmaceutical claims is it is a relatively new field of study, said to be in its adolescence;128 
therefore its methods require critical analysis. This is particularly true for assessing methods 
quantifying prescription drug misuse in pharmaceutical claims, as there are no validated 
definitions of misuse and limited consensus on the behaviour that constitutes extramedical 
use. Pharmaceutical data generally contain limited clinical information, including no 
indication of diagnoses; confounders including smoking or alcohol use; or, severity of 
illness.120,126,127,129,130,132 Finally, given the large sample sizes, findings are often considered 
statistically significant so it is important to determine the clinical relevance of all results.  
 
Despite these limitations, pharmaceutical claims are, arguably, the only Australian data 
available to examine whole-of-population, real world trends in prescription drug use and 
access patterns. Furthermore, despite the availability of these data and Australia’s universal 
healthcare system, there has been relatively limited research focusing on opioids in 
pharmaceutical claims. In the next section we focus on the Australian context, specifically, 
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we document the prevalence of chronic pain, the prevalence of extramedical prescription 
drug use, and summarise aspects of the Australian healthcare system, focusing on the 
Australian Pharmaceutical Benefits Scheme, and research examining opioid use and related 
harms using pharmaceutical claims. 
 
1.7 Australia 
1.7.1 Pain: prevalence and economic burden 
In Australia in 2001, 17% of males and 20% of females reported chronic pain (experienced 
pain every day for 3 months in the preceding 6-month period).19 Prevalence increased with 
age; at the peak, over one-quarter of Australian males aged 65-69 years and almost one-
third of Australian females aged 80-84 years reported chronic pain.19  
 
In 2007/2008, the Australian Bureau of Statistics National Health Survey (NHS) quantified 
the extent of bodily pain in Australia. The NHS found 67% of Australian adults (11.1 million 
persons) reported experiencing bodily pain in the preceding 4 weeks.150 Between 1995 and 
2007, rates of bodily pain increased from 57% to 68%, respectively, and severe/very severe 
pain increased from 7% to 10%.150 In 2007, the cost of chronic pain in Australia was AU$34.3 
billion, equating to AU$11 000 per person with chronic pain.151 Specifically, productivity 
costs ($11.7 billion; 34%) and the burden of disease ($11.5 billion; 34%) account for 68% of 
costs followed by the burden of the health care system ($7 billion; 20%) and informal care 
($1.3 billion; 0.7%).151 Due to Australia’s ageing population, the proportions of persons 
experiencing chronic pain and economic burden have likely increased over the past decade. 
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1.7.2 Rates of non-medical prescription drug use  
National Australian surveys report increasing rates of extramedical prescription drug use. 
Lifetime rates of non-medical use for any prescription drug range from 4.7-11.4%;152,153 in 
the 12-months prior to survey completion the rate ranged from 4.2-5.1%.153-155 Not 
surprisingly, opioids are the drug class most frequently associated with non-medical use;153 
3.3% of Australians (approximately 600 000 persons) used opioids for an extramedical 
purpose over 12 months.153  
 
1.7.3 Australian healthcare system 
For all studies in this thesis, we analyse Australian Pharmaceutical Benefits Scheme (PBS) 
data, which is a national pharmaceutical claims dataset. In the remainder of this section, we 
detail the Australian healthcare system as it relates to our work and data collections that 
result from interactions with the system. 
 
Medicare is a publically funded universal healthcare system operating in Australia. It was 
established as Medibank in 1975 and renamed Medicare in 1984.156 This universal 
healthcare system entitles all Australian citizens and permanent residents to free or 
subsidised healthcare including prescription drugs. 
 
1.7.4 Australian Pharmaceutical Benefits Scheme (PBS) 
The PBS is a national system that subsidises the cost of a wide range of prescription drugs 
and provides access to necessary and cost-effective drugs. The PBS was first established in 
1948 and provided all drugs free to pensioners and 139 drugs considered to be ‘life-saving 
and disease preventing’ free for the community.157 As of December 2009, the PBS covers 
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874 drug substances (generic drugs), available in 2 168 formulations/strengths, and 
marketed as 3 949 products.152  
 
The Australian Government Department of Human Services (DHS) are the data custodians of 
PBS data. These data are restricted to PBS-listed drugs dispensed for a PBS-listed indication 
where the Australian government provides reimbursement. 
 
1.7.4.1 The process of the Pharmaceutical Benefits Scheme listing a prescription drug on the 
formulary 
To be listed on the PBS, a drug must be assessed and approved by multiple agencies and 
committees.  
 
The Australian Government Department of Health, Therapeutic Goods Administration (TGA) 
approves the drug for marketing in Australia based on its clinical efficacy and safety 
compared to other treatments for the same medical indication.162 This decision is based on 
submissions from the drug sponsor who may subsequently apply for PBS-subsidy.  
 
The Pharmaceutical Benefits Advisory Committee (PBAC) evaluate the drug for public 
subsidy. The PBAC assesses the efficacy, safety and cost-effectiveness of the drug compared 
to existing treatments for the same indication, as well as the overall cost to the Australian 
Government.163 When a drug is PBS-subsidised, it increases community access to the drug 
and a record is created when it is dispensed. If a drug is not PBS-subsidised but approved by 
the TGA, it is available for prescription in Australia, however, a patient must pay the full cost 
of the drug and no dispensing records are collected in PBS claims. 
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All PBS-listed prescription drugs are assigned a PBS-item code which denotes the 
prescription drug, strength, formulation and quantity. The PBS-item codes may be mapped 
to the WHOs Collaborating Centre for Drug Statistics Methodology, Anatomical Therapeutic 
Chemical (ATC) classification system.160 According to the ATC methodology, the active 
substance in all prescription drugs are categorised based on the organ or system on which 
they act and their therapeutic, pharmacological and chemical properties. The ATC code for 
opioid analgesics to provide pain relief is N02A. In this thesis we include the PBS-listed 
opioids: buprenorphine, codeine, fentanyl, hydromorphone, methadone, morphine, 
oxycodone, tapentadol and tramadol. However, tapentadol is excluded from the majority of 
our analyses as it was PBS-listed in 2014; after the observation period of our studies. 
 
1.7.4.2 Australian Pharmaceutical Benefit Scheme patient beneficiary categories 
The PBS defines two beneficiary levels: concessional and general. Concessional beneficiaries 
account for approximately 25% of the PBS-eligible Australian population;161 but in 2014 they 
obtained almost three-quarters of the 289 million drug dispensings in Australia.159  
 
The PBS beneficiary category has implications for data collection, for a detailed discussion of 
this issue please see our practical guide for researchers using the PBS, provided in Appendix 
G. In short, historically a PBS dispensing record is created only when the Australian 
government provides reimbursement for a dispensed drug. Consequently, in the PBS data 
we have complete dispensing history for concessional beneficiaries, as the government 
provides reimbursement for all their drug dispensings. However, data completeness varies 
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for general beneficiaries’ data by drug and formulation, as the government only provides 
reimbursement for higher cost drugs. 
 
Concessional beneficiaries receive a government pension (unemployment, disability, 
sickness, single-parent or aged pension). In January 2016, the concessional beneficiary 
copayment was AU$6.20;162 the copayment generally increases annually on 1 January. All 
PBS-listed drugs are priced above the concessional beneficiary copayment so they pay a 
maximum of their copayment per drug dispensing. The PBS also has a family safety net 
threshold to subsidise prescription drug costs for chronically ill patients. A family includes 
the patient, partner, children aged <16 years and full-time students aged <25 years.163 Once 
a family spends the safety net threshold on prescription drugs, in a calendar year, their 
copayment reduces. For concessional beneficiaries, the safety net threshold is AU$372 (as at 
1 January 2016), equating to 60 drug dispensings priced at the concessional beneficiary 
copayment per calendar year.167 Once the threshold is reached, the patient copayment 
reduces to zero for all drug dispensings for the remainder of the calendar year as the 
Australian government completely subsidises the cost of these dispensings. 
 
General beneficiaries do not receive a government pension. The general beneficiary 
copayment is currently AU$38.30 (as at 1 January 2016).162 PBS-listed drugs may be priced 
either above or below the general beneficiary copayment. The general beneficiary pays 
either the cost of the drug or their copayment whichever is less. The cost of any PBS-listed 
dispensed drug contributes to the safety net threshold. The safety net threshold for general 
beneficiaries is AU$1475.70 (as at 1 January 2016), equating to at least 39 dispensings 
priced at their copayment per calendar year.162 Once this threshold is reached, the family 
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pays the concessional beneficiary copayment amount (currently AU$6.20) for all drug 
dispensings for the remainder of the calendar year. 
 
1.7.4.3 Australian Pharmaceutical Benefits Scheme data sources 
Historically, PBS dispensing data are collected from two data sources. Firstly, a PBS 
dispensing record is created when a PBS-listed drug is dispensed in the community for a 
PBS-listed indication, and the cost of the drug is higher than the relevant copayment (in 
2016, AU$6.20 for concessional beneficiaries and AU$38.30 for general beneficiaries). 
Consequently, PBS records capture all concessional beneficiary drug dispensings, as all PBS-
listed drugs are priced above their copayment. These data exclude under-copayment 
dispensings (for general beneficiaries only) and private prescriptions, i.e. when a medical 
practitioner prescribes either a drug that is not PBS-listed or a PBS-listed drug for a medical 
indication for which it is not PBS-listed. 
 
From 1989 the Drug Utilisation Sub-Committee (DUSC) commissioned the Pharmacy Guild of 
Australia (PGA) to conduct an annual survey (Pharmacy Guild Survey) to estimate the 
national volume of dispensings for drugs that are not PBS-listed or subsidised, i.e. private 
prescriptions and under-copayment dispensings. Total drug dispensings information was 
collected monthly from pharmacies that were members of the PGA. In 2007, the survey 
included 370 pharmacies across Australia; representing approximately 6% of the 5 450 
community pharmacies currently operating across Australia.164  
 
However, in 2012 DHS started collecting data for under-copayment drug dispensings and 
the Pharmacy Guild Survey ceased. Now, DHS captures dispensings for all concessional and 
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general beneficiaries, regardless of the drug cost, but no private prescription data. Of note, 
none of the PBS data examined in this thesis includes under-copayment dispensings. 
Therefore, we restricted all analyses in this thesis to concessional beneficiaries to ensure 
complete capture of all drug dispensings for our cohort. 
 
1.7.4.4 Limitations of Australian Pharmaceutical Benefits Scheme data 
There are several limitations regarding PBS data. Prior to 2012, PBS data did not collect any 
information regarding private prescriptions, under-copayment dispensings or drugs that are 
not PBS-listed. PBS data does not include dispensings for drugs dispensed from public 
hospitals located in New South Wales or the Australian Capital Territory. In the other six 
Australian jurisdictions, the Public Hospital Pharmaceutical Reforms allows participating 
hospitals to provide discharging inpatients and outpatients with PBS-subsidised drugs,165 
which are included in PBS data collections. 
 
In Australia, methadone and buprenorphine are PBS-listed for the indications of pain and 
opioid dependence. Opioids dispensed for opiate maintenance therapy are classified under 
the Section 100 Highly Specialised Drugs Program (S100 HSDP) which are run by each 
individual Australian State or Territory. As the S100 HSDP is not a national scheme, no 
dispensing records for opioids dispensed for opiate dependence are collected in PBS data. 
Consequently, these dispensings are not included in any data analysed in this thesis. 
 
The Australian government do not reimburse over-the-counter (OTC) drugs, consequently 
they are not captured in PBS data. OTC drugs are outside the scope of this thesis, but a few 
Australian studies have investigated OTC opioid use based on other data.166-168 
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1.7.5 National Pharmaceutical Drug Misuse Strategy 
Prescription drug and opioid misuse are recognised as a national issue which needs to be 
addressed, particularly in light of the evidence demonstrating the considerable increases in 
opioid use and harms in the US. In 2011, the National Centre for Education and Training on 
Addiction (NCETA) published a report outlining the major challenges in quantifying 
prescription drug misuse in Australia.169 They stipulate: 
 
“in order to develop appropriate responses to pharmaceutical misuse 
problems, it is important to establish current levels and patterns of use and 
misuse, and the extent and nature of harms.”169 
 
They continue to list other difficulties that prevent accurately quantifying misuse including: 
a lack of pre-existing monitoring systems to identify and track all prescription drug use in a 
timely manner at the person-level; inability to track drug use across Australian jurisdictions 
due to different opioid access policies between States and Territories; and a lack of national 
information to provide a comprehensive picture of prescription drug use.169 However, 
routinely collected data, particularly PBS claims, overcome these perceived challenges. 
Despite this fact, there is scant Australian research investigating prescription drug misuse in 
pharmaceutical claims.  
 
1.7.6 Australian prescription opioid research using pharmaceutical claims 
A recent systematic review identified all Australian pharmacoepidemiological studies using 
pharmaceutical claims published since 1987.170 Over one-third (36%) of the 228 Australian 
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pharmacoepidemiological studies focused on nervous system drugs. However, only five 
reviewed studies included opioid analgesics. 
 
Australian studies using routinely collected data demonstrated considerable increases in 
opioid use between 1986 and 20097,171-174 and opioid-related harms between 2000 and 
2011.8-10,99 None of these studies provided a national picture of opioid use and opioid-
related harms. Excluding the studies presented in this thesis, only one other Australian 
study has used person-level PBS data to examine opioid use. They found approximately 25% 
of elderly patients initiating oxycodone did not follow PBS opioid treatment guidelines,145 
i.e. their prescriber did not trial a non-opioid analgesic prior to initiating strong opioid 
treatment.  
 
There are large gaps in Australia’s understanding of opioid use and potential misuse. In this 
thesis we will explore the issues identified by the NCETA in quantifying national opioid use, 
patterns of access and the extent of opioid-related harms, by using routinely collected data, 
predominantly pharmaceutical claims. 
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Chapter Two: Harmonising post-market surveillance of prescription 
drug misuse: a systematic review of observational studies using 
routinely collected data (2000-2013) 
 
To quantify the extent of population prescription drug misuse we first need to understand 
how this concept is defined across jurisdictions. Consequently, in this chapter we present 
the results of a global systematic review investigating the extent and methods of quantifying 
prescription drug misuse through pharmaceutical claims. 
 
This chapter is based on the following publication: 
Bianca Blanch, Nicholas A. Buckley, Leigh Mellish, Andrew H. Dawson, Paul S. Haber, Sallie-
Anne Pearson. Harmonizing post-market surveillance of prescription drug misuse: a 
systematic review of observational studies using routinely collected data (2000-2013). Drug 
Safety. 2015; 38: 553-564. 
 
Formatting note: To increase the readability of viewing this thesis electronically, we provide 
all figures or tables on the page following its first citation in the text. The key points and 
abstract are formatted according to the Drug Safety style guide. We provide the reference 
list at the end of this chapter. Due to the length of the supplementary materials for this 
chapter we provide them in Appendix A only. 
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Key Points 
 Prescription drug misuse is increasing globally. This can be readily monitored using 
routinely collected data to quantify drug access patterns at the population-level. 
 Our review identified only four common proxies for prescription drug misuse 
(number of prescribers, number of dispensing pharmacies, volume of drug[s] 
dispensed and/or overlapping prescriptions/early refills); however, these proxies 
were used to derive 89 unique definitions of drug misuse due to variations in 
thresholds or measures (single or multiple behaviour measures).  
 We recommend the development of consistent and replicable metrics to facilitate 
monitoring and comparisons of the extent of prescription drug misuse across 
healthcare settings and over time. 
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Abstract 
Background  
Prescription drug misuse is a growing public health concern globally. Routinely collected 
data provide a valuable tool for quantifying prescription drug misuse. 
 
Objective 
To synthesise the global literature investigating prescription drug misuse utilising routinely 
collected, person-level prescription/dispensing data to examine reported measures, 
documented extent of misuse and associated factors. 
 
Methods  
The MEDLINE, EMBASE, CINAHL, MEDLINE In Process, Scopus citations and Google Scholar 
databases were searched for relevant articles published between 1 January 2000 and 31 July 
2013. A total of 10 803 abstracts were screened and 281 full-text manuscripts were 
retrieved. Fifty-two peer-reviewed, English language manuscripts met our inclusion 
criteria—an aim/method investigating prescription drug misuse in adults and a measure of 
misuse derived exclusively from prescription/dispensing data. 
 
Results  
Four proxies of prescription drug misuse were commonly used across studies: number of 
prescribers, number of dispensing pharmacies, early refills and volume of drugs dispensed. 
Overall, 89 unique measures of misuse were identified across the 52 studies, reflecting the 
heterogeneity in how measures are constructed: single or composite; different thresholds, 
cohort definitions and time period of assessment. Consequently, it was not possible to make 
56 
definitive comparisons about the extent (range reported 0.01–93.5%), variations and factors 
associated with prescription drug misuse. 
 
Conclusions  
Routine data collections are relatively consistent across jurisdictions. Despite the 
heterogeneity of the current literature, our review identifies the capacity to develop 
universally accepted metrics of misuse applied to a core set of variables in prescription/ 
dispensing claims. Our timely recommendations have the potential to unify the global 
research field and increase the capacity for routine surveillance of prescription drug misuse. 
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2.1 Introduction 
Research demonstrates a high degree of variability in how drugs are prescribed and used.1 
Prescription drugs including sedatives, anxiolytics, analgesics and stimulants are often taken 
excessively to enhance desired effects.1 The consequences of excessive use are a major 
public health concern and include drug tolerance,2,3 increased risk of side effects,3–5 
overdose,6 dependence,7 hospitalisation,5 or death.2,8,9 These risks are escalated with 
concomitant prescription drug, alcohol or illicit drug use.10–16 
 
Research methodologies, including medical chart review,17 surveys,18 qualitative,19,20 and 
observational studies,21 have been used to explore prescription drug misuse. In recent 
decades, the growing availability of routinely collected health information has increased 
opportunities to undertake population-based surveillance of prescription drugs. The 
evidence generated from routinely collected data can further enhance our understanding of 
prescription drug misuse, patient and prescriber behaviour outcomes of misuse, and 
influence policy changes on these issues.  
 
There are no universally accepted definitions of prescription drug misuse22,23 making 
quantification challenging. Due to the limited clinical information held in routine data 
collections, prescription drug misuse is not directly measured at the population level23 but is 
commonly inferred based on patterns of drug access and by investigating patient 
interactions with prescribers and pharmacies. 
 
In response to concerns about the management of chronic pain treated with opioid 
analgesics, the US Food and Drug Administration (FDA) has recently sought submissions 
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related to the post-market surveillance of extended release and long-acting opioid 
formulations.24 In particular, the FDA requested submissions relating to defining misuse, 
abuse, addiction and their consequences measured in routine data collections.24 Clearly, 
synthesising the global literature will add significant value to this endeavour. 
 
Our timely systematic review aims to examine the measures, extent and factors associated 
with prescription drug misuse in observational studies based on routinely collected person-
level prescription or dispensing data. 
 
2.2 Methods 
2.2.1 Eligible studies 
Our review included English-language, peer-reviewed manuscripts published between 1 
January 2000 and 31 July 2013, which satisfied the following criteria: 
• aim or method investigated prescription drug misuse; 
• measure of prescription drug misuse derived exclusively from person-level 
prescription/dispensing data; 
• investigated misuse in adult persons (≥18 years). 
 
We excluded grey literature (government reports), case reports, letters, editorials, opinion 
pieces, reviews and conference abstracts. 
 
2.2.2 Study identification 
Search strategy (Supplementary Material [SM] 1) 
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A search was conducted of the MEDLINE, EMBASE, CINAHL and MEDLINE In Process 
databases combining keywords and subject headings to identify studies investigating 
prescription drug misuse measured in routinely collected prescription/dispensing data using 
observational approaches. Search terms included misuse; problematic; prescription drugs; 
factual databases; population surveillance and cohort studies. Three further searches were 
completed using Google Scholar25 (we reviewed first 200 results per search), Scopus 
citations (for articles citing included manuscripts) and screened back references of included 
studies, review articles and selected excluded studies. 
 
Two reviewers (BB and LM) screened the abstracts and titles of articles to identify 
potentially relevant studies. These studies were assessed independently (BB and LM) for 
inclusion in the review using a five-item tool based on the eligibility criteria (SM 2). A third 
reviewer (SP) arbitrated when consensus about inclusion was not reached (18% of articles). 
 
2.2.3 Data extraction 
Two independent reviewers (BB and LM) completed comprehensive data extraction for 
articles meeting our eligibility criteria (SM 3), with the following information being 
extracted: 
1. Study characteristics: year of publication; publishing journal; observation period 
(beginning and end year, and duration in months); funding source; objectives; setting; 
generic names of prescription drug(s) investigated; data source; including extent of 
population coverage and terminology related to misuse. We also calculated lag time (year of 
publication minus last year of observation). 
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2. Cohort characteristics: number of cohort(s); cohort size(s) and cohort details, including 
study inclusion/exclusion criteria. Studies reported the extent of prescription drug misuse in 
drug-user cohorts (persons dispensed or prescribed the drug[s] of interest) or in misuse 
cohorts (persons exhibiting behaviour considered to be above the norms of prescription 
drug use). 
3. Measures of prescription drug misuse: the characteristic or behaviour of interest (e.g. 
number of prescribers), threshold defining behaviour indicative of misuse as defined by the 
study authors (e.g. ≥4 prescribers) and time period of assessment (e.g. 6 months). Each 
measure was identified as follows: 
• stand-alone: investigated a single characteristic or behaviour (e.g. the proportion of 
persons accessing ‘≥4 prescribers’ in 6 months); or 
• composite: in drug-user cohorts, the measurement of two or more characteristics or 
behaviours (e.g. the proportion of persons using ‘≥4 prescribers AND ≥4 dispensing 
pharmacies’ in 6 months). In misuse cohorts (e.g. defined by persons visiting ‘≥4 prescribers’ 
in 6 months) the measurement of at least one additional characteristic or behaviour (e.g. 
the proportion of misusers accessing ‘≥4 dispensing pharmacies’ in 6 months). 
4. Other prescription drug misuse-related outcomes, e.g. dispensed specific drug classes or 
drugs associated with misuse. 
5. Summary statistics: percentages or other statistics (e.g. means with standard deviation or 
medians with ranges) related to all misuse measures. Where possible, we calculated the 
extent of misuse in user cohorts if not reported in individual studies. 
6. Rationale for measure(s) of misuse: any reference to previously published studies; expert 
panel recommendations; empirical derivation, or any other rationale. 
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7. Comprehensiveness of reporting (BB only) according to the Strengthening the Reporting 
of Observational Studies in Epidemiology (STROBE) Statement Checklist for Observational, 
Population-Based Cohort Studies.26,27 
 
2.2.4 Terminology 
In the global literature, a range of terms are used to encapsulate prescription drug misuse 
including abuse, dependence, diversion, misuse, extramedical, problematic or non-medical 
use.1,28–30 As such, our search strategies included 24 unique misuse-related terms to capture 
relevant articles. For the purposes of this review, we use the umbrella term ‘prescription 
drug misuse’ to capture the continuum of misuse, ranging from use above the norms, 
through to dependence, abuse and diversion. This is consistent with the FDA’s terminology 
in their recent call for submissions on post-market opioid surveillance.24 
 
2.2.5 Analysis 
In reviewed studies there was considerable variation in study design including: study 
population(s), drug(s) of interest, definition(s) of misuse and outcome measures. Due to this 
variation, it was not possible or appropriate to use traditional meta-analytic approaches to 
pool individual study results. Instead, we provide a descriptive analysis, detail the key 
findings of individual studies and summarise study features in tables and figures. Our review 
is consistent with AMSTAR (A Measurement Tool to Assess Systematic Reviews) and PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses) reporting criteria 
(SM 4). 
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2.3 Results 
2.3.1 Studies identified 
The titles/abstracts of 10 803 articles were screened and 281 full-text manuscripts were 
reviewed. Fifty-two studies met our eligibility criteria; 38 were identified from MEDLINE, 
EMBASE, CINAHL or MEDLINE In Process, two from Google Scholar, four from Scopus 
citations and eight from back references (Figure 2.1). The bibliography of the 229 excluded 
and 52 included studies are detailed in SM 5 and 6, respectively. 
 
2.3.2 Study features 
The studies were set in the US (27 studies), France (17 studies), Norway (seven studies) or 
Canada (one study) (Table 2.1; SM 7). All studies from Norway used dispensing data for the 
entire national population; the remaining 45 studies used populations within a specific 
province, state or region. Of the 52 included studies, 32 (61.5%) were published between 
2010 and July 2013. The median study observation period was 18 months (range: 4–132 
months; interquartile range [IQR]: 12–37.5 months) and the median lag time was 4 years 
(range: 2–15 years; IQR: 3–6 years). Twenty-one studies did not report a funding source, and 
the remaining studies were funded primarily by research grants (15 studies) or the 
pharmaceutical industry (seven studies). Fifty-one studies utilised dispensing data; one 
study used prescription data. Forty-six unique terms were used by study authors to 
encapsulate the concept of ‘prescription drug misuse’ (Box 2.1). 
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Figure 2.1. Flow chart of systematic review methodology to identify included manuscripts  
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Table 2.1 Characteristics of included studies (N= 52 studies) 
  N % 
Study setting 
   United States 27 51.9 
   France 17 32.7 
   Norway 7 13.5 
   Canada 1 1.9 
Year of publication 
   2000-2004 7 13.5 
   2005-2009 13 25.0 
   2010-2013 32 61.5 
Length of observation period for routinely collected data 
   <12 months 5 9.6 
   12 months to 24 months (inclusive) 28 53.8 
   25 months to 48 months (inclusive) 11 21.2 
   49 months to 108 months (inclusive) 7 13.5 
   >108 months 1 1.9 
Publication lag (year published - last year of observation) 
   1-2 years 4 7.7 
   3-5 years 34 65.4 
   6-10 years 8 15.4 
   >10 years 6 11.5 
Study funding 
   Grants: government, non-government or research 15 28.8 
   Industry: pharmaceutical company 7 13.5 
   Core government funding 3 5.8 
   Other 4 7.7 
   No funding 2 3.8 
   Not disclosed 21 40.4 
Number of prescription drug classes investigated per study 
   One  39 75.0 
   Two 5 9.6 
   Three 6 11.5 
   Four 2 3.8 
Drug classes investigated for misusea 
   Opioids (includes controlled substances) 35 46.1 
   Benzodiazepine 20 26.3 
   Z-drug (zopiclone; zolpidem) 5 6.6 
   Antidepressant 4 5.3 
   Other sedative (carisoprodol) 4 5.3 
   Central nervous system stimulant 3 3.9 
   Anorectic (diuretic) 2 2.6 
   Anticholinergic antiparkinson drug 1 1.3 
65 
   Antipsychotic 1 1.3 
   Psychotropic (not further specified) 1 1.3 
a 13 studies investigated more than one drug class; % represents prevalence of each drug class 
studied (denominator of 76)
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Box 2.1 Terminology used in reviewed studies to describe prescription drug misuse 
We noted 46 different terms including: abuser, clinical abuser, decedent, dependence, 
deviant (behaviour), deviant consumer, doctor shopper/shopping, excess use, excessive dose, 
excessive use, excessive user, extreme population, forgery behaviour, fraudulent behaviour, 
heavy shopper, high consumer, high risk use, high usage, high user, inappropriate dispensing, 
inappropriate prescription, inappropriate use, long term user, misuse, moderate user, 
multiple prescriber episode, occasional user, overconsumption, overconsumer, 
overutilisation, persistent use(r), pharmacy hopping, pharmacy shopper, potentially aberrant, 
potentially inappropriate use, potentially problematic use, probably problematic behaviour, 
problematic use(r), putative acceptable use, questionable activity, recurrent user, repeat 
user, shopper, shopping behaviour, transgression behaviour, or user.  
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2.3.2.1 Prescription drugs of interest 
All studies specified the drug class(es) of interest; the majority focused on opioids (35 
studies) and/or benzodiazepines (20 studies) (Table 2.1). Twenty-nine studies further 
detailed the specific drugs of interest; the most commonly investigated drugs were codeine 
(ten studies) and/or diazepam (nine studies). Eleven studies investigated a single drug, five 
of which focused on buprenorphine, for the indications of opiate maintenance therapy or 
pain. 
 
2.3.2.2 Cohort characteristics 
Thirty-nine studies investigated misuse in a drug-user cohort (dispensed drug of interest); 17 
in a misuse cohort (authors determined drug use or access pattern of cohort to be above 
the norms), 14 included both cohort types, and one did not define the user group. 
Approximately 93 million prescription drug-users were observed across the studies with 
considerable variability in cohort size (<100 persons to >25 million persons). Twenty-six 
studies used a comparison cohort differing from the other cohort most commonly due to 
the drug of interest (nine studies); nature, degree or extent of misuse (seven studies) or 
region of residence (five studies). Two studies matched the cohorts on specific variables, 
including month of index prescription, geographic area of dispensing pharmacy, prescriber 
specialty, age and/or number of prescriptions (total and for drugs with abuse potential). 
 
2.3.3 Measures of prescription drug misuse 
Fifty studies defined a measure with a specific misuse threshold (e.g. ≥4 prescribers) (Table 
2.2; SM 8). Overall, four metrics were the basis of the misuse measures, either alone or in 
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combination: number of prescribers, number of dispensing pharmacies, volume of drug(s) 
dispensed and/or overlapping prescriptions/early refills. 
 
Twenty-four studies used at least one stand-alone measure of misuse, 46 studies used at 
least one composite measure of misuse and 20 studies used both types of measures. Of the 
46 studies that used a composite measure, only five reported the proportion of the cohort 
exhibiting each component of a composite measure.31–35 The other studies did not detail the 
relative contribution of each component to the extent of misuse. 
 
2.3.4 The extent of prescription drug misuse 
The extent of misuse ranged from 0.01 to 93.5%, and was generally higher for stand-alone 
measures compared with composite measures (for the latter, individuals needed to exhibit 
at least two characteristics or behaviours, as opposed to one) (SM 8). The variability in the 
extent of misuse reported across the studies reflected the heterogeneity in methodology; 
more specifically, measures and thresholds of misuse, cohort definition and the time period 
of assessment. 
 
2.3.4.1 Measures and thresholds of misuse 
Overall, 89 unique definitions of misuse were identified across 50 studies; only 13 measures 
were utilised in two or more studies (32 studies in total). There appeared to be an attempt 
to use pre-existing measure(s) of misuse within, but not between, research groups; 
however, some groups changed their misuse measures between studies. 
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Table 2.2 Summary of measures with a defined threshold of prescription drug misuse (N=50 studies) 
Measure details 
(author-defined threshold of 
misuse behaviour) 
Stand-alone 
measure 
(24 studies) 
References 
Metric used in 
composite measure 
(46 studies) 
References Totala 
Number of prescribers  
(mode: 4; range: 2-7) 
9 37, 44, 64-70 32 
16, 34, 37, 39-43, 45-48, 65, 
67, 68, 70-86 36 
Number of dispensing pharmacies 
(mode: 4; range: 2-4) 
10 36, 37, 64, 67-70, 87-89 25 
34, 36, 37, 39-41, 43, 46, 48, 
67, 68, 70-73, 75, 78-82, 85, 
86, 88, 90 
29 
Volume of drug dispensed (including 
number of dispensings, and 
dispensed DDD) 
14 
35, 38, 65, 67-69, 85, 87, 
88, 91-95 23 
36, 38, 46, 65-68, 70, 72, 73, 75, 
77, 79, 80, 82-85, 88, 90-92, 94 28 
Overlapping prescriptions or early 
refills 
6 34, 35, 39, 68, 95, 96 21 
35, 39, 42, 43, 45-47, 68, 69, 
71, 74-78, 81, 85-87, 95, 96 22 
Use of specific prescribed drug (e.g. 
alprazolam) 
3 35, 69, 87 6 35, 69, 72, 73, 87, 95 6 
Duration of prescription drug use 
(e.g. >120 days use) 
2 87, 95 2 36, 69 4 
Dose escalation 
(e.g. 50% dosage increase in mean 
mg of drug in 2 months) 
2 68, 89 1 68 2 
Other 
(Latent analysis based on age, sex 
and method of payment) 
0 – 1 97 1 
DDD: defined daily dose; mg: milligrams 
a Number of unique studies investigating behaviour as a stand-alone and/or composite measure of misuse 
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Sixteen studies reported the number of prescribers and/or dispensing pharmacies accessed 
routinely by prescription drug-users. As thresholds increased, the proportion of the 
population exhibiting the behaviour decreased (Figures 2.2A and 2.2B). Importantly, the 
highest proportion of drug-users visited 1–2 prescribers or pharmacies when accessing their 
drug(s). Thirteen of these studies defined a threshold of misuse; nine studies (69.2%) set the 
threshold of misuse as ≥3 prescribers or dispensing pharmacies. The thresholds defining 
misuse impacts on the extent of the problem reported across studies. 
 
2.3.4.2 Cohort definition (prescription drug-user and misuse cohorts) 
Misuse was measured more frequently in drug-user cohorts (87 instances) than misuse 
cohorts (33 instances). The extent of misuse was most commonly ≤10% for drug-users (58 
instances, 66.7%) and ≥20% in misuse cohorts (23 instances, 69.7%). However, the extent of 
misuse ranged considerably between drug-user (0.01–63.2%) and misuse (0.2–93.5%) 
cohorts, reflecting the variation in the measures and thresholds utilised, and the cohort 
definition. A strict cohort definition increased the reported extent of misuse; misuse cohorts 
had stricter cohort definitions than drug-user cohorts. In general, for drug-user cohorts a 
high reported extent of misuse reflected a low threshold for misuse, and for misuse cohorts 
the higher the reported extent of misuse, the stricter the cohort definition. 
 
2.3.4.3 Time period of assessment 
Measures of misuse were assessed from 7 days to 4 years. The most commonly investigated 
time period was 12 months, utilised in 44% of instances of reporting misuse. Due to the 
heterogeneity of thresholds of misuse and cohort definitions, we were unable to make any 
further observations concerning the time period of assessment.  
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Figure 2.2 Variation in prevalence of prescription drug access and misuse according to 
thresholds  
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2.3.5 Factors associated with prescription drug misuse 
Fifteen studies investigated variations in the extent of misuse based on drug class (four 
studies), specific drug(s) (12 studies) and/or formulation(s) of interest (three studies) (SM 9). 
 
Four studies compared the extent of misuse across different drug classes based on the same 
measure of misuse within each study and found opioid misuse was higher than 
benzodiazepine misuse (no statistical comparisons were performed).36–39 
 
Six studies compared the extent of misuse for two or more drugs in the same class. In the 
opioid class, oxycodone (compared with tapentadol) and methadone (compared with 
morphine, oxycodone, fentanyl and hydrocodone) had a significantly higher risk of misuse-
related behaviour.40,41 Within the benzodiazepine class, three studies demonstrated that 
flunitrazepam had the highest extent of misuse compared with several other 
benzodiazepines.42,43 Within the antidepressant class, tianeptine (compared with mianserin) 
had the highest extent of misuse.44 However, no statistical comparisons were performed in 
the benzodiazepine or antidepressant studies. 
 
Three studies explored the influence of the drug formulation on the extent of misuse. A 
larger proportion of stronger benzodiazepines42 and short-acting opioids45 were dispensed 
to the misuse cohort compared with weaker or long-acting counterparts, respectively. 
 
2.3.6 Justification of measures of misuse 
Thirty-four studies reported a basic rationale for at least one measure of misuse by either 
citing previously published work (24 studies), mostly their own; using recommendations of 
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an expert panel (six studies); and/or via empirical analysis (14 studies). Ten studies utilised 
more than one method of justification. Eighteen studies (34.6%) did not report a rationale 
for their choice of measure of misuse. 
 
2.3.7 Comprehensiveness of reporting observational studies 
The median STROBE score was 27 (range: 19–33; IQR: 23–29) out of a possible 36. Many 
studies did not report basic cohort details, including sex (20 studies), age (18) and/or cohort 
size (8). Studies did not identify how they managed any bias (26), loss to follow up (39), 
missing data (39) or sensitivity analyses (38). Furthermore, 21 studies did not report the 
funding source. 
 
Forty studies were published from 2008, after the STROBE statement was published; the 
median STROBE score was 25.5 (range: 19–31; IQR: 22–30) for studies published prior to the 
STROBE statement, and 27 (range: 19–33; IQR: 24–29) for studies published after the 
STROBE statement. 
 
2.4 Discussion 
Our systematic review synthesised the global literature quantifying prescription drug misuse 
based on population-level, routinely collected data. Our aim was to examine the measures, 
extent and factors associated with prescription drug misuse. We found a high level of 
consistency in the behaviours measuring misuse across the 52 studies, reflecting common 
jurisdictional data holdings and the limited number of variables with the capacity to 
investigate misuse behaviour in routine data collections. However, due to the heterogeneity 
in thresholds of misuse, cohort definitions and time period of assessment, we were unable 
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to make definitive comparisons regarding the extent or factors associated with misuse 
across time or healthcare settings. Despite this significant limitation in the current literature, 
going forward, the international research community has the capacity to make significant 
and timely inroads in this field by developing and harmonising minimum reporting standards 
for a core set of pre-defined metrics. Our review and recommendations are timely and 
highly pertinent to the recent FDA call for submissions regarding the post-market 
surveillance of specific prescription opioids.24 
 
The harms associated with prescription drug misuse, particularly opioid misuse, have now 
reached epidemic proportions in many jurisdictions internationally.46,47 Despite the 
escalation in prescription drug use and consequences of misuse,8,48,49 we have limited 
knowledge about the extent of, and variations in, population-level misuse globally. We 
propose that a comprehensive and harmonised evidence-base, underpinned by routinely 
collected data, monitoring the extent of prescription drug misuse, will add significant value 
to the global effort in quantifying this problem. Moreover, this effort will enhance our 
understanding of the impact of policy responses attempting to address this problem. 
 
The use of dispensing claims for post-market drug surveillance is a cost effective means of 
monitoring longitudinal, population-level prescription drug use and misuse. Many regulatory 
and funding agencies use dispensing claims to monitor prescription drug use, misuse and/or 
diversion.23 In this review, we demonstrate routine dispensing data are used increasingly in 
peer-reviewed literature to explore prescription drug misuse, with over 60% of reviewed 
studies published since 2010. Findings from population-level, routinely collected 
dispensing/prescription data have the capacity to complement other methodological 
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approaches, such as detailed medical record reviews, surveys and in-depth qualitative 
studies, to enhance our understanding of prescription drug misuse. Moreover, linking 
dispensing claims with other routinely collected health data, such as hospitalisations and 
vital status will also provide further insight into the risk factors and drug access patterns 
related to harm. 
 
Our review has several limitations. It is not certain that all relevant studies were captured. 
Over 10,000 abstracts were reviewed and despite employing a comprehensive search 
strategy to identify relevant articles;50 14 studies were identified through back references, 
Scopus citations or Google Scholar searches, indicating the challenges of targeted searching 
and the diversity of keywords and subject headings used across studies. Articles that were 
not published in English were excluded; as nearly half of the included studies originated 
from Europe, we may have missed studies published in other languages.51,52 Our estimates 
of prescription drug misuse are solely from the perspective of the healthcare payer; we are 
unable to address access issues outside the dispensing episodes observed in the data 
including drugs obtained illegally. The STROBE guidelines were applied to all studies, 
irrespective of publication date. However, the results did not vary considerably for studies 
published prior to or post STROBE statement publication. A search of journal contents was 
not undertaken due to the diversity of journals where the studies were published (32 
unique journals published the 52 reviewed studies).52 These limitations do not impact our 
key findings. In fact, adding more studies is likely to contribute further to the heterogeneity 
we found across the field. Studies and metrics were categorised to synthesise the disparate 
literature. For example, misuse measures were categorised as stand-alone or composite 
measures. All measures based on a single metric (e.g. ≥4 prescribers in 6 months) applied to 
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a previously identified misuse cohort (e.g. ≥4 dispensing pharmacies in 6 months) were 
categorised as composite measures. These occurrences could have been categorised as 
stand-alone measures; however, this choice impacts on data presentation, not key findings. 
Finally, a key limitation of the literature is the notable absence of validation to establish 
whether the proxies actually measure misuse or are associated with harm.23 
 
Despite these limitations, this is one of the most comprehensive systematic reviews of this 
field to date. Our review was highly focused on measuring prescription drug misuse in 
routinely collected data. Other published reviews focused on jurisdiction-specific 
literature,23,47,53–56 self-report or medical chart data to ascertain use,47,55–57 specific drug 
classes23,53,54,57 or patient populations.54–57 The interpretation of these reviews were also 
impeded by the heterogeneity in study design54,56 and/or methods.47,54–56 However, the 
authors of these reviews did not suggest any practical solutions for unifying research in the 
field. Our recommendations provide a foundation that will increase the dialogue between 
researchers and unify future routine monitoring and post-market surveillance research (see 
section 2.4.1 Reporting recommendations). Our study complements two recent 
comprehensive reviews; one examining the patient, prescriber and environmental 
characteristics associated with opioid-related death,54 and the other an overview by FDA 
researchers of the appropriateness of US data sources for measuring prescription opioid 
abuse.23 
 
2.4.1 Reporting recommendations 
We have developed recommendations to harmonise the measurement and reporting of 
prescription drug misuse in routine data collections. These recommendations were not part 
77 
 
of the original study objectives; instead they are underpinned by our learning in this review, 
particularly the challenges we faced in identifying studies and comparing the extent of 
misuse across studies (Box 2.2). Our recommendations centre around three key areas: 
methodology (promotion of consistent metrics to determine appropriate measures of 
misuse), reporting (listing all drugs by generic name included in each study and the specifics 
of the misuse measures) and study nomenclature (where possible, consistency in the use of 
keywords including ‘prescription drug misuse’, that facilitate direct mapping to searchable 
subject headings). Future studies should combine these recommendations with the current 
standard reporting requirements for observational studies,26,27 which will support the 
current FDA initiative and add value across other jurisdictions.  
 
2.5 Conclusions 
Prescription drug misuse has reached epidemic proportions in the US and is fast increasing 
in other jurisdictions. Despite the consistency in data holdings and metrics used to define 
misuse in routine data collections we found considerable variation in measures of 
prescription drug misuse, cohort definitions and time period of assessment. The adoption 
and modification of policies targeting prescription drug misuse are easier to argue for, or 
against, when the impacts are measured robustly and reproducible effects have been 
demonstrated across multiple settings. Thus, having consistent metrics for prescription drug 
misuse across jurisdictions is a very simple step, but one with potentially far-reaching 
consequences. 
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Box 2.2 Recommendations for observational studies investigating prescription drug misuse 
We recommend researchers should state explicitly the following issues in each published 
manuscript: 
Methodology 
1. Detail the distribution of the metric(s) and the rationale for the threshold(s) for 
misuse 
Reporting 
2. List the generic name of all prescription drugs studied  
3. Detail cohort characteristics for every analysis undertaken 
4. Identify all metrics (variables) and thresholds used to measure misuse  
5. State the time period in which the metric(s) is measured (we recommend that 
studies should report misuse over at least a 6-month period) 
6. When using a composite measure of misuse, report the extent of misuse for each 
component and the composite 
Study identification 
7. Use ‘prescription drug misuse’ as a keyword or subject heading 
Study terminology   
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Chapter Three: An overview of the patterns of prescription opioid 
use, costs and related harms in Australia 
 
Prescription opioid use and associated harms have increased to concerning levels in many 
jurisdictions, particularly in the US and Canada. Therefore, it is not surprising that in our 
systematic review, opioid analgesics are the most commonly investigated drug class in 
relation to potential misuse. Several Australian studies have demonstrated increases in 
opioid use or harms for specific opioids, such as oxycodone and fentanyl, with a focus on 
specific Australian States. However, no Australian studies have quantified national opioid 
use and opioid-related harms for all PBS-listed opioids. 
 
In this chapter we present an ecological study examining three national, routinely collected, 
publically available datasets (pharmaceutical claims, hospitalisation claims and cause of 
death data) to examine national prescription opioid use and related harms over 20 years. 
 
This chapter is a reproduction of the following publication: 
Bianca Blanch, Sallie-Anne Pearson, Paul S. Haber. An overview of the patterns of 
prescription opioid use, costs and related harms in Australia. British Journal of Clinical 
Pharmacology. 2014; 78(5): 1159-1166. 
 
Formatting note: To increase the readability of viewing this thesis electronically, we provide 
all figures or tables on the page following its first citation in the text. The key points and 
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abstract are formatted according to the British Journal of Clinical Pharmacology style guide. 
We provide the reference list at the end of this chapter.   
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Key Points 
What is already known about this subject? 
 Prescribed opioid use is rising, particularly in the US and Canada, to treat cancer and 
non-cancer pain. 
 The consequences of prescribed opioid misuse are increasing, specifically in the US. 
 Currently, there is no Australian research demonstrating patterns/consequences of 
opioid utilisation for all opioids subsidised by the national reimbursement drug 
scheme. 
 
What does this study add? 
 In Australia opioid use is increasing, as is the cost to the government and the 
personal consequences of opioid use including number of hospitalisations and 
deaths. 
 Further research is required to understand the patterns of prescribed drug use to 
reduce/prevent associated adverse consequences.  
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Abstract 
Objective  
To report Australian population trends in subsidised prescribed opioid use, total costs to the 
Australian government to subsidise these drugs and opioid-related harms based on 
hospitalisations and accidental poisoning deaths. 
 
Methods  
We utilised three national aggregated data sources including dispensing claims from the 
Pharmaceutical Benefits Scheme, opioid-related hospitalisations from the National Hospital 
Morbidity Database and accidental poisoning deaths from the Australian Bureau of 
Statistics. 
 
Results  
Between 1992 and 2012, opioid dispensing episodes increased 15-fold (500 000 to 7.5 
million) and the corresponding cost to the Australian government increased 32-fold ($8.5 
million to $271 million). Opioid-related harms also increased. Prescription opioid-related 
hospitalisations increased from 605 to 1464 cases (1998–2009), outnumbering 
hospitalisations due to heroin poisonings since 2001. Deaths due to accidental poisoning 
(pharmaceutical opioids and illicit substances combined) increased from 151 to 266 (2002–
2011), resulting in a rise in the death rate of 0.78 to 1.19 deaths/100 000 population over 10 
years. Death rates increased 1.8 fold in males and 1.4 fold in females. 
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Conclusions  
The striking increase in opioid use and related harms in Australia is consistent with trends 
observed in other jurisdictions. Further, there is no evidence to suggest these increases are 
plateauing. There is currently limited evidence in Australia about individual patterns of 
opioid use and the associated risk of adverse events. Further research should focus on these 
important issues so as to provide important evidence supporting effective change in policy 
and practice. 
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3.1 Introduction 
There has been a long-standing role for opioid analgesics to treat patients with cancer pain. 
Over the past 20 years, the indication for opioids has expanded to treat acute and chronic, 
non-cancer pain. Opioids have been shown to be effective for short term pain relief but 
there is only limited evidence of the long term benefits of opioid use for any indication.1,2 As 
a consequence of extending these indications, opioid utilisation has increased significantly in 
many jurisdictions, most notably in the US.3–7 Increased use, coupled with prolonged use in 
patients with chronic non-cancer pain, have led to concerns on the part of policy makers, 
health professionals and the general public about population and individual risks and 
benefits of prescribed opioids.8,9  
 
Three professional bodies from the US and Australia have outlined concerns about the 
staggering increases in opioid use and the increase in related harms. However, they caution 
against strict regulations in accessing these prescription drugs for patients requiring pain 
relief.8–10  
 
There has been an increase in opioid use in Australia over the past 30 years.11–18 In 2013, 
there were 241 preparations for 12 opioid analgesics available for prescribing in Australia. 
Morphine (87 preparations), tramadol (48 preparations), fentanyl (43 preparations) and 
oxycodone (37 preparations) have the highest number of preparations (Table 3.1). Eight 
opioids are currently subsidised by the Pharmaceutical Benefit Scheme (PBS): 
buprenorphine, codeine, fentanyl, hydromorphone, methadone, morphine, oxycodone and 
tramadol. As of December 2013, four opioids are available for prescription in Australia, but 
are not PBS-listed; alfentanil, dextropropoxyphene, pethidine and tapentadol. 
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Table 3.1 The number of opioids available in Australia for prescription 
Opioids available in 
Australia for prescription 
Number of opioid 
preparations available in 
Australiaa for analgesia 
Number of opioid preparations 
available in Australiaa to treat 
opiate maintenance therapy 
Alfentanil 2 0 
Buprenorphine 5 5 
Codeine 2 0 
Dextropropoxyphene 1 0 
Fentanyl 43 0 
Hydromorphone 5 0 
Methadone 2 5 
Morphine 87 0 
Oxycodone 37 0 
Pethidine 4 0 
Tapentadol 5 0 
Tramadol  48 0 
TOTAL 241 10 
a A preparation is defined as an entry in the ‘narcotic analgesics’ section of MIMS regardless of PBS 
status, pack size and preparation. This reflects the product range available to prescriber and 
consumer (MIMS data accessed 27 September 2013). 
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In Australia, studies have investigated the harms related to the use of specific opioids such 
as oxycodone, fentanyl and morphine.14,15,18 This paper updates our previous report11 on 
trends in PBS-subsidised opioid use in Australia. We also report the total costs to the 
Australian government to subsidise these prescription drugs. Lastly, we report the opioid-
related harms based on hospitalisations and accidental deaths. 
 
3.2 Methods 
3.2.1 Setting 
In 2012, the population of Australia was approximately 22.7 million. Australia has a 
publically funded universal healthcare system entitling all citizens and permanent residents 
to a range of subsidised health services including free treatment in public hospitals and 
subsidised treatment in private hospitals. It also includes a range of subsidised outpatient 
services including consultations with clinicians and prescribed drugs. These arrangements 
place Australia in a unique position to analyse patterns of prescription drug utilisation and 
reported harms at a population level. 
 
3.2.2 Data sources and method 
Three national publically available, online aggregated data sources were utilised to report 
patterns of PBS-listed opioid utilisation and costs to the government; number of 
hospitalisations due to opioid poisonings, and number of accidental deaths related to illicit 
drugs and pharmaceutical opioids. 
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3.2.3 Prescribed opioid use and costs 
The PBS is a national drug reimbursement system subsidising a range of prescribed drugs. 
PBS dispensing records are available in aggregate (de-identified) form via Medicare Australia 
(http://www.medicareaustralia.gov.au/provider/pbs/stats.jsp) where data queries can be 
performed to establish volume and costs of specific PBS-item numbers according to time 
periods of interest. We report the number of dispensing episodes and cost to the 
government for the eight PBS-listed opioids by calendar year from 1992 to 2012 inclusive. 
We do not report volume of combination drugs, nor population-, age- or sex-adjusted data. 
 
There are several limitations associated with PBS data. The dispensing of a PBS drug is not 
recorded in the database if: the Commonwealth does not contribute to the cost of the drug; 
it is given within some public hospital settings; or the indication is to treat an opiate 
maintenance therapy (drugs for this indication are funded by the Section 100 Highly 
Specialised Drugs Program). Consequently, there is under-ascertainment of PBS-listed drugs 
that fall below the general beneficiary copayment. In 2013, 78 of the 146 PBS item numbers 
related to an opioid preparation were priced under the general beneficiary copayment of 
AU$36.10. It is not possible to report the number of opioids priced under the copayment 
per year so we cannot determine the extent to which the data presented underestimates 
total use. We cannot determine the indication for opioid use (i.e. cancer or non-cancer 
pain), as the same PBS-item number is used for both indications. We excluded opioids that 
are listed on the Pharmaceutical Benefits Scheme for the indication of palliative care 
exclusively including fentanyl lozenges (PBS item numbers: 5401G, 5402H, 5404J, 5404K, 
5405L, 5406M, 5407N, 5408P, 5409Q, 5410R, 5411T, 5412W). 
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3.2.4 Opioid-related hospitalisations 
The National Hospital Morbidity Database (NHMD) reports hospitalisations in Australia, 
since July 1993. In this context, a hospitalisation refers to the completion of treatment for 
an admitted patient due to death, discharge or transfer to another facility. Each 
hospitalisation is coded according to the International Classification of Diseases (ICD). We 
report the number of hospitalisations for any opioid-related poisoning, either prescribed or 
illicit, by financial year (from July 1 to June 30) from 1998 to 2009 inclusive, hereafter 
referred to as year. These are coded according to the ICD and related health problems, 10th 
revision, Australian modification (ICD-10-AM).19 In 1998 the codes across Australian 
jurisdictions changed to ICD-10 codes, to ensure the reported data are consistent and 
comparable, therefore we chose to limit the date range. We present the hospitalisations 
where the ICD-codes indicate the principal diagnosis as a poisoning due to ‘other opioids’ 
(T40.2) (includes morphine, oxycodone and codeine), methadone (T40.3) and ‘other and 
unspecified narcotics’ (T40.6). We also present heroin-related (T40.1) hospitalisations to 
track changes over time. The total number of opioid-related poisonings reported are the 
sum of hospitalisations using these ICD-10 codes only.20,21 
 
The NHMD is a national dataset compiled from data supplied by the State and Territory 
health authorities. However, one Australian state (South Australia) did not contribute to the 
data from 1999 to 2001 inclusive. Over-the-counter and prescription codeine preparations 
may contribute to the ‘other opioids’ poisoning category as the database does not 
differentiate between these preparations. The NHMD relies on individual coders at each 
hospital to enter data accurately and consistently regarding principal diagnosis, which is of a 
high standard in Australia.22 Hospital data are likely to under-ascertain the true number of 
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pharmaceutical opioid-related poisonings as they may not be recognised or accurately 
recorded by clinicians, and hospital coders may under-detect such diagnoses. 
 
3.2.5 Accidental poisoning deaths 
Cause of death data were obtained from the Australian Bureau of Statistics (ABS), Causes of 
Death, 2011 report.23 The cause of death included in this report is ‘accidental poisoning by 
and exposure to narcotics and hallucinogens not elsewhere classified’ (ICD-10 code X42). 
We report the number of deaths for each calendar year from 2002 to 2011 inclusive. We 
calculated the rate of death based on the number of deaths and ABS reported Australian 
population per year. 
 
This is a national dataset recording cause of death based on death certificate data. The ICD-
10 code X42 excludes deaths with suicidal or homicidal intent, or where the drug dosage is 
consistent with therapeutic doses. These data record accidental poisoning deaths caused by 
codeine, pharmaceutical opioids [methadone, morphine and opium (alkaloids)] and non-
pharmaceutical drugs (cannabis, cocaine, heroin, lysergide and mescaline). The ABS cause of 
death coding does not distinguish between pharmaceutical and illicit substances, therefore 
it is not possible for us to delineate the contribution of each cause of death in the data. 
Death certificate data are likely to under-ascertain the true number of pharmaceutical 
opioid-related poisonings as the cause of death may be attributed to other outcomes such 
as cardiac arrest or respiratory depression.  
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3.3 Results 
3.3.1 Prescribed opioid use and costs 
Between 1992 and 2012, there was a 15-fold increase in the number of PBS-listed opioid 
dispensing episodes (500 568 to 7 495 648) (Figure 3.1A). Oxycodone has been the main 
contributor to the increase in opioid utilisation. The most striking recent trend has been the 
escalating use of buprenorphine and fentanyl for the treatment of pain. This finding reflects 
buprenorphine use for the indication of pain only, as data on drugs used to treat opiate 
maintenance therapy are not available through this data source.
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Figure 3.1B Benefits paid by the Australian government for opioid analgesics in Australia: 1992 – 2012.  
 
Figure 3.1A Number of dispensing episodes for opioid analgesics by medicine in Australia: 1992 – 2012.  
 
104 
 
In 1992, the Australian government paid approximately $8.5 million (for 500 568 dispensing 
episodes) in subsidies for PBS-listed opioids, increasing to $270.8 million (for 7.5 million 
dispensing episodes) in 2012, a 32-fold increase (Figure 3.1B). In 2012, oxycodone 
preparations accounted for 38% of the total number of dispensing episodes (2.8 million) and 
34% of the benefits paid ($92.7 million). The cost of buprenorphine and fentanyl to the PBS 
are rising at a striking rate and now rank second and third in terms of opioid-related costs, 
respectively. Since 2009, the combined annual cost of buprenorphine and fentanyl has 
exceeded the annual cost of oxycodone. 
 
3.3.2 Opioid-related harms 
In 1998, 65% of hospitalisations due to opioid poisoning were attributable to heroin and 
23% due to ‘other opioids’. In 2001, ‘other opioids’ overtook heroin as the leading cause of 
opioid-related hospitalisations; by 2009, ‘other opioids’ accounted for 58% (Figure 3.2). 
There was a decline in the total number of opioid poisonings from 1999 to 2002 but since 
2005 the number of opioid-related poisonings has increased primarily due to ‘other opioids’. 
Methadone and ‘other and unspecified narcotics’ hospitalisation numbers have remained 
stable over this time period. 
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Figure 3.2 Number of hospitalisations by opioid poisoning type across Australia: 1998 – 2009. 
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3.3.3 Accidental poisoning deaths 
The number of accidental deaths due to pharmaceutical opioids and other illicit substances 
increased from 151 in 2002 to 266 in 2011 (Figure 3.3), representing a 1.7-fold increase. The 
rate of increase was higher for males (1.8-fold) than females (1.4-fold). The rate of 
accidental poisoning deaths increased over the time period from 0.78 to 1.19 deaths per 
100 000 population. 
 
3.4 Discussion 
This report confirms and extends previous findings documenting the escalation of 
prescription opioid use in Australia. This study found that opioid utilisation has continued to 
increase at a striking rate since our previous report just 5 years ago.11 The use of 
buprenorphine and fentanyl combined has escalated since that report and their combined 
total cost to government now exceeds that for oxycodone. We found an increase in the past 
decade in the number of hospitalisations related to prescribed opioids and the number of 
accidental deaths due to illicit drugs and pharmaceutical opioids. These data indicate the 
need for broad new strategies to manage opioid use.  
 
A number of explanations may account for the exponential increase in opioid utilisation in 
Australia in the past 20 years including changes in PBS listings, prescriber/patient preference 
for specific opioids, the ageing population, increase in prevalence of pain and/or reduced 
availability of illicit drugs.  
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Figure 3.3 Number of accidental deaths due to illicit drugs and pharmaceutical opioids in Australia: 2002 – 2011 
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The increase in opioid dispensing may reflect PBS-listing changes. The increase in oxycodone 
and tramadol dispensing from 2000 (Figure 3.1A) is likely due to the extension of the PBS-
listings for opioid analgesics to treat both cancer and non-cancer pain.24 Moreover, in 2004 
the maximum quantity and number of repeat PBS prescriptions allowed to be prescribed 
per physician visit increased for strong opioids including oxycodone, hydromorphone, 
methadone and morphine. Tramadol is a weaker analgesic compared with these opioids and 
it appears that when doctors were given the opportunity to prescribe larger quantities of 
stronger opioids, the rate of tramadol dispensing decreased. Despite the broadening of 
restrictions for all opioids, oxycodone has experienced the greatest increase in dispensing. 
These data suggest the increase in pack size of oxycodone influenced prescribing practices.  
 
A recent Australian study found a significant proportion of older persons initiating 
oxycodone for non-cancer pain had not been treated in the previous 12 months with any 
other analgesic.25 This is a concern as PBS-listed opioids are funded as ‘second line 
treatment for pain not relieved by non-narcotic analgesics’ such as paracetamol. This may 
be due to Australian prescribers being less aware of the best practice prescribing guidelines 
for analgesia. An alternate explanation may be due to prescriber preference. In Denmark, 
hospital physicians and general practitioners preferred to prescribe oxycodone over 
morphine to opioid naïve patients,26 and in Spain, oxycodone and fentanyl may be 
prescribed instead of morphine, due to the latter drugs association with the end of life.27 
 
Australia’s ageing population may also account for the observed increase in opioid 
utilisation. Of all oxycodone and fentanyl dispensed, the rate of utilisation in the ≥80 
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year age group is higher than any other age group.14,15 Rates of concomitant prescription 
drug use are also high in the elderly,28 as well as an increased sensitivity to drug toxicity 
suggests opioid-related harm may be a particular issue in this age group. 
 
The prevalence of pain has increased at a population level in Australia since 1995, 
consequently we would expect an increase in the demand for analgesia. According to 
Australia’s National Health Survey, the reported prevalence of body pain was 57% in 1995 
and increased to 68% in 2008 as assessed by the SF-36, a validated quality of life measure. 
Similarly, there was an increase in self-reported severe/very severe pain, from 7% in 1995 to 
10% in 2008.29 Despite the increase in opioid use and availability of different opioids and 
formulations, there remain many cases where pain is undertreated.30 
 
The limited availability of illicit drugs may also impact on prescribed opioid utilisation. 
Australia experienced a heroin drought in 2001, and due to the reduction of heroin 
availability, some drug seekers may have sought pharmaceutical opioids as a 
replacement.13,31  
 
3.4.1 Cost of opioid utilisation 
Since 1992, the Australian government paid over $2 billion in prescription opioid subsidies. 
The cost of opioids has risen significantly in the past 5 years, primarily due to the increase in 
dispensing of buprenorphine and fentanyl. The newer opioids are more expensive as they 
include controlled release preparations. This increased rate of prescribing most likely 
accounts for the extraordinary 32-fold increase in cost to the government compared with 
the 15-fold increase in opioid dispensing episodes. This is likely to be of concern for the 
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Australian government, as the utilisation and hence cost to the government for these 
opioids is yet to plateau (Figures 3.1A and 3.1B). 
 
Of note is the escalating cost of buprenorphine and fentanyl. Since 2005, the PBS has 
subsidised buprenorphine transdermal patches to treat pain costing between $24.67 and 
$56.18 per dispensing. The buprenorphine patch singularly accounts for all buprenorphine 
use and has been the driver for increased buprenorphine use in other jurisdictions.27,32 For 
fentanyl, the transdermal patch and lozenge are PBS-subsidised. From 2006 to 2008 the 
fentanyl patch was the only PBS-listed fentanyl formulation costing between $41.53 and 
$171.63 per dispensing. The lozenge was introduced in 2008 costing between $114.62 and 
$680.23 per dispensing and used exclusively in palliative care. We note the significant 
upward trend in number of dispensings and cost did not appear to be impacted by the 
introduction of the lozenge, meaning that the patch is likely the biggest contributor to 
volume and cost. Other jurisdictions have also reported the transdermal patch to be the 
primary driver of increased fentanyl use.27,32,33 
 
3.4.2 Opioid-related harms 
There is a plethora of literature reporting the medical harms associated with opioid 
use14,15,34–44 and all of these findings indicate opioid-related harms are increasing. 
 
Based on publically available data we were able to examine opioid-related hospitalisations 
and accidental poisoning deaths, both of which have been increasing since the early 2000s. 
These patterns are consistent with the US with one notable exception. In Australia, between 
2002 and 2011 the rate of increase in opioid-related deaths was higher in males (1.8-fold) 
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than females (1.4-fold). In contrast, in the US, between 1999 and 2010, the rate of increase 
for opioid-related deaths was higher for females (400%) compared to males (265%).45 
However, the absolute number of overdose deaths in males exceeded the number in 
females in both countries. One explanation for this discrepancy may be the inclusion of illicit 
drugs in the Australian cause of death data, as males are more likely to overdose on illicit 
substances than females.  
 
The strengths of this report include combining multiple national data sources to document 
opioid prescription availability, utilisation, costs and related harms in the Australian context. 
To our knowledge, no previous Australian study has synthesised the information presented 
from these data sources to describe the rise and consequences of an increase in the use of 
all PBS-funded opioids. This overview also demonstrates the wide array of high quality data 
freely available documenting trends of opioid use, costs and harms that can be utilised to 
assess the effectiveness of strategies to contain usage. 
 
This paper relies on routinely collected datasets, which are not without limitations as 
described above. One of the main limitations of the PBS dataset is it underestimates whole-
of-population use, making the accuracy of the trends uncertain and all interpretations are 
subject to this limitation. However, a recent study analysing data from the state of 
Queensland found that PBS data correlate closely with data derived from State-based 
mandatory reporting for all Schedule 8 (drugs with a high abuse potential) opioid 
prescriptions.17 All opioids reported in this study are Schedule 8, except tramadol, listed as a 
Schedule 4 drug indicating a reduced risk of abuse.  
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The present study shows that opioid use is increasing in Australia, with no sign of 
stabilisation. Within the same time period, the number of opioid-related hospitalisations 
and deaths has also increased. A national pharmaceutical drug strategy has been devised46 
but does not appear to have impacted on the rising opioid use to date. We recommend 
further population based studies exploring individual level data on opioid use. Such studies 
could assess the safety of opioids through identifying risky prescribing patterns, ensure 
prescribing patterns are consistent with health policy guidelines and limit concomitant use 
of opioids with other potentially dangerous drugs such as benzodiazepines, particularly in 
the elderly. We also need to understand patterns of prescription drug use that may indicate 
evolving dependence on opioids. This information could in turn be communicated to 
prescribers to guide interventions aimed at preventing opioid dependence and consequent 
harms. 
 
3.5 Conclusions 
Opioid analgesics are effective in treating both cancer and non-cancer pain. However, the 
ongoing increase in opioid utilisation and related harms in Australia demonstrates there is 
an urgent need for further research to understand patterns of opioid use that moves from 
aggregated data to individual level analyses for the Australian population. Through this 
research we hope to generate strategies to optimise the use of opioid analgesics and pain 
relief with minimal complications. 
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Chapter Four: Benchmarking prescription drug access patterns in 
dispensing claims: a method for identifying high and potentially 
harmful opioid use in Australia and Canada? 
 
Our systematic review in Chapter Two highlighted the major methodological limitations in 
quantifying prescription drug misuse based on pharmaceutical claims. The dominant 
approach is to dichotomise use and misuse based on a specific measure with generally 
limited empirical evidence justifying these choices. Few studies reported the spectrum of 
prescription drug access. Reporting the spectrum of use or access across jurisdictions and 
drug classes will allow us to: understand the norms of drug access and assess what factors 
may impact on access including abuse potential, policies, healthcare setting/arrangement 
and patient factors. Over the next three chapters, we present two methodologies to 
examine prescription opioid use and access using alternative methods to those 
predominantly used in the global literature.  
 
In this chapter, we examine the spectrum of opioid access, based on number of unique 
prescribers, and compare against statins, a drug class with no known abuse potential. This 
approach will allow us to compare access patterns and identify differences based on abuse 
potential of the drug class. This method was replicated in British Columbia, Canada, to 
determine whether prescriber access patterns for both drug classes are similar across 
jurisdictions with universal healthcare arrangements.  
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This chapter is currently under consideration for publication; it has been peer-reviewed 
twice by the Journal of Pharmaceutical Health Services Research; we responded to 
reviewers’ comments on 7 November 2016.  
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Key Points 
 We used number of unique prescribers to measure access patterns for opioids and 
statins and found the vast majority of persons visited one or two prescribers to 
access both prescription drug classes in 2011, which was consistent across 
jurisdictions.  
 Accessing ≥4 prescribers represents unusual drug access patterns for both 
prescription drug classes; however, the number of persons accessing ≥7 prescribers 
was at least 35-fold higher in opioids compared to statins in both Australia and 
British Columbia. 
 Our benchmarking approach has the potential to inform post-market surveillance 
activities and flag outlying access patterns; however, further research is required to 
validate this measure. 
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Abstract 
Objective 
We use dispensing claims to benchmark prescriber access patterns for opioids against 
statins (a drug class with no known abuse potential) in Australia and British Columbia, 
Canada. 
 
Study design  
Observational cohort study. 
 
Methods  
We used pharmaceutical claims from the Australian Pharmaceutical Benefits Scheme and 
British Columbian PharmaCare. Specifically, we used individual-level claims in adults with 
complete capture of subsidised prescription drugs and ≥1 opioid or statin dispensing(s) in 
2011. We report the distribution of unique opioid and statin prescribers overall, by age and 
jurisdiction.  
 
Results  
In 2011, the vast majority of persons visited one or two prescribers to access opioids and 
statins (Australia: 86.0% vs. 91.5%; British Columbia: 90.2% vs. 92.1%, respectively). The 
proportion of persons accessing ≥4 prescribers was higher for persons dispensed opioids 
compared to statins (Australia: 6.5% vs. 1.3%; British Columbia: 4.2% vs. 1.7%, respectively). 
For opioids, a greater proportion of persons aged <65 years accessed ≥4 opioid prescribers 
compared to their older counterparts (≥65 years); these differences were more pronounced 
in British Columbians receiving income assistance. 
123 
 
 
Conclusions  
Benchmarking the entire spectrum of use for specific prescription drug classes could provide 
a useful tool for informing post-market surveillance activities and may identify potentially 
problematic drug access behaviour(s).  
 
  
124 
 
4.1 Introduction 
Prescription opioid use and related harms have increased globally.1 In the period 2002-2011, 
prescription opioid use at least doubled in Australia, Canada and US,2, 3 accompanied by 
considerable increases in opioid-related hospitalisations and deaths.4-7 Not surprisingly, the 
increase in opioid consumption and associated harms have raised concerns regarding 
prescription opioid misuse, abuse and addiction and identified the need for a public health 
response to promote the safe and appropriate use of opioids. The first necessary step to 
evidence-informed action is to quantify the extent of the problem. Consequently, in 2014 
the US Food and Drug Administration endorsed the use of population-based routinely 
collected health data, including pharmaceutical claims, to quantify opioid misuse.8  
 
We recently published a systematic review synthesising 13 years of international literature 
to identify common methods for examining prescription drug misuse in pharmaceutical 
claims.9 Across the 52 reviewed studies, opioids were the most frequently studied drug class 
and accessing multiple prescribers (or ‘doctor shopping’) was the most commonly used 
metric to define misuse.9, 10 Access patterns were frequently dichotomised with a threshold 
applied to delineate use from misuse. These thresholds varied between studies and were 
generally informed by existing literature or expert opinion. Importantly, few studies 
explored the full spectrum of access patterns, reported the norms of access or compared 
prescriber access patterns across drug classes with varying abuse potential. Our review also 
highlighted that younger persons were more likely to ‘doctor shop’ or visit a larger number 
of prescribers to access opioids compared with their older counterparts.11-14 
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Therefore, our objective is to use pharmaceutical claims to benchmark (or compare) opioid 
prescriber access patterns against a drug class with no known abuse potential. Specifically, 
we will contrast opioid and statin access patterns, overall and by age. We will apply this 
methodology in Australia and British Columbia, Canada to demonstrate the utility of 
benchmarking prescription drug access patterns across different healthcare settings. 
 
4.2 Methods 
4.2.1 Study design  
This was an observational study of persons with ≥1 opioid or statin dispensing(s) across two 
healthcare settings. The study analysed data from the calendar year of 2011, the latest 
common year of data across jurisdictions.  
 
4.2.2 Settings 
Australia and Canada have universal healthcare arrangements including subsidised access to 
prescription drugs via Australia’s Pharmaceutical Benefits Scheme (PBS)15 and PharmaCare 
in British Columbia.16 In 2011, the population of Australia and British Columbia were 21.5 
and 4.4 million respectively. 
  
4.2.3 Data sources  
4.2.3.1 Australia  
The Australian Government Department of Human Services (DHS) provided a de-identified, 
standardised dataset of drug dispensing claims from a random 10% sample of PBS 
beneficiaries.15 To ensure complete ascertainment of dispensings, we restricted our 
Australian analyses to individuals with concessional beneficiary status (low income, 
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unemployment, sick, disability, single parent or aged pensioners) for the entirety of 2011. 
Concessional beneficiaries have a lower copayment threshold (AU$5.60 in 2011) than 
general beneficiaries (AU$34.20 in 2011); consequently, all PBS-dispensed drugs for the 
former attract government reimbursement. Concessional beneficiaries represent 25% of the 
PBS-eligible Australian population.17 Dispensing records included: patient unique identifier, 
sex, month/year of birth, Anatomical Therapeutic Chemical (ATC) classification code,18 date 
of supply, formulation, strength, quantity dispensed, beneficiary status and prescriber 
unique identifier.  
 
4.2.3.2 British Columbia  
Population Data British Columbia provided de-identified data for all British Columbians, with 
the exception of beneficiaries of federal health programs (4% of the population whose 
dispensing records were not recorded in our dataset). Pharmaceutical data for British 
Columbians were from PharmaNet, a province-wide system capturing all drugs dispensed at 
retail pharmacies. Residents of British Columbia were covered by a universal, income-based 
drug plan (Fair PharmaCare) that involved deductibles set as a percentage of household 
income. A minority of these British Columbian residents received income assistance 
(PharmaCare Plan C) and did not pay any copayments under the PharmaCare program. 
Persons eligible for income assistance comprised 4% of the total British Columbian 
population in 2011. Dispensing records included all variables available in our Australian data 
(excluding beneficiary status) as well as days of therapy, cost and type of coverage. 
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4.2.4 Prescription drugs of interest 
We included all publically subsidised opioid analgesics and statins with ATC codes N02A and 
C10AA respectively. Opioid analgesics were listed on both schemes to treat episodic, 
chronic, cancer or non-cancer pain, in contrast, statins lower blood cholesterol levels and 
were prescribed for both primary and secondary prevention of cardiovascular disease. 
Statins were chosen as the comparator drug class as they are commonly dispensed in both 
jurisdictions and have no known abuse potential. Supplementary Table 4.1 details the 
prescription drugs common and unique to each jurisdiction.  
 
4.2.5 Cohort inclusion criteria 
We derived two cohorts based on dispensing history for prescription drugs of interest in 
each jurisdiction; persons could be part of both the opioid and statin cohorts. The cohorts in 
both jurisdictions included persons aged ≥18 years (as of January 1, 2011), ≥1 opioid or 
statin dispensing(s) in 2011 and alive for the entire year (Supplementary Figure 4.1A). 
 
To ensure complete capture of subsidised prescription drugs for all individuals in each 
jurisdiction, the Australian cohort was restricted to persons with a concessional beneficiary 
status for the entire year and the British Columbian cohort was restricted to residents living 
in the province for all of 2011. We also stratified the British Columbian cohort by receipt of 
income assistance19 defined as ≥1 opioid or statin dispensing(s) in 2011 reimbursed by 
PharmaCare Plan C. Of note, these individuals may not have received income assistance for 
the entirety of 2011. Persons receiving income assistance comprised 10.5% of the opioid 
cohort and 5.4% of the statin cohort in British Columbia (Supplementary Figure 4.1B).  
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To ensure complete capture of subsidised prescription drugs for all individuals in each 
jurisdiction, the Australian cohort was restricted to persons with a concessional beneficiary 
status for the entire year and the British Columbian cohort was restricted to residents living 
in the province for all of 2011. We also stratified the British Columbian cohort by receipt of 
income assistance19 defined as ≥1 opioid or statin dispensing(s) in 2011 reimbursed by 
PharmaCare Plan C. Of note, these individuals may not have received income assistance for 
the entirety of 2011. Persons receiving income assistance comprised 10.5% of the opioid 
cohort and 5.4% of the statin cohort in British Columbia (Supplementary Figure 4.1B).  
 
4.2.7 Statistical analysis 
Our primary outcome measure was number of unique prescribers of dispensed opioids or 
statins in 2011. In both jurisdictions, we report the distribution of number of prescribers 
visited to access these drugs overall and by age group (18-44; 45-64; ≥65 years), and in 
British Columbia, by persons receiving income assistance. The Australian analyses were 
completed using SAS 9.2 (SAS Institute Inc., Cary, NC, USA) and the British Columbian 
analyses were completed using Stata 13.1 (College Station, TX: StataCorp LP).  
 
4.3 Results 
4.3.1 Cohort demographics 
The opioid cohorts in both jurisdictions were predominantly female (Australia: 59.6%; 
British Columbia [all]: 53.0%). The Australian and British Columbian cohorts had median 
ages of 64 (interquartile range [IQR]: 45-75) and 51 (IQR: 38-64) years respectively (Table 
4.1). In Australia in 2011, codeine (27.8%) and oxycodone (25.6%) together comprised more 
than half of all opioid dispensings. In British Columbia, codeine alone accounted for almost 
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half (46.7%) of all opioid dispensings, while oxycodone dispensings were comparatively low 
(11.7%) (Table 4.2).  
 
The Australian statin cohort was predominantly female (55.2%) while the British Columbian 
statin cohort was mostly male (43.2% female). The median ages were 71 (IQR: 65-78) and 66 
(IQR: 58-75) years respectively. 
 
Approximately, 10.5% of British Columbians dispensed an opioid in 2011 received income 
assistance (Supplementary Figure 4.1B), yet they obtained approximately one-quarter 
(27.6%; n = 594 689) of all opioid dispensings (Table 4.2). Furthermore, 5.4% of British 
Columbians dispensed a statin in 2011 received income assistance (Supplementary Figure 
4.1B) and obtained 10.7% (n = 264 088) of all statin dispensings (Table 4.2).  
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Table 4.1 Cohort demographics 
 Australia British Columbia 
All Income Assistance 
Opioid users (N) 118 125 482 591 50 633 
Age (median, IQR) 64 (45-75) 51 (38-64) 48 (37-56) 
Age groups (N, %)    
18-44 years 28 752 (24.3) 173 875 (36.0) 20 473 (40.4) 
45-64 years 31 424 (26.6) 195 585 (40.5) 25 613 (50.6) 
≥65 years 57 949 (49.1) 113 131 (23.4) 4 547 (9.0) 
Female sex (N, %) 70 369 (59.6) 255 174 (53.0) 25 038 (49.4) 
 
Statin users (N) 
 
147 728 
 
397 345 
 
21 267 
Age (median, IQR) 71 (65-78) 66 (58-75) 59 (52-67) 
Age groups (N, %)    
18-44 years 3 672 (2.5) 15 715 (4.0) 2 045 (9.6) 
45-64 years 30 812 (20.9) 169 191 (42.6) 12 866 (60.5) 
≥65 years 113 244 (76.7) 212 439 (53.5) 6 356 (29.9) 
Female sex (N, %) 81 542 (55.2) 171 554 (43.2) 10 162 (47.8) 
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Table 4.2 Three most frequently dispensed prescription drugs by class and jurisdiction (2011) 
 Australia (%) British Columbia 
  All (%) Income Assistance (%) 
Opioid dispensings 
(N) 
737 016 2 155 678 594 689 
Codeine (27.8) 
Oxycodone (25.6) 
Tramadol (20.4) 
Codeine (46.7) 
Morphine (14.2) 
Hydromorphone (14.2) 
 
Codeine (42.5) 
Morphine (27.1) 
Hydromorphone (14.6) 
Statins dispensings 
(N) 
1 444 407 2 417 617 264 088 
Atorvastatin (47.3) 
Rosuvastatin (24.8) 
Simvastatin (22.0) 
Atorvastatin (45.8) 
Rosuvastatin (31.0) 
Simvastatin (19.1) 
Atorvastatin (48.6) 
Rosuvastatin (27.6) 
Simvastatin (20.2) 
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4.3.2 Number of unique prescribers  
4.3.2.1 Overall prescriber access patterns  
In Australia and British Columbia (all), most people accessed one or two prescribers for 
opioids (86.0% in Australia and 90.2% in British Columbia) and statins (91.5% in Australia 
and 92.1% in British Columbia) (Figures 4.1A-C; Table 4.3). The majority of the British 
Columbian income assistance group also accessed one or two prescribers, but the 
proportion of persons with this access pattern were lower for both opioids (74.0%) and 
statins (85.0%) compared to the entire British Columbian cohort. In both jurisdictions, the 
proportion of persons accessing ≥4 prescribers was higher for opioids than statins (Australia: 
6.5% and 1.3%; British Columbia [all]: 4.2% and 1.7%; [income assistance]: 14.3% and 4.9% 
respectively). Further, a greater proportion of persons visited ≥7 prescribers to access 
opioids (Australia: 1.1%; British Columbia [all]: 0.7%; [income assistance]: 3.4%) than statins 
(≤0.3% in Australia, British Columbia [all] and [income assistance]). The 99th centile of the 
number of unique prescribers was higher for opioids than statins in both Australia (opioids: 
7; statins: 4) and British Columbia ([all]: opioids: 6; statins: 4), particularly for British 
Columbians receiving income assistance (opioids: 10; statins: 5). 
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Figure 4.1A Australia 
Figure 1b. British Columbia: all 
Figure 1c. British Columbia: income 
assistance 
 
Figure 4.1C British Columbia: income assistance 
Figure 4.1B British Columbia: all 
 
 Figure 4.1 Violin plot distribution of unique number of prescribers by drug class and 
jurisdiction 
  
 
Legend: 1st to 84th centiles in grey (median 
= 1 prescriber for all groups); 85th to 94th 
centiles in dark grey; ≥95th centiles in black. 
Mean = red line. 
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Table 4.3. Comparison of unique number of prescribers by prescription drug class and age group in Australia and British Columbia (2011) 
 
Number of unique 
prescribers  
(age group [years]) 
    Australia British Columbia 
All Income Assistance 
Opioid (%) 
N = 118 125 
Statin (%) 
N = 147 728 
Opioid (%) 
N = 482 591 
Statin (%) 
N = 397 345 
Opioid (%) 
N = 50 633 
Statin (%) 
N = 21 267 
1 prescriber 
All ages 
 
66.1 
 
63.9 
 
72.8 
 
68.0 
 
50.8 
 
57.8 
18-44 
45-64 
≥65 
 
2 prescribers 
All ages 
18-44 
45-64 
≥65 
68.4 
63.8 
66.1 
 
 
19.9 
17.8 
20.5 
20.7 
65.0 
62.1 
64.3 
 
 
27.6 
25.1 
28.4 
27.5 
76.2 
70.6 
71.3 
 
 
17.4 
15.0 
18.3 
19.5 
70.8 
68.4 
67.4 
 
 
24.1 
21.2 
23.6 
24.6 
51.5 
49.0 
57.9 
 
 
23.2 
22.2 
23.9 
24.2 
57.0 
57.3 
59.2 
 
 
27.2 
26.5 
27.2 
27.6 
 
3 prescribers 
All ages 
18-44 
45-64 
≥65 
 
 
7.5 
6.4 
8.3 
7.6 
 
 
7.2 
7.6 
7.9 
7.0 
 
 
5.6 
4.7 
6.3 
6.0 
 
 
6.2 
5.7 
6.2 
6.3 
 
 
11.6 
10.6 
12.7 
10.1 
 
 
10.1 
10.0 
10.4 
9.3 
 
4-6 prescribers 
All ages 
18-44 
45-64 
≥65 
 
 
5.4 
5.5 
5.9 
5.0 
 
 
1.3 
2.2 
1.6 
1.2 
 
 
3.6 
3.3 
4.1 
3.0 
 
 
1.7 
2.2 
1.7 
1.6 
 
 
10.9 
11.3 
11.3 
6.8 
 
 
4.6 
5.8 
4.9 
3.8 
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7-9 prescribers 
All ages 
18-44 
45-64 
≥65 
 
 
0.7 
1.2 
1.0 
0.5 
 
 
0.0 
0.1 
0.0 
0.0 
 
 
0.5 
0.6 
0.6 
0.2 
 
 
0.0 
0.1 
0.0 
0.0 
 
 
2.3 
2.7 
2.2 
0.8 
 
 
0.2 
0.6 
0.2 
0.1 
 
≥10 prescribers 
All ages 
18-44 
45-64 
≥65 
 
 
0.4 
0.7 
0.4 
0.1 
 
 
0.0 
0.0 
0.0 
0.0 
 
 
0.2 
0.3 
0.2 
0.0 
 
 
0.0 
0.0 
0.0 
0.0 
 
 
1.1 
1.7 
0.9 
0.2 
 
 
0.0 
0.1 
0.0 
0.0 
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4.3.2.2 Access patterns by age group  
In Australia and British Columbia (all), opioid access patterns for persons aged 18-44 and 45-
64 years were similar (Table 4.3). However, a greater proportion of persons aged <65 years 
accessed more opioid prescribers than their older counterparts (≥65 years) (Figure 4.2). For 
example, a larger proportion of persons aged <65 years accessed ≥7 opioid prescribers 
compared to persons aged ≥65 years in Australia (18-44: 1.8%; 45-64: 1.4%; ≥65: 0.6%) and 
British Columbia ([all]: 18-44: 0.9%; 45-64: 0.7%; ≥65: 0.2%). There was no distinction in 
statin prescriber access patterns among age groups in Australia or British Columbia (all) 
(Supplementary Figure 4.2). 
 
Among British Columbians receiving income assistance, a greater proportion of persons 
aged <65 years also accessed more opioid prescribers than their older counterparts (≥65 
years). However, within those aged <65 years, a larger proportion of persons aged 18-44 
years accessed more opioid prescribers than those aged 45-64 years; apparent from ≥5 
prescribers (18-44: 9.8%; 45-64: 8.3%) (Figure 4.2). Moreover, a greater proportion of 
persons aged 18-44 years, compared to those aged ≥45 years, accessed a larger number of 
statin prescribers, particularly from ≥4 prescribers (18-44: 6.6%; 45-64: 5.1%; ≥65: 3.9%) 
(Supplementary Figure 4.2C). 
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Figure 4.2 Cumulative frequency of unique statin or opioid prescribers by age group (2011) 
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4.2A. Australian concessional beneficiaries: entire spectrum (left); upper decile (right) 
 
4.2B. British Columbia (all): entire spectrum (left); upper decile (right) 
 
4.2C. British Columbia (income assistance): entire spectrum (left); upper decile (right) 
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4.4 Discussion 
Our benchmarking study demonstrated that the vast majority of persons accessed one or 
two prescribers for prescription opioids and statins in 2011. Two notable differences in the 
spectrum of prescriber access patterns were a greater proportion of persons accessing ≥4 
prescribers for opioids compared to statins and persons aged <65 years accessed more 
opioid prescribers than their older counterparts (≥65 years). These differences were more 
pronounced for British Columbians receiving income assistance. Interestingly, prescriber 
access patterns by drug class were remarkably similar across Australia and British Columbia 
despite their unique healthcare systems, prescription drugs listed on formularies and most 
frequently dispensed drugs. Together, these findings suggest benchmarking opioid access 
patterns against a drug class with no known abuse potential has utility in identifying 
potentially problematic access patterns across jurisdictions. 
 
We demonstrated a greater proportion of persons accessing opioids are represented at the 
higher end of the access spectrum compared to statins; this was apparent at ≥4 prescribers 
but accentuated from ≥7 prescribers. The global literature investigating potential 
prescription drug misuse using pharmaceutical claims is dominated by studies based on 
thresholds that dichotomise access patterns, with higher access patterns signifying ‘misuse.’ 
This study highlights that using a ‘doctor shopping’ threshold of ≥4 prescribers in 12 
months20 may be indicative of problematic use, however, this threshold-based approach 
does not advance our understanding of the full spectrum of use nor how these access 
patterns compare with those of other drug classes. This benchmarking study provides a first 
step to developing alternative methods of examining extreme access behaviour which are 
potentially problematic and/or harmful.  
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Our findings suggest that when benchmarked against statin access patterns, a drug with no 
known abuse potential, a small proportion of persons from both jurisdictions engaged in 
opioid access behaviour that likely puts themselves or others at risk. In absolute terms this 
equates to around 13 500 Australians (numbers extrapolated from the 10% random sample) 
and 3 300 British Columbians visiting ≥7 unique opioid prescribers (Supplementary Table 
4.2). In comparison, <300 Australians (number extrapolated from the 10% random sample) 
and <100 British Columbians accessed ≥7 unique statin prescribers in 2011. 
 
Interestingly, we also identified a small but higher than expected proportion of persons 
visiting ≥4 statin prescribers. Statins are commonly prescribed in both jurisdictions as an 
original prescription with five refills; one prescription provides up to a 6-month supply. 
While it is not unreasonable to expect that a person may access up to three prescribers over 
a year due to variations in filling behaviour associated with altering the daily dose, 
switching/adding drugs etc., it is harder to understand how accessing ≥4 prescribers in a 
given year would reflect appropriate statin use. In absolute terms, this equates to 
approximately 3 200 Australians (extrapolated as above) and 6 700 British Columbians. This 
finding further highlights the benefits of examining the full spectrum of access patterns for 
all prescription drugs, not just those with known abuse potential.  
 
There is considerable evidence demonstrating age differences in prescription opioid use and 
related harms across jurisdictions. For example, in Canada, younger persons have increased 
risk of opioid-related mortality.21 Accordingly, we demonstrated notable differences in 
opioid prescriber access patterns by age, with a larger proportion of persons aged 18-44 
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years accessing more opioid prescribers than persons aged ≥65 years; reflecting findings 
from recent US studies.11-14, 22 Interestingly, this pattern was particularly pronounced in 
British Columbians receiving income assistance for both opioids and statins.  
 
It is difficult to ascertain what the behaviour at the higher end of the spectrum of use truly 
represents. Australian concessional beneficiaries account for only 25% of the PBS-eligible 
population17 but the majority of PBS-subsidised prescription drug use.23 In this study, we 
found British Columbians receiving income assistance also obtain large quantities of 
dispensings relative to their population size. These findings may simply reflect these 
populations are sicker than the general population.23 However, persons exhibiting higher 
access patterns also obtain disproportionately large quantities of prescription drugs.24-27 For 
example, in Australia in 2013, only 3.9% of persons accessed ≥5 opioid prescribers yet 
obtained 15.4% of all opioid dispensings.27 So whether our findings reflect specific 
population characteristics, poor continuity of care, deliberate misuse, abuse or diversion 
(most likely observed at the highest end of the spectrum), it is almost certain the individual 
and societal consequences will be negative. Diversion for the purposes of selling or sharing 
prescription drugs with others has been reported in the literature;28-30 this behaviour may 
be more common in persons who obtain drugs at minimum cost (such as through 
government subsidised healthcare programs) and given to individuals with higher 
copayments and/or restricted drug access. Accordingly, diversion may partly explain the 
greater proportion of persons on income assistance in British Columbia, who have no 
copayments, accessing higher numbers of statin and opioid prescribers.  
 
141 
 
Our study is not without limitations. This study used only one metric as a means of 
demonstrating the utility of benchmarking access patterns across drug classes. Our data did 
not allow us to determine if prescribers were from the same medical practice; feasibly 
persons could visit one practice but access multiple prescribers to access their prescription 
drugs. We chose statins as our comparator drug class because they have no known abuse 
potential, they are subsidised and widely used in both jurisdictions; used by persons of all 
ages; and are prescription only (not available over-the-counter). However, there are notable 
differences between opioid and statins; they have different medical indications; statins are 
most likely to be used chronically, unlike opioids that can be used either episodically or 
chronically, and different restrictions on access. Generally, in both jurisdictions, a maximum 
of a 30-day opioid supply is provided per prescription compared to a 6-month supply for 
statins. Consequently, persons with multiple opioid dispensings are required to visit 
prescribers more frequently compared to statins. For these reasons, more research is 
warranted to further explore this methodology by benchmarking other drug classes with 
different parameters for comparison. 
 
The generalisability of our findings are uncertain, but it is encouraging that we 
demonstrated many similarities in access patterns by drug class across two jurisdictions. 
Further research in other healthcare settings should form part of the ongoing research 
agenda. The Australian cohort was restricted to persons with complete ascertainment of 
their prescription drugs (concessional beneficiaries). From April 2012, DHS captured all PBS-
listed drugs dispensed irrespective of whether it attracted government reimbursement, 
removing the need to restrict to concessional beneficiaries. Future studies will undoubtedly 
benefit from this development and the facilitation of whole of population drug studies. We 
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did not compare access patterns between the Australian and Canadian populations; even 
the concessional Australian population was not directly comparable to the British Columbian 
income assistance population. We were unable to examine use of over-the-counter opioids 
or those available via private prescription or unsubsidised by the PBS or PharmaCare, thus it 
is likely our results underestimate total use and prescriber access patterns. 
 
4.5 Conclusions 
The utility of pharmaceutical claims for the post-market surveillance of prescription drugs is 
increasingly recognised, and interrogation of these large databases represents a useful way 
of tracking potentially problematic prescribed opioid use. Our benchmarking approach has 
identified the utility of considering access patterns across the entire spectrum and across 
drug classes. These findings provide a first step toward an alternative method of quantifying 
problematic prescription drug use using routinely collected data.
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Supplementary Table 4.1 Publically subsidised opioid analgesics and statins included in 
analysis by jurisdiction 
Prescription drug (ATC code[s]) Australia British Columbia 
Opioid analgesics 
Buprenorphine (N02AE01) 
Codeine (N02AA59; N02AA79; R05DA04b) 
Dextropropoxyphene (N02AC04) 
Fentanyl (N02AB03)  
Hydromorphone (N02AA03) 
Methadone (N02AC) 
Morphine (N02AA01)  
Oxycodone (N02AA05; N02AA55) 
Pentazocine (N02AD01) 
Pethidine (N02AB02)  
Tapentadol (N02AX06) 
Tramadol (N02AX02, N02AX52) 
 
 
 
c 
 
 
 
 
 
d 
c 
c  
 
 
a 
 
 
 
 
a 
 
 
 
 
 
 
 
Statins 
Atorvastatin (C10AA05) 
Fluvastatin (C10AA04)  
Lovastatin (C10AA02) 
Pravastatin (C10AA03)  
Rosuvastatin (C10AA07)  
Simvastatin (C10AA01) 
 
 
 
 
d 
 
 
 
 
 
 
 
 
 
 
 
a Unable to distinguish between use for pain or opiate maintenance treatment 
b Codeine dispensed under this Anatomical Therapeutic Chemical (ATC) classification code may be 
dispensed for the indication of cough suppression or pain 
c Not PBS-listed in Australia in 2011 
d Not available via prescription in Australia 
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Supplementary Table 4.2 Distribution of number of unique statin or opioid prescribers in Australia and British Columbia (2011) 
 Australiaa,b British Columbia  
(all) 
British Columbia  
(income assistance) 
Number of 
unique 
prescribers 
Opioid cohort 
N = 118 125 
N (%) 
Statin cohort 
N = 147 728 
N (%) 
Opioid cohort 
N = 482 591 
N (%) 
Statin cohort 
N = 397 345 
N (%) 
Opioid cohort 
N = 50 633 
N (%) 
Statin cohort 
N = 21 267 
N (%) 
Median (range) 1 (1-81) 1 (1-9) 1 (1-45) 1 (1-12) 1 (1-45) 1 (1-11) 
For 1-3 prescriber(s) descriptive statistics see Table 4.3 
4 prescribers 3 737 (3.2) 1 565 (1.1) 10 393 (2.2) 5 371 (1.4) 2 983 (5.9) 689 (3.2) 
5 prescribers 1 734 (1.5) 263 (0.2) 4 567 (1.0) 1 061 (0.3) 1 627 (3.2) 229 (1.1) 
6 prescribers 848 (0.7) 64 (0.0)   2 218 (0.5) 228 (0.1) 904 (1.8) 69 (0.3) 
7 prescribers 494 (0.4) <60 (0.0)    1 230 (0.3) 56 (0.0) 579 (1.1) 32 (0.2) 
8 prescribers 273 (0.2) <60 (0.0)   710 (0.2) 18 (0.0) 356 (0.7) 12 (0.1) 
9 prescribers 168 (0.1) <60 (0.0)   419 (0.1) 9 (0.0) 235 (0.5) 5 (0.0) 
10 prescribers 123 (0.1) <60 (0.0) 278 (0.1) 7 (0.0) 158 (0.3) 7 (0.0) 
11 prescribers 73 (0.1) <60 (0.0) 206 (0.0) 1 (0.0) 124 (0.2) 1 (0.0) 
12 prescribers 64 (0.1) <60 (0.0) 125 (0.0) 1 (0.0) 81 (0.2) 0 (0.0) 
13 prescribers <60 (0.0) <60 (0.0) 74 (0.0) 0 (0.0) 53 (0.1) 0 (0.0) 
14 prescribers <60 (0.0) <60 (0.0) 62 (0.0) 0 (0.0) 38 (0.1) 0 (0.0) 
15 prescribers <60 (0.0) <60 (0.0) 53 (0.0) 0 (0.0) 31 (0.1) 0 (0.0) 
16 prescribers <60 (0.0) <60 (0.0) 31 (0.0) 0 (0.0) 20 (0.0) 0 (0.0) 
17 prescribers <60 (0.0) <60 (0.0) 22 (0.0) 0 (0.0) 13 (0.0) 0 (0.0) 
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18 prescribers <60 (0.0) <60 (0.0) 23 (0.0) 0 (0.0) 16 (0.0) 0 (0.0) 
19 prescribers <60 (0.0) <60 (0.0) 20 (0.0) 0 (0.0) 14 (0.0) 0 (0.0) 
≥20 prescribers <60 (0.0) <60 (0.0) 50 (0.0) 0 (0.0) 27 (0.1) 0 (0.0) 
a Australian concessional beneficiaries only 
b Due to our Australian data agreement, we are unable to report cell sizes pertaining to <60 persons 
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Supplementary Figure 4.1A Australian cohort inclusion criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
≥18 years (January 1, 2011), concessional beneficiary and 
alive for entirety of 2011 
N = 479 743 
 
Opioid cohort: 
≥1 opioid dispensings 
N = 118 125 
Statin cohort: 
≥1 statin dispensings 
N = 147 728 
 
 
 
Excluded:  
134 046 persons <18 years 
319 327 persons with ≥1 
general beneficiary 
dispensings  
8 299 decedents 
Persons with ≥1 PBS-reimbursed dispensings between 
January 1 and December 31, 2011 (inclusive) 
N = 941 415 
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Supplementary Figure 4.1B British Columbian cohort inclusion criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Persons with ≥1 dispensings between January 1 and 
December 31, 2011 (inclusive) 
N = 2 990 466 
≥18 years (January 1, 2011), alive and resident living in 
British Columbia for entirety of 2011 
N = 2 470 973 
Opioid cohort (all): 
≥1 opioid dispensings  
N = 482 591 
 
Opioid cohort (income assistance): 
≥1 opioid dispensings covered by 
Plan C 
N = 50 633 (10.5%) 
 
Statin cohort (all): 
≥1 statin dispensings  
N = 397 345 
 
Statin cohort (income assistance): 
≥1 statin dispensings covered by 
Plan C 
N = 21 267 (5.4%) 
 
 
Excluded:  
438 151 persons aged <18 
25 273 decedents 
56 069 persons not British 
Columbian residents 
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 Supplementary Figure 4.2 Cumulative frequency of unique statin prescribers by age group  
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4.2A Australian concessional beneficiaries: entire spectrum (left); upper decile (right) 
4.2B British Columbia (all): entire spectrum (left); upper decile (right) 
4.2C British Columbia (income assistance): entire spectrum (left); upper decile (right) 
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Chapter Five: The POPPY research program protocol: investigating 
opioid utilisation, costs and patterns of extramedical use in Australia 
 
In Chapter Four we present the results of the first cross-jurisdictional study examining 
whole-of-population prescription drug access patterns across drug classes. We demonstrate 
statins and opioids are accessed similarly across two jurisdictions with similar healthcare 
arrangements; albeit a higher proportion of opioid users access ≥4 prescribers. We also 
found specific patient factors are associated with higher prescriber access patterns including 
younger age and persons receiving income assistance. In Chapter Six we focus on several 
patient factors associated with increasing opioid access patterns across multiple metrics 
commonly used to define misuse. This chapter contains the POPPY project protocol to 
provide background information for the pharmaceutical data analysed in Chapter Six. 
 
This chapter is a reproduction of the following publication: 
Louisa Degenhardt, Bianca Blanch, Natasa Gisev, Briony Larance, Sallie-Anne Pearson. The 
POPPY Research Programme protocol: investigating opioid utilisation, costs and patterns of 
extramedical use in Australia. BMJ Open. 2014; 4: e007030. 
 
Formatting note: To increase the readability of viewing this thesis electronically, we provide 
all figures or tables on the page following its first citation in the text. The key points and 
abstract are formatted according to the BMJ Open style guide. We provide the reference list 
at the end of each chapter. Supplementary materials are provided after the reference list for 
this chapter. 
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Key Points 
Strengths and limitations of this study 
 Using data on prescriptions reimbursed by the Pharmaceutical Benefiots Scheme 
(PBS), this study will provide novel data on the patterns and costs of opioid use, 
including extramedical use, in the Australian population. This will provide the most 
detailed information to date regarding person-level patterns of opioid consumption 
in Australia. 
 The research program is limited by: 
o The extent to which these data reflect total opioid consumption. PBS data do 
not include private prescriptions or over-the-counter opioids. In addition, 
parts of the study will not capture low-cost PBS-listed items dispensed to 
Australians with the highest patient copayment threshold.  
o Dispensing claims do not detail clinical information, including indication for 
use, which poses challenges given doses for opioids vary depending on the 
nature of the pain being managed. However, by using complete PBS 
dispensing history for each individual, we will be able to identify patients with 
a recent cancer treatment history. 
o The absence of gold-standard proxy indicators of extramedical opioid use. As 
such, we will develop indicators through consultation of the literature and 
feedback from expert clinicians in the fields of pain, cancer and addiction. 
Sensitivity analyses will be used to establish whether our conclusions are 
affected by variations in definitions. 
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Abstract 
Introduction  
Opioid prescribing is increasing in many countries. In Australia, there is limited research on 
patterns of prescribing and access, or the outcomes associated with opioid use. The aim of 
this research program is to use national dispensing data to estimate opioid use and costs, 
including problematic or extramedical use in the Australian population. 
 
Methods and analysis  
In a cohort of persons dispensed at least one opioid in 2013, we will estimate monthly 
utilisation and costs of prescribed opioids, overall and according to individual opioid 
formulations and strengths. In a cohort of new opioid users, commencing therapy between 
1 July 2009 and 31 December 2013, we will examine patterns of opioid use including 
initiation of therapy, duration of treatment and concomitant use of opioids and other 
prescribed drugs. We will also examine patterns of extramedical opioid use based on 
indicators including excess dosing, use of multiple opioids concomitantly, doctor/ pharmacy 
shopping and accelerated time to prescription refill. 
 
Ethics and dissemination  
This protocol was approved by the NSW Population and Health Services Research Ethics 
Committee (March 2014) and data access was approved by the Australian Government 
Department of Human Services External Review Evaluation Committee (June 2014). This will 
be one of the first comprehensive Australian studies with the capability to investigate 
individual patterns of opioid use and track extramedical use. In the first instance our analysis 
will be based on 4.5 years of dispensing data but will be expanded with ongoing annual data 
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updates. This research has the capability to contribute significantly to pharmaceutical policy 
within Australia and globally. In particular, the trajectory of extramedical prescription opioid 
use has been the subject of limited Australian research to date. The results of this research 
will be published widely in general medical, pharmacoepidemiology, pain, addiction and 
psychiatry journals. 
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5.1 Introduction 
The global increase in prescribed opioid use over the past 30 years has been well 
documented.1–8 In Australia, between 1992 and 2007, there was a 300% increase in the 
number of opioid dispensings in the community.5 In 2012, 7.4 million opioid prescriptions 
were dispensed via the Australian Pharmaceutical Benefits Scheme (PBS), costing the 
Australian government approximately AU$271 million. In the 20-year period 1992–2012, the 
Commonwealth of Australia subsidised over AU$2 billion in prescribed opioids, with 
oxycodone and morphine accounting for AU$1.1 billion.9 Europe and the USA have seen 
even larger increases in opioid dispensings than Australia.10 Despite the Australian 
government’s significant investment in these prescription drugs, we know little about the 
way they are used in routine clinical care.  
 
The observed global increase in opioid use can be attributed, in part, to the broadening of 
regulatory and subsidy approval of opioids to manage chronic noncancer pain; previously 
use was restricted to the management of cancer pain. As opioid use has increased, so too 
has the concern from healthcare professionals and the public in relation to the harms of 
prolonged medical use, including concerns about the appropriateness of prescribing opioids 
long term and the risk of iatrogenic dependence.11 The most serious risk associated with 
opioid use is the harm related to opioid overdose. In the USA, prescribed drugs account for 
more fatal and non-fatal overdoses than illicit drugs.12 People dying from opioid overdoses 
often use other prescription drugs concomitantly such as benzodiazepines, antidepressants, 
antipsychotics and psychostimulants,13,14 which may further contribute to the risk of an 
adverse outcome. In Australia, notable increases in reported opioid dispensings have 
occurred.5 This has been associated with hospital separations for opioid poisoning, 
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treatment episodes3,9 and deaths attributed to pharmaceutical opioids such as 
oxycodone.4,15 
 
‘Extramedical use’ is defined as use not as directed by a doctor.16 Among other things, it 
may include using more than directed by the doctor; asking for escalating doses; obtaining 
prescriptions from multiple doctors without their knowledge; tampering with opioids and 
taking opioids via routes other than intended (e.g. snorting or injecting).16 A 2010 Australian 
national survey reported a 7.4% lifetime prevalence and 4.2% 12-month prevalence of using 
prescription drugs such as analgesics, sedatives/hypnotics, methadone, other opioids and 
steroids when not medically indicated,17 equating to approximately 1 in 14 Australians 
engaging in extramedical use of a prescribed drug in their lifetime (with a higher prevalence 
in younger age groups).  
 
Observational cohort studies from the USA and Europe have examined the natural history of 
opioid analgesic use for chronic non-cancer pain.18 Small retrospective cohort studies have 
examined treatment duration, pain reduction, adverse drug events19 and aberrant 
behaviours.20 Larger retrospective cohort studies have examined the risk of overdose,21 the 
impact on disability,22 non-medical use,23 conditions treated in older adults,24 and rates of 
adverse events.25  
 
However, in Australia, few studies have examined person-level behaviours of people 
prescribed opioids, prescribing patterns, patterns of use, or the outcomes and costs 
associated with this use.26–28 In order to gain a comprehensive understanding of these 
issues, we started a program of research examining the patterns and costs of PBS-subsidised 
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opioid use, including extramedical use in the Australian population. This protocol 
summarises the scope of our program. 
 
The overall objective of this research program is to evaluate the patterns and costs of opioid 
use in Australia. Specifically, we aim to:  
1. Estimate monthly and annual utilisation and costs of prescribed opioids, overall and 
according to individual opioid formulations and strengths. 
2. Examine patterns of opioid use including initiation of therapy, duration of treatment, 
concomitant use of opioids and other therapy. 
3. Examine patterns of extramedical opioid use based on indicators including excess dosing, 
use of multiple opioids concomitantly, doctor/pharmacy shopping, and accelerated time to 
prescription refill. 
 
5.2 Methods 
5.2.1 Setting 
Australia has a publically funded universal healthcare system entitling all Australian citizens 
and permanent residents to a range of subsidised health services. This includes free 
treatment in public hospitals (funded jointly by Commonwealth and State/Territory 
governments), subsidised outpatient services including consultations with medical and 
selected healthcare professionals (funded by the Commonwealth’s Medicare Benefits 
Scheme) and drugs dispensed in the community and private hospitals (funded by the PBS). 
Drugs prescribed to public hospital inpatients are covered primarily by hospital budgets. 
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5.2.2 Opioids of interest 
The prescribed opioids of interest in this study include drugs belonging to the World Health 
Organization’s Anatomical Therapeutic Chemical classification system 
(http://www.who.int/classifications/atcddd/en/) categories N02A, N07B and R05D (Table 
5.1). We requested data for all formulations and strengths of these drugs (individual PBS 
item numbers). Methadone or buprenorphine may be prescribed for the indication of opiate 
maintenance therapy or pain. For the indication of opiate maintenance therapy, these drugs 
are listed under the S100 Highly Specialised Drugs Program (S100 HSDP) administered by 
individual Australian States and Territories rather than under the national funding system. 
We listed these indications for completeness, however, the Australian Government 
Department of Human Services (DHS) do not record dispensings for opioids dispensed under 
the state-based S100 HSDP. All opioid dispensing records we obtain will be for the indication 
of pain. 
 
5.2.3 Data of interest 
Our research program will be underpinned by access to dispensing claims processed by the 
DHS, the PBS administering body. Until recently, DHS only recorded dispensing claims 
attracting a PBS-subsidy. As such, drug dispensings costing less than the patient copayment 
threshold were not ascertained in the collection. In effect, low-cost drugs dispensed to 
beneficiaries with the highest patient copayment threshold (referred to as general 
beneficiaries) have been under-ascertained; this issue does not impact on drugs dispensed 
to beneficiaries with lower copayment thresholds (PBS concessional beneficiaries). In April 
2012, DHS began recording under-copayment dispensings.  
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Table 5.1 Opioids of interesta  
Drug ATC code(s)b 
Buprenorphine N02AE01, N07BC01, N07BC51 
Codeine N02BE51, N02AA59, R05DA04c 
Fentanyl N02AB03 
Hydromorphone N02AA03 
Methadone N02AC52, N07BC02 
Morphine N02AA01 
Oxycodone N02AA05, N02AA55 
Tapentadol N02AX06 
Tramadol N02AX02 
ATC: Anatomical Therapeutic Chemical; PBS: Australian Pharmaceutical Benefits Scheme; WHO: 
World Health Organiiation 
a Tapentadol PBS-subsidised from 2014 
b ATC classification system is an internationally established methodology endorsed by the WHO that 
is used to classify drugs based on the organ or system on which they act, or their therapeutic and 
chemical characteristics. Details of the ATC classification system are found online at: 
http://www.who.int/classifications/atcddd/en/.  
c Single ingredient codeine 30 mg tablets (opium alkaloids and derivatives) are ATC coded to the 
respiratory system R05D and not the nervous system N02A.  
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Our PBS-data requests were structured in two parts as described below: 
 Prevalent user cohort: comprising Australians dispensed at least one opioid. This is a 
national cohort of all persons (of any age) prescribed at least one opioid of interest 
in a given calendar year (with the first year of data being 2013). The cohort will 
provide contemporary information about the prevalence of monthly and annual 
prescribed opioid use across the Australian population, including data from under-
copayment opioid prescriptions. Data will be updated annually. 
 
 Incident user cohort: comprising Australians starting new opioid therapy. This is a 
national cohort focusing on persons dispensed at least one opioid in the period 1 July 
2009 to 31 December 2013 inclusive. Our observation period was chosen as the DHS 
holds PBS data for a period of only 4 years and 6 months. These data are updated 
daily and when each additional day is added, the earliest date in the data set is 
deleted. Therefore, our exact study period is dependent on the date of extraction. 
This cohort will be used to examine patterns of prescribed opioid use, including 
extramedical use. Inclusion criteria are as follows: (1) opioid naïve for at least 90-
days prior to the index prescription (see Supplementary Material 5.1 for details on 
the way in which this was operationalised); (2) aged ≥18 years at the index 
prescription. We chose a 90-day wash-out period for cohort inclusion because it was 
considered sufficient time to ensure that any new, index prescriptions reflected a 
new ‘course’ of treatment for a new or recurrent indication. It is possible that some 
individuals will receive a new prescription under this definition for an indication for 
which they have been treated previously. However, we will also undertake sensitivity 
analyses by extending the period of non-use to 180-days. This cohort will also be 
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updated annually. Tables 5.2 and 5.3 detail the variables requested from DHS for the 
prevalent and incident user cohorts. 
 
5.2.4 Statistical analysis 
We will use best-practice pharmacoepidemiological methods to explore prescribed opioid 
use in the two cohorts. The general approaches are detailed below: 
Utilisation and costs: we will estimate the monthly and annual prevalence and costs of 
opioid use overall and according to individual opioid formulations and strengths. Utilisation 
estimates will be based on number of prescriptions, defined daily dose (DDD)/1000 
population per day or in oral morphine equivalent mg.29 Analyses will be stratified according 
to patient age, sex, location of residence and indices of socioeconomic disadvantage. Data 
from the Australian Bureau of Statistics will determine population estimates for each 
subgroup of interest. Estimates will also be presented using ESRI ArcGIS (a mapping 
software program). This will show overall national patterns of use by geographical area of 
patient, prescriber or dispensing pharmacy (e.g. Statistical Local Area, jurisdictionally), as 
well as graphical presentation of variations in levels of use. Publically available data on the 
demographic characteristics of geographical areas will be obtained from the Australian 
Bureau of Statistics (e.g. age distribution, income, education and unemployment). 
 
1. Patterns of opioid use: we will examine patterns of use in the following ways: 
A. Median duration of opioid treatment: defined as the time from the first opioid 
dispensing record to the last dispensing record plus 30 days. These estimates can 
also detail different courses of opioid therapy by accounting for breaks in 
treatment of more than 60 days.  
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Table 5.2 Variables requested regarding cohort demographics  
  
Variables Justification 
Scrambled patient ID A unique sequence number enabling person-level analysis and linkage to PBS dataset  
Month and year of birth (mm/yy) To report demographics of cohort and used to stratify analyses according to age group 
Sex To report demographics of cohort and used to stratify analyses according to sex 
Month and year of death (mm/yy) To censor the follow-up time for each individual in the cohort 
Postcode of residence mapped to SLA  Used to identify location of residence and map to indices of socioeconomic 
disadvantage (i.e. the Socio-Economic Indexes for Areas [SEIFA]a) and remoteness (i.e. 
the Accessibility/Remoteness Index of Australia [ARIA]b).  
Geographic location of residence 
according to the SA2 
Used to identify geographic location of residence and map to SEIFA and ARIA 
classifications.  
ABS: Australian Bureau of Statistics; ARIA: Accessibility/Remoteness Index of Australia; PBS: Australian Pharmaceutical Benefits Scheme; 
SA2: Statistical Area Level 2; SLA: Statistical Local Area 
a SEIFA is a product developed by the ABS that ranks areas in Australia according to relative socioeconomic advantage and disadvantage. 
The indexes are based on information from the 5-yearly census. Details can be found at: 
http://www.abs.gov.au/websitedbs/censushome.nsf/home/seifa.  
b The ABS’ Remoteness Areas classification include ‘major cities’, ‘inner regional’, ‘outer regional’, ‘remote’ and ‘very remote’. Details have 
been reported elsewhere.54,55  
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Table 5.3 Australian Pharmaceutical Benefits Scheme data on opioid dispensing (and other 
drug dispensing) history 
ID: identifier; SLA: Statistical Local Area  
Variables Description  Justification 
Scrambled patient ID A unique sequence number  Enable person-level analysis and 
linkage to sociodemographic dataset 
Month and year of 
birth 
Month and year when each 
person was born 
Determine age at time of dispensing. 
Also used as a cross-check with data 
in demographic file 
Sex Patient sex  Cross-check with data in demographic 
file 
Date of supply Date drug is dispensed Establish temporal relationship in 
dispensing records 
Item code A unique number which 
represents the dose, form 
and strength of the 
pharmaceutical item patients 
are dispensed  
Identify drugs of different forms and 
strengths 
ATC code Anatomical Therapeutic 
Chemical classification code 
Delineate between drug types 
Generic name Generic drug name  Delineate between drug types 
Quantity dispensed Quantity of drug dispensed  Calculate defined daily dose and 
durations of treatment 
Original or repeat 
prescription 
A variable to distinguish 
between repeat or new 
prescriptions  
Understand pattern of treatment 
Beneficiary level General beneficiary + safety 
net; concession card holder + 
safety net 
Identify level of entitlement and 
determine comprehensiveness of data 
capture  
PBS benefit Amount paid by the 
Australian government 
Determine the total cost incurred by 
the Australian government to supply 
opioids in a given calendar year 
Prescriber scrambled 
ID 
A unique sequence number 
given to each prescriber  
Delineate between prescriptions 
written by different doctors  
Prescriber location Postcode mapped to SLA Establish location of practice  
Prescriber type Identifies primary specialty of 
the prescribing doctor 
Identify what type of doctors 
prescribe drugs of interest 
Pharmacy scrambled 
ID 
A unique sequence number 
given to each dispensing 
pharmacy  
Delineate between prescriptions 
dispensed at different pharmacies 
Pharmacy location Postcode mapped to SLA Establish location of pharmacy  
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B. Dose escalation: we will estimate the average daily dose of each opioid dispensing 
using the internationally recognised DDD unit.30 At the individual level, we will 
calculate the changes in average DDDs by prescription and report the number of 
patients in whom doses are increasing, and by what level, over time. 
C. Concomitant opioid and other concomitant drug use: we will investigate the 
concomitant use of multiple opioids, in addition to the use of opioids with other 
prescribed drugs, such as benzodiazepines, antidepressants and antipsychotics. 
Concomitant use will generally be defined as the observation of at least two 
dispensing records from different drugs within a specific time frame. The rules will 
vary according to the therapy of interest. Furthermore, we will identify individuals 
at risk of potentially harmful drug–drug interactions deemed to be clinically 
relevant in the literature and common drug information resources.31–33 These will 
be examined using a previously published approach34 overall, and for specific 
population subgroups such as older adults. 
 
2. Extramedical use: indicators of extramedical opioid use —we will adopt measures of 
extramedical use described previously in the literature16 and report on the rates of 
these patterns of extramedical use:  
A. Excess dosing: defined as average daily dosing outside guideline   
recommendations.35–37 
B. Concomitant opioid use: as described above.36,38 
C. Doctor shopping: opioid prescriptions written by more than one doctor and 
dispensed within a specific time frame.14,39–45 
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D. Pharmacy shopping: opioid dispensings from more than one pharmacy within a 
specified time frame.40–44 
E. Accelerated prescription refill: repeated dispensing of opioid prescriptions earlier 
than the estimate of when the prescription is complete.36,37,46–49 The drug 
possession ratio and refill compliance rate are measures which use administrative 
data to assess drug adherence. We have included accelerated prescription refill as 
one of our measures of extramedical use. 
 
We may restrict some of our analyses to concessional beneficiaries (persons receiving a 
government pension), as not all prescription opioids of interest are above the general 
beneficiary copayment amount. Other drugs of interest including psychotropic drugs such as 
antidepressants, antipsychotics, benzodiazepines and central nervous system stimulants, 
also fall below the general beneficiary copayment. We will also undertake analyses with and 
without persons dispensed drugs for cancer treatment to establish how the inclusion of 
patients with cancer (who generally receive significantly higher opioid doses than patients 
without cancer) impact on our estimates.  
 
5.2.5 Data access approval 
Data access has been approved by the DHS External Review Evaluation Committee 
(MI0166). However, DHS have recently advised that it may be necessary to restrict our 
cohorts due to the considerable amount of data they will be required to provide to us. For 
example, to access the entire dispensing history of all people dispensed an opioid in our 
incident user cohort, it has been estimated that we would be provided with 40% of the 
168 
 
entire DHS data holdings. As such, our cohorts may be restricted to a 10% random sample of 
the national opioid user cohort. 
 
5.2.6 Consent and privacy considerations 
Use and disclosure of information: Commonwealth data are governed under the Privacy Act 
1988. Information Privacy Principle (IPP) 2 under the Privacy Act 1988 provides that 
personal information should not be used or disclosed for any purpose other than the 
primary purpose of the collection. We have obtained approval for the use of data for a 
secondary purpose: that of research involving access to person-level information. Under 
IPP2.1(d), use or disclosure for another purpose is allowed if (A) it is necessary for research 
and it is impracticable to gain consent AND (B) the use is in accordance with Section 95A 
guidelines (which provides a process to resolve the conflict that may arise between the 
public interest in privacy and the public interest in medical research). 
 
Consent: The waiver for individual consent was approved by the Population and Health 
Services Research Ethics Committee in accordance with Section 95A of the Commonwealth 
Privacy Act 1988. This was because:  
 There were hundreds of thousands of people in the cohort, so it was not possible or 
practical to obtain consent because of the large study population. 
 Obtaining consent would prejudice the scientific value of the research due to the high 
participation rates required for unbiased samples (at least 90%),50 and the Australian 
evidence about the sociodemographic differences between participants who consent to 
data linkage research and those who do not.51 
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 We believe the public interest in this research outweighs the public interest in privacy 
protection. We consider the benefits to be great and the risk to be small. Currently we 
know little about the way in which opioids are used in the real world marketplace. Our 
research has the potential to address key issues such as the risks and benefits of 
prescribing opioids in Australia. These findings are likely to have national and global 
significance. 
 
We have minimised the risk to personal privacy by ensuring: 
 Only researchers involved in data analysis will have access to the data. 
 Data will be securely stored at both sites (see below).  
 The research team will not be in possession of any personally identifying information. 
The files released to the research team will not contain patients’ name, rather a unique 
patient number will be generated by the DHS staff. 
 
Finally, all data will be presented in aggregated form only and potentially identifiable 
information will not be published. We will suppress data with small cell sizes. 
 
5.2.7 Confidentiality of data and record retention 
This is a collaborative project involving two research teams, one based at the National Drug 
and Alcohol Research Centre, The University of New South Wales, Australia, and one based 
at the Faculty of Pharmacy, The University of Sydney, Australia. To ensure consistency 
between analyses and research teams, decision rules will be developed in group meetings 
and all analyses will be conducted in Statistical Analysis Software (SAS) so all relevant code 
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can easily be shared where necessary. The confidentiality of records will be ensured by strict 
adherence to the study protocol in relation to access to, transfer and storage of study data.  
 
5.3 Discussion 
The rate of pharmaceutical opioid use is increasing across the globe. However, the actual 
extent of such use and extramedical use, is currently unknown. The research program 
outlined in this protocol will be the first large-scale and nationally representative Australian 
study to examine patterns of opioid use, including extramedical use, and the costs 
associated with this use. Previously, PBS opioid dispensing data has typically been analysed 
using aggregated data.5,9 This research will also form the foundation of additional studies 
that can examine the medical consequences of excessive prescription opioid use. This type 
of research will be possible by access to emergency department and hospitalisation plus 
cause of death data. 
 
From a clinical perspective, we will investigate common opioid utilisation patterns and 
identify behaviour indicative of extramedical use of opioids. Furthermore, we will 
investigate the prevalence of potentially inappropriate combinations of drugs prescribed 
with opioids, estimating the number of individuals at risk of adverse drug events due to 
potentially harmful drug–drug interactions. Together, this information could provide a 
strong evidence base for targeted future intervention program to identify and treat high-risk 
individuals across Australia, as well as form the basis of developing appropriate harm 
reduction strategies. 
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From a public health perspective, this research program will serve as an important first step 
to understanding and monitoring prescription opioid use, costs and extramedical use of 
opioids, now and into the future. Regulators across jurisdictions currently use different 
criteria for authorising long-term opioid therapy, identifying at-risk patients and measuring 
potentially problematic opioid use. Valid indicators are required to identify the emergence 
of problems and provide information that will allow the extent of the problem to be 
monitored. Therefore, through the development of robust proxies or indicators of 
extramedical opioid use, this study will yield a useful surveillance tool for public health 
authorities. Currently no universally accepted indicators exist,52 and given the growing 
problem of opioid use in Australia and globally, the indicators have many potentially useful 
future applications. 
 
5.3.1 Limitations 
It is important to acknowledge several limitations of these data. The first relates to the 
extent to which these data reflect total opioid consumption in Australia. As noted earlier, 
until 2012 only drug dispensings reimbursed under the PBS appear in PBS data. Therefore, 
drug dispensings costing less than the general beneficiary contribution that did not attract a 
PBS-subsidy are not captured in these data. This is particularly problematic for selected 
opioids. Private prescriptions are also not included in the PBS collection, which account for 
an unknown but potentially substantial number of opioid prescriptions in Australia. Finally, 
these data do not include opioids that are available in pharmacies without a prescription 
(over-the-counter opioids), which in Australia includes codeine, the unit sales of which were 
more than 15 million in 2013 (personal communication, Gisev N, Nielsen S, Bruno R, et al, 
2014). Notwithstanding these limitations, these data certainly comprise the most detailed 
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information to hand about person-level patterns of opioid consumption in Australia, 
permitting detailed estimates of clinical issues that are of increasing community concern 
and great public health importance. 
 
Second, dispensing claims do not detail clinical information, particularly relating to 
indication for use. This poses particular challenges given opioids are prescribed at different 
doses depending on the nature of the pain being managed; dosing for cancer and non-
cancer pain are likely to differ significantly. Given we will be provided with the PBS-
dispensing history of all persons undergoing opioid treatment, we have the capacity to 
undertake sensitivity analyses excluding patients with a history of cancer treatment. 
However, this approach will not be definitive as cancer drug dispensing history is likely to be 
a specific but not sensitive proxy for a cancer diagnosis. 
 
The final limitation relates to the extent to which indicators of extramedical use accurately 
reflect the problem. We will develop our proxies through a process of consultation of the 
extant literature,53 and ongoing discussion with and feedback from expert clinicians in the 
fields of pain, cancer and addiction. We will make ongoing efforts to generate valid 
indicators to the fullest extent possible. Our use of sensitivity analyses to check whether our 
conclusions are affected by variations in definitions will also be a feature of our analyses. 
 
5.4 Conclusions 
This is a novel Australian research program of opioid use, costs and extramedical use at an 
individual level, with ongoing updates over time. This research has the capability to 
contribute significantly to pharmaceutical policy within Australia and globally.  
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Supplementary material: POPPY project definition of opioid naïve 
In relation to defining the cohort as “opioid naïve for at least 3-months prior to the index 
opioid prescription being supplied”, in this document we define opioid naïve, index 
prescription and write the logic for the drug dispensing history of a person INCLUDED in our 
data extraction. 
 
Definitions 
 Opioid naïve: no opioid dispensing for ≥90 days. 
 Index prescription: first opioid dispensing record after the opioid naïve period, i.e. ≥90 
days. 
 
People who were eligible for inclusion in the cohort 
We are interested in people with an opioid dispensing record (irrespective of the type of 
opioid dispensed; therefore searching was undertaken by ATC code rather than individual 
PBS item codes). All ATC codes related to any opioid were included. For people that have 
been dispensed ≥1 opioids during the data extraction period, there are two scenarios in 
which we want to INCLUDE people in the extraction: if a person’s opioid dispensing record is 
consistent with scenario A or B at any time throughout the data extraction period. 
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Scenario A: No opioid dispensing record in the first ≥90 days of available data; after this 
time period, the person has ≥1 opioid dispensing records (irrespective of the type of opioid 
dispensed. 
 
 
 
Scenario B: A person was dispensed an opioid in the first 90 days of data available, BUT at 
some point during the data extraction period, there is a gap of ≥90 days between any two 
opioid dispensing records. The two opioid dispensing records can be for the same or 
different opioids. 
 For all people included in our cohort, we requested their complete drug dispensing history 
for the entire data extraction period. For example, if the data extraction period starts 
January 1, 2010; but the index opioid dispensing record occurs in December 2012, we want 
their dispensing records from January 1, 2010 to the final day of the data extraction period. 
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People who were not eligible for inclusion in the cohort 
From this logic, we EXCLUDED scenarios C through E.  
 
Scenario C: People without any opioid dispensing records in the entire data extraction 
period. 
 
Scenario D: People with continuous use of opioids: persons with an opioid dispensing record 
in the first 90 days of data availability, and continuous opioid dispensing records throughout 
the data extraction period, i.e. <90 days gap between any two sequential opioid dispensing 
records. 
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Scenario E: Persons who stopped using opioids with no further opioid use: persons with an 
opioid dispensing record in the first 90 days of data availability, who have no further opioid 
dispensing records during the rest of the data extraction period. 
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Chapter Six: Prescription opioid access patterns and factors 
associated with increasing number of prescribers, pharmacies and 
dispensings: an observational study using pharmaceutical claims 
 
In this chapter we build upon the findings of Chapter Four and further examine the 
associations between patient factors and increasing opioid access patterns across multiple 
metrics including number of prescribers, number of dispensing pharmacies and volume of 
drugs dispensed. To date, the literature has focused predominantly on the association 
between patient age and sex and potential misuse; relatively few studies have controlled for 
other factors including drug dispensing history. 
 
This chapter is currently under consideration for publication; it has been peer-reviewed by 
Pain Medicine; we responded to reviewers’ comments 20 October 2016. 
 
Formatting note: To increase the readability of viewing this thesis electronically, we provide 
all figures or tables on the page following its first citation in the text. The abstract is 
formatted according to the Pain Medicine style guide. We provide the reference list at the 
end of this chapter. Supplementary materials are located after the reference list for this 
chapter. 
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Abstract 
Objective  
To examine associations between patient factors and increasing opioid access measured by 
three metrics: number of unique prescribers, dispensing pharmacies and dispensings in 12 
months. 
 
Methods 
We used pharmaceutical claims for a random 10% sample of Australians aged ≥18 years 
initiating or reinitiating strong opioid treatment (≥90-days of no strong opioid dispensing) 
between July 2010 and December 2012. We report the distribution of opioid access by 
metric. We used three separate zero-truncated negative binomial regressions to explore 
associations. We censored individuals 365-days after index date or at death, whichever 
occurred first. 
 
Results 
Approximately 69 088 persons initiated or reinitiated strong opioid treatment; they were 
predominantly female (59.7%) with a median age of 71 (interquartile range [IQR]: 58-81). 
Over one year, persons visited a median of two prescribers (IQR: 1-3), one dispensing 
pharmacy (IQR: 1-2) and had four opioid dispensings (IQR: 2-10). Three percent of people 
were in the top decile of opioid access distribution for all three metrics (≥4 prescribers, ≥3 
dispensing pharmacies or ≥20 dispensings). Increasing opioid access was strongly associated 
with male sex, history of pain treatment (3-12 months prior to index date) malignancy 
treatment or treatment for ≥3 other medical conditions.   
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Conclusions 
Delineating legitimate from extramedical opioid use based on pharmaceutical claims is 
imprecise. We demonstrated ‘high’ levels of access, defined in previous research, may 
reflect routine care for complex patients. Pharmaceutical claims have utility in examining 
population norms of prescription drug use and access patterns, and flagging persons at the 
extreme end of access, for at least one measure, who may warrant further investigation.    
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6.1 Introduction 
Over the past two decades, prescription opioid use has increased globally,1 coinciding with 
expanding its indication to include the treatment of non-cancer as well as cancer pain. At 
this time, opioid-related harms including hospitalisations and deaths also increased.2-6 In 
recognition of these escalating harms, the US Food and Drug Administration endorsed the 
post-market surveillance of opioids using routine data collections,7 with a particular focus 
on identifying extramedical use8 including doctor and pharmacy shopping. 
 
Our recent systematic review, synthesised 13 years of international literature attempting to 
quantify extramedical use of prescription drugs in pharmaceutical claims. In the 52 studies 
reviewed, number of prescribers, number of dispensing pharmacies and volume of drugs 
dispensed were frequently used metrics defining extramedical use,9,10 based on the 
assumption that higher access patterns are likely to be associated with harm to that 
individual or others. Despite these common metrics, we found 89 unique definitions of 
extramedical prescription drug use, 57 of which related to opioids. The vast majority of 
studies dichotomised access behaviours using a specific threshold delineating routine from 
extramedical use, which were predominantly based on previously published work, empirical 
analysis or expert opinion.9 Few studies reported the full spectrum of access patterns 
(lowest to highest) or the determinants of higher access patterns.  
 
The overall objective of this study was to explore the full spectrum of opioid access over a 
one-year period in Australian adults initiating or reinitiating strong opioid treatment 
between July 2010 and December 2012. We used national, population-based, person-level 
pharmaceutical claims to examine the distribution of opioid access in the year following the 
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date of initiating or reinitiating strong opioid treatment across three metrics: number of 
unique opioid prescribers, number of unique dispensing pharmacies for opioids and number 
of opioid dispensings. We also examined the association between patient characteristics 
and increasing opioid access patterns. 
 
6.2 Methods 
6.2.1 Setting 
Australia has a publicly funded universal healthcare system entitling its 24 million citizens 
and permanent residents to a range of subsidised health services including free treatment in 
public hospitals, subsidised treatment in private hospitals and outpatient services, including 
subsidised prescription drugs via the Australian Pharmaceutical Benefits Scheme (PBS).11 
 
6.2.2 Data source 
This study is part of the POPPY research project, evaluating the patterns and costs of 
prescription opioid use in Australia.12 The data supplied by the Australian Government 
Department of Human Services (DHS) comprised the dispensing history of a 10% random 
sample of persons aged ≥18 years initiating or reinitiating strong opioid treatment13 
between 1 July 2009 and 31 December 2013, defined as a strong opioid dispensing after a 
period of at least 90-days where no strong opioids were supplied.  
 
PBS data capture all dispensings (original and repeats) for PBS-subsidised prescription drugs 
that attract government subsidy, which occurs when the price of the drug is above the PBS 
copayment threshold.11 As such, we have complete ascertainment of concessional 
beneficiaries’ PBS records (persons receiving government benefits including the old age, 
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sickness, unemployment, single-parent or disability pension), as all PBS-subsidised drugs 
cost more than concessional beneficiaries’ copayment amount (2009-2013: AU$5.30-
5.90).14 Consequently, we restricted all analyses to concessional beneficiaries. Concessional 
beneficiaries comprise approximately 25% of the Australian population.15  
 
6.2.3 Prescription opioids of interest  
We use the World Health Organization’s Anatomical Therapeutic Chemical (ATC) 
classification system code N02A to identify PBS-subsidised opioid analgesics dispensed for 
the indication of pain (Supplementary Table 6.1). We also use the WHO’s cancer pain ladder 
for adults to categorise PBS-listed buprenorphine, fentanyl, hydromorphone, morphine or 
oxycodone as strong opioids and the mild opioids codeine and tramadol as weaker 
opioids.13  
 
6.2.4 Study population (Figure 6.1) 
We restricted the study cohort to persons who were concessional beneficiaries for the 
entire data period (1 July 2009 to 31 December 2013 inclusive) and initiated or reinitiated 
strong opioid treatment between 1 July 2010 and 31 December 2012. By definition, our 
cohort does not include persons dispensed PBS-subsidised weaker opioids exclusively, or 
persons who do not have a gap of at least 90 days between strong opioid dispensings for all 
or part of the observation period.  
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Adults (≥18 years) with ≥90-day period of no 
strong opioid (buprenorphine, fentanyl, 
hydromorphone, morphine or oxycodone) 
dispensings 
N = 143 681 
 
Figure 6.1 Cohort inclusion criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Strong opioid dispensing from July 1 2010 – 
December 31 2012 (no strong opioid dispensings in 
≥90-day period prior to date of initiating or 
reinitiating strong opioid treatment) 
 
N = 69 088 
Excluded:  
36 943 persons with no applicable strong opioid 
dispensings 
621 persons missing residential level of remoteness or 
relative socioeconomic disadvantage data 
2 606 decedents with same month of death as date of 
initiating or reinitiating strong opioid treatment 
  
Concessional beneficiary for data period  
(1 July 2009 – 31 December 2013) 
 
N = 109 258 
 
Excluded: 34 423 persons 
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We observed cohort members for up to two years; 365 days prior to the date of initiating or 
reinitiating strong opioid treatment and 365 days from this date (inclusive). We censored 
persons 365 days after initiating or reinitiating strong opioid treatment or at death, 
whichever occurred first. If a person had multiple episodes of strong opioid treatment, we 
report only the first strong opioid treatment episode. 
 
6.2.5 Study measures 
6.2.5.1 Outcome measures 
Number of unique opioid prescribers, number of unique dispensing pharmacies for opioids, 
and number of opioid dispensings recorded up to 365 days after the date of initiating or 
reinitiating strong opioid treatment (details in Table 6.1). To understand complete opioid 
access patterns, for each metric we counted all PBS-subsidised opioid dispensings (strong 
and weaker). 
 
6.2.5.2 Explanatory variables  
On the date of initiating or reinitiating strong opioid treatment we recorded patient age 
(years), sex and location of patient residence (according to Statistical Local Area [SLA]). We 
used location of patient residence (SLA) as a proxy for residential level of remoteness and 
relative socioeconomic disadvantage of residence (see previous publications for further 
details).12,16,17  
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Table 6.1 Summary and description of all measures and time period of assessment 
Measure Descriptiona Time period of assessment 
Outcome measures   
Number of unique opioid 
prescribers 
Total unique prescribers for any opioid dispensedb  365 days from date of initiating or reinitiating 
strong opioid treatmentc,d 
Number of unique opioid 
dispensing pharmacies 
Total unique dispensing pharmacies for any opioid 
dispensedb 
365 days from date of initiating or reinitiating 
strong opioid treatmentc,d 
Total opioid dispensings Total number of opioid dispensingsb 365 days from date of initiating or reinitiating 
strong opioid treatmentc,d 
Explanatory variables   
Age Patient age (years) 
Categories: 18-44; 45-64; 65-84; ≥85 years 
Date of initiating or reinitiating strong opioid 
treatment 
Sex Patient sex 
Categories: female; male 
Date of initiating or reinitiating strong opioid 
treatment 
Residential level of 
remotenesse 
Proximity to services based on last known patient address 
based on 2011 Remoteness Area Indices 
Categories: major city; inner regional; outer regional; 
remote/very remote 
Date of initiating or reinitiating strong opioid 
treatment 
Relative socioeconomic 
disadvantage of residencee 
Level of socioeconomic disadvantage based on last known 
patient address defined by Index of Relative 
Socioeconomic Disadvantage 2006  
Categories: lowest disadvantage; medium disadvantage; 
highest disadvantage 
Date of initiating or reinitiating strong opioid 
treatment 
History of 
pain/inflammation (NSAID) 
treatment 
Evidence of a prescription drug dispensing classified to 
treat condition of pain/inflammation according to the Rx-
Risk tool (ATC code: M01AB01-M01AH06) 
Categories: no; yes 
365 days prior to date of initiating or 
reinitiating strong opioid treatmentf 
History of pain (opioid) 
treatment  
Evidence of a prescription drug dispensing classified to 
treat condition of pain according to the Rx-Risk tool (ATC 
365 days prior to date of initiating or 
reinitiating strong opioid treatmentf 
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code: N02AA01-N02AX02) 
Categories: no; yes  
History of malignancy 
treatment 
Evidence of a prescription drug dispensing classified to 
treat condition of malignancy according to the Rx-Risk tool 
(ATC code: L01AA01-L01XX31) 
Categories: no; yes 
365 days prior to date of initiating or 
reinitiating strong opioid treatmentf 
Number of medical 
conditionsg 
Total unique medical conditions for which there is 
evidence of a prescription drug dispensing classified to 
treat one of 39 conditions according to the Rx-Risk tool 
(for all conditions and ATC codes see Supplementary Table 
6.2). Maximum value is 39. 
Categories: 0-2; 3-5; ≥6 conditions  
365 days prior to date of initiating or 
reinitiating strong opioid treatmentf 
Exposure time   
Days until death Number of days from date of initiating or reinitiating 
strong opioid treatment to death. Our data includes 
month and year of death alone. To calculate time in model 
death dates were set to 16th of the month. 
365 days from date of initiating or reinitiating 
strong opioid treatmentd 
ATC: Anatomical Therapeutic Classification; NSAID: nonsteroidal anti-inflammatory drug   
a Reference group is the first category listed  
b Includes all PBS-subsidised opioids: buprenorphine, codeine (single and combination products), fentanyl, hydromorphone, methadone, morphine, 
oxycodone (single and combination products) and tramadol  
c Or death, whichever occurred first  
d Including date of initiating or reinitiating strong opioid treatment  
e See references12,16,17 for further details 
f Excluding date of initiating or reinitiating strong opioid treatment  
g Excluded conditions of pain/inflammation (NSAID), pain (opioid) and malignancy   
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In the year prior to initiating or reinitiating strong opioid treatment, we identified treatment 
for a number of medical conditions using the Rx-Risk tool (hereafter Rx-Risk), a validated 
measure using 12-month dispensing records to identify the treatment and presence of 
specific medical conditions18,19 (Table 6.1, Supplementary Table 6.2). We identified 
separately the conditions of pain/inflammation (nonsteroidal anti-inflammatory drug 
[NSAID]), pain (opioid) and malignancy. 
 
6.2.6 Statistical analysis 
We characterised opioid access over one year for our three outcome measures using 
descriptive statistics (mean, range and medians with interquartile range). For each outcome, 
we detailed the number and proportion of persons exhibiting opioid access patterns equal 
to or above the 90th centile, and the overlap between metrics. We conducted further 
descriptive analyses, stratifying each metric by the number and proportion of persons, 
number and proportion of opioid dispensings, and patient factors of age; sex; history of 
pain/inflammation (NSAID), pain (opioid) and malignancy treatment, and number of medical 
conditions (excluding pain/inflammation [NSAID], pain [opioid] and malignancy).  
 
Finally, we examined the association between each outcome measure and potential 
explanatory variables using three separate zero-truncated negative binomial multivariable 
regressions. This statistical analysis was required as each outcome was a count variable 
starting from one (cohort included persons with at least one opioid dispensing), meaning 
our outcome variables did not contain zeros. We used the negative binomial regression, an 
extension of the Poisson regression, that allows for overdispersion (where the variability of 
the data is larger than expected under the Poisson distribution).20 Our explanatory variables 
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included patient age; sex; residential level of remoteness; relative socioeconomic 
disadvantage of residence; dispensing history of drugs for pain/inflammation (NSAID), pain 
(opioid) and malignancy treatment, and number of medical conditions (excluding 
pain/inflammation [NSAID], pain [opioid] and malignancy). In each regression model, we did 
not include either of the other two outcomes as explanatory variables in the models as all 
three outcomes were highly correlated and we were interested in the independent effects 
of patient factors on each specific opioid access pattern. For each multivariable model, we 
reported the incidence rate ratio (IRR) with 95% confidence intervals (CIs). We censored 
persons 365 days from initiating or reinitiating strong opioid treatment (inclusive) or at 
death; whichever occurred first. In our data, we received date of death as month and year 
of death, therefore, the precise temporal relationship between death and dispensing date 
are unknown. We therefore excluded persons who died in the same month as the date of 
initiating or reinitiating strong opioid treatment (n = 2 606) and conducted sensitivity 
analyses to assess the impact of this decision. 
 
We used SAS software version 9.4 (SAS Institute, Cary, NC, USA) for all analyses. 
 
6.2.7 Ethics approval 
The Population and Health Services Research Ethics Committee approved this project 
(2013/10/481). 
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6.3 Results 
6.3.1 Cohort demographics (Table 6.2) 
We identified 69 088 concessional beneficiaries initiating or reinitiating strong opioid 
treatment between 1 July 2010 and 31 December 2012. The cohort was predominantly 
female (59.7%) with a median age of 71 (interquartile range [IQR]: 58-81) at cohort entry. 
Approximately 11% of the cohort was censored at death (median days from date of 
initiating or reinitiating strong opioid treatment to death: 108, IQR: 45-212). 
 
In the year prior to initiating or reinitiating strong opioid treatment, two-thirds (67.7%) of 
the cohort were dispensed prescription drugs to treat ≥3 medical conditions and over one-
quarter (29.3%) were treated for at least six medical conditions (excluding 
pain/inflammation [NSAID], pain [opioid] and malignancy). Only 4.4% were previously 
dispensed drugs to treat malignancy. Almost half (43.3%) were dispensed drugs for pain 
(opioid; includes both strong and weaker opioids) treatment in the 3 to 12 months prior to 
initiating or reinitiating strong opioid treatment. In the year prior to initiating or reinitiating 
strong opioid treatment, 60.2% of the cohort were dispensed an NSAID or paracetamol. 
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Table 6.2 Cohort sociodemographics and clinical profile 
 Cohort 
N = 69 088 
% 
Sociodemographicsa   
Female sex 41 241 59.7 
Age group (years) 
18-44 
45-64 
65-84 
≥85 
 
9 735 
13 113 
34 930 
11 310 
 
14.1 
19.0 
50.6 
16.4 
Residential level of remotenessb 
Major city 
Inner regional 
Outer regional 
Remote/very remote 
 
43 494 
17 846 
7 045 
703 
 
63.0 
25.8 
10.2 
1.0 
Relative socioeconomic disadvantage of residencec 
Least disadvantage 
Medium disadvantage 
Highest disadvantage  
 
21 076 
31 051 
16 961 
 
30.5 
44.9 
24.6 
Clinical profiled   
History of pain/inflammation (NSAID) treatment 
History of pain/inflammation (NSAID) or 
paracetamole treatment 
History of pain (opioid) treatment 
History of malignancy treatment 
Number of medical conditionsf 
0-2 
3-5 
≥6 
22 695 
 
41 619 
29 884 
3 057 
 
22 279 
26 554 
20 255 
32.8 
 
60.2 
43.3 
4.4 
 
32.3 
38.4 
29.3 
NSAID: nonsteroidal anti-inflammatory drug 
a Measured at date of initiating or reinitiating strong opioid treatment 
b Level of residential remoteness based on 2011 Remoteness Area Indices which considers distance 
for specific service centres 
c Determined by Index of Relative Socio-economic Disadvantage (IRSD) 2006 
d Evidence of a prescription drug dispensing classified to treat a specific medical condition as defined 
by the Rx-Risk tool in 12 months prior to date of initiating or reinitiating strong opioid treatment 
e Paracetamol is not included in the Rx-Risk tool but is frequently prescribed for pain/inflammation. 
Paracetamol use identified based on ATC codes: N02BE01, N02BE51, N02BE71  
f Excluded medical conditions of pain, pain/inflammation and malignancy defined by Rx-Risk tool   
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6.3.2 Opioid use and access patterns  
There were 530 215 opioid dispensing episodes for the cohort in the year after initiating or 
reinitiating strong opioid treatment. Oxycodone, buprenorphine and codeine together 
comprised more than 75% of opioid dispensings (42.1%, 20.2% and 14.9% respectively). To 
access all opioids (strong and weaker), persons visited a median of two unique prescribers 
(IQR: 1-3), one dispensing pharmacy (IQR: 1-2) and received four opioid dispensings (IQR: 2-
10) (Figure 6.2). Over half the cohort (52.4%) visited ≤2 prescribers and one dispensing 
pharmacy to access opioids over one year; these persons obtained a median of two opioid 
dispensings (IQR: 1-4).  
 
At the other end of the spectrum, the 90th centile for each metric was four prescribers, 
three dispensing pharmacies and 20 dispensings. In the cohort, 13.4% (n = 9 261) visited ≥4 
prescribers, 17.2% (n = 11 894) visited ≥3 dispensing pharmacies and 10.7% (n = 7 418) 
obtained ≥20 dispensings; only 3.1% (n = 2 151) were in the top decile for all three metrics 
(Figure 6.3). 
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Figure 6.2 Spectrum of opioid access patterns over one year after initiating or reinitiating 
strong opioid treatment: violin plot with shaded centile bounds 
 
Legend: The X axis represents the number of opioid prescribers, dispensing pharmacies or 
dispensings accessed in 12 months. 1st to 25th centiles in brown; 26th to 75th centiles in grey; 76th to 
94th centiles in darker grey; ≥95th centiles in black. Blue line indicates the median; turquoise line 
indicates the mean.
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Figure 6.3 Relationship between persons at the 90th centile or greater for at least one metric 
 
Persons exhibiting none of these access patterns = 50 327 (72.8%) 
 
 
 
 
  
≥3 pharmacies 
 
N = 5 352 
(7.7%) 
 
≥20 dispensings 
 
N = 3 091 (4.5%) 
 
≥4 prescribers 
 
N = 2 657 
(3.8%) 
 
N = 1 057 
(1.5%) 
 
N = 3 334 
(4.8%) 
 
N = 2 151 
(3.1%) 
 
N = 1 119          
 
(1.6%)          
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Factors associated with increasing opioid access patterns (Tables 6.3A-C and 6.4) 
We stratified access patterns for number of unique prescribers, dispensing pharmacies and 
dispensings by individual factors and opioid dispensings over one year (Tables 6.3A-C). As 
the value for each metric increased, the proportion of persons who exhibited the pattern 
decreased. For example, 47.4% of the cohort visited one prescriber whereas only 0.6% 
visited ≥10 prescribers. Generally, as the value for each metric increased, so did the 
proportion of persons with a history of treatment for pain/inflammation (NSAID) (one 
dispensing: 26.4% to 39.5% for ≥31 dispensings) or pain (opioid) (one prescriber: 34.1% to 
75.3% for ≥10 prescribers).  
 
The relationship with other patient factors varied by metric. As the number of prescribers or 
dispensing pharmacies increased, the median age and median number of medical conditions 
decreased. For example, the median age was higher for persons accessing one pharmacy 
(73; IQR: 61-82) compared to persons accessing ≥10 pharmacies (40; IQR: 34-49). Whereas 
for dispensings, as the number of dispensings increased both the median age and median 
number of conditions increased.  
 
Finally, persons who visited at least three prescribers, at least two dispensing pharmacies or 
obtained at least eight dispensings, obtained disproportionately large amounts of opioids, 
i.e. the proportion of dispensed opioids obtained was larger than the proportion of persons 
exhibiting the access pattern (Tables 6.3A-C). This became particularly marked as the 
threshold increased; for example, 13.3% of persons visited ≥4 prescribers but obtained 
almost one-third (32.6%, n = 172 797) of all opioid dispensings.   
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Table 6.3A Number of unique opioid prescribers stratified by dispensings, persons and individual factors 
 Cohort (N=69 088) Individual factorsa 
Unique opioid 
prescribersb,c 
Opioid 
dispensingsc 
(N, %) 
Persons 
(N, %) 
Age (years)d 
(Median, IQR) 
Female sexd 
(N, %) 
Pain/inflammation 
(NSAID) treatmente  
(N, %) 
Pain (opioid) 
treatmente 
(N, %) 
Malignancy 
treatmente 
(N, %) 
Number of 
medical 
conditionse,f 
(Median, IQR) 
1 prescriber 125 284 (23.6) 32 710 (47.4) 72 (60-82) 19 553 (59.8) 9 682 (29.6) 11 139 (34.1) 1 067 (3.3) 4 (2-6) 
2 prescribers 134 879 (25.4) 18 238 (26.4) 72 (60-81) 10 930 (59.9) 6 263 (34.3) 8 410 (46.1) 784 (4.3) 4 (2-6) 
3 prescribers 97 255 (18.3) 8 879 (12.9) 71 (60-81) 5 327 (60.0) 3 234 (36.4) 4 690 (52.8) 533 (6.0) 4 (2-6) 
4 prescribers 63 780 (12.0) 4 373 (6.3) 71 (57-80) 2 643 (60.4) 1 682 (38.5) 2 549 (58.3) 292 (6.7) 4 (2-6) 
5 prescribers 38 255 (7.2) 2 149 (3.1) 69 (53-79) 1 275 (59.3) 802 (37.3) 1 307 (60.8) 180 (8.4) 4 (2-6) 
6 prescribers 23 666 (4.5) 1 124 (1.6) 69 (50-78) 645 (57.4) 421 (37.5) 691 (61.5) 79 (7.0) 4 (2-6) 
7 prescribers 14 093 (2.7) 597 (0.9) 66 (47-78) 351 (58.8) 219 (36.7) 381 (63.8) 45 (7.5) 4 (2-6) 
8 prescribers 8 766 (1.7) 347 (0.5) 63 (43-75) 175 (50.4) 125 (36.0) 226 (65.1) 26 (7.5) 4 (2-6) 
9 prescribers 6 476 (1.2) 218 (0.3) 59 (39-74) 115 (52.8) 86 (39.5) 150 (68.8) 20 (9.2) 4 (1-6) 
≥10 prescribers 17 761 (3.4) 453 (0.6) 49 (37-66) 227 (50.1) 181 (40.0) 341 (75.3) 31 (6.8) 3 (2-5) 
Entire cohort 530 215 (100) 69 088 (100) 71 (58-81) 42 179 (59.6) 22 695 (32.8) 29 884 (43.3) 3 057 (4.4) 4 (2-6) 
IQR: interquartile range; N: number; NSAID: nonsteroidal anti-inflammatory drug 
a Denominator is ‘persons’ accessing same number of unique opioid prescribers 
b Measured in 12 months after the date of initiating or reinitiating strong opioid treatment  
c Any PBS-subsidised opioid: buprenorphine, codeine, fentanyl, hydromorphone, methadone, morphine, oxycodone or tramadol  
d Measured at the date of initiating or reinitiating strong opioid treatment 
e Defined by Rx-Risk tool measured in 12 months prior to the date of initiating or reinitiating strong opioid treatment 
f Excluded medical conditions of pain, pain/inflammation and malignancy as defined by Rx-Risk tool 
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Table 6.3B Number of unique opioid dispensing pharmacies stratified by dispensings, persons, and individual factors 
 Cohort (N=69 088) Individual factorsa 
Unique 
dispensing 
pharmacies for 
opioidsb,c 
Opioid 
dispensingsc 
(N, %) 
Persons 
(N, %) 
Age (years)d 
(Median, IQR) 
Female sexd 
(N, %) 
Pain/inflammation 
(NSAID) treatmente  
(N, %) 
Pain (opioid) 
treatmente 
(N, %) 
Malignancy 
treatmente 
(N, %) 
Number of 
medical  
conditionse,f 
(Median, IQR) 
1 pharmacy 197 672 (37.3) 40 031 (57.9) 73 (61-82) 23 854 (59.6) 11 983 (29.9) 14 334 (35.8) 1 544 (3.9) 4 (2-6) 
2 pharmacies 145 705 (27.5) 17 163 (24.8) 72 (59-81) 10 257 (59.8) 6 015 (35.1) 8 322 (48.5) 834 (4.9) 4 (2-6) 
3 pharmacies 79 577 (15.0) 6 622 (9.6) 70 (55-79) 3 983 (60.2) 2 555 (38.6) 3 684 (55.6) 394 (6.0) 4 (2-6) 
4 pharmacies 41 866 (7.9) 2 646 (3.8) 67 (50-77) 1 570 (59.3) 1 057 (40.0) 1 643 (62.1) 161 (6.1) 4 (2-6) 
5 pharmacies 24 852 (4.7) 1 222 (1.8) 61 (44-73) 737 (60.3) 522 (42.7) 848 (69.4) 70 (5.7) 4 (2-6) 
6 pharmacies 14 439 (2.7) 638 (0.9) 56 (40-71) 380 (59.6) 257 (40.3) 453 (71.0) 25 (3.9) 3 (2-5) 
7 pharmacies 7 868 (1.5) 300 (0.4) 50 (38-67) 202 (67.3) 128 (42.7) 233 (77.7) 16 (5.3) 3 (2-5) 
8 pharmacies 5 186 (1.0) 159 (0.2) 51 (39-66) 88 (55.4) 66 (41.5) 117 (73.6) 5 (3.1) 3 (2-5) 
9 pharmacies 3 279 (0.6) 102 (0.2) 44 (35-57) 56 (54.9) 44 (43.1) 81 (79.4) 3 (2.9) 3 (2-5) 
≥10 pharmacies 9 771 (1.9) 205 (0.3) 40 (34-49) 114 (55.6) 68 (33.2) 169 (82.4) 5 (2.4) 2 (1-4) 
Entire cohort 530 215 (100) 69 088 (100) 72 (59-81) 42 179 (59.6) 22 695 (32.8) 29 884 (43.3) 3 057 (4.4) 4 (2-6) 
IQR: interquartile range; N: number; NSAID: nonsteroidal anti-inflammatory drug 
a Denominator is ‘persons’ accessing same number of unique dispensing pharmacies for opioids 
b Measured in 12 months after the date of initiating or reinitiating strong opioid treatment  
c Any PBS-subsidised opioid: buprenorphine, codeine, fentanyl, hydromorphone, methadone, morphine, oxycodone or tramadol  
d Measured at the date of initiating or reinitiating strong opioid treatment 
e Defined by Rx-Risk tool measured in 12 months prior to the date of initiating or reinitiating strong opioid treatment 
f Excluded medical conditions of pain, pain/inflammation and malignancy as defined by Rx-Risk tool 
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Table 6.3C Total opioid dispensings by dispensings, persons, and individual factors 
 Cohort (N=69 088) Individual factorsa 
Number of opioid 
dispensingsb,c 
Opioid 
dispensingsc 
(N, %) 
Persons 
(N, %) 
Age (years)d 
(Median, 
IQR) 
Female sexd 
(N, %) 
Pain/inflammation 
(NSAID) treatmente  
(N, %) 
Pain (opioid) 
treatmente 
(N, %) 
Malignancy 
treatmente 
(N, %) 
Number of 
medical 
conditionse,f 
(Median, IQR) 
1 dispensing 17 087 (3.2) 17 087 (24.7) 70 (53-79) 10 023 (58.7) 4 513 (26.4) 4 148 (24.3) 543 (3.2) 3 (1-5) 
2 dispensings 21 424 (4.0) 10 712 (15.5) 71 (55-80) 6 368 (59.5) 3 288 (30.7) 3 491 (32.6) 375 (3.5) 3 (1-6) 
3 dispensings 20 034 (3.8) 6 678 (9.7) 71 (58-81) 3 912 (58.6) 2 210 (33.1) 2 692 (40.3) 303 (4.5) 4 (2-6) 
4 dispensings 18 764 (3.5) 4 691 (6.8) 72 (59-81) 2 719 (58.0) 1 613 (34.4) 2 167 (46.2) 218 (4.7) 4 (2-6) 
5 dispensings 17 465 (3.3) 3 493 (5.1) 72 (61-81) 2 087 (59.8) 1 220 (34.9) 1 653 (47.3) 155 (4.4) 4 (2-6) 
6 dispensings 16 632 (3.1) 2 772 (4.0) 72 (61-82) 1 660 (59.9) 1 000 (36.1) 1 422 (51.3) 155 (5.6) 4 (2-6) 
7 dispensings 15 848 (3.0) 2 264 (3.3) 72 (62-81) 1 346 (59.5) 853 (37.7) 1 177 (52.0) 138 (6.1) 4 (2-6) 
8 dispensings 15 312 (2.9) 1 914 (2.8) 73 (62-82) 1 160 (60.6) 738 (38.6) 1 048 (54.8) 133 (7.0) 4 (2-6) 
9 dispensings 14 463 (2.7) 1 607 (2.3) 73 (62-82) 955 (59.4) 590 (36.7) 929 (57.8) 82 (5.1) 4 (2-6) 
10 dispensings  
11-15 dispensings 
16-20 dispensings 
21-25 dispensings 
26-30 dispensings 
≥31 dispensings  
14 520 (2.7) 
74 832 (14.1) 
68 131 (12.8) 
55 226 (10.4) 
52 304 (9.9) 
108 173 (20.4) 
1 452 (2.1) 
5 971 (8.6) 
3 828 (5.5) 
2 417 (3.5) 
1 882 (2.7) 
2 500 (3.6) 
73 (63-82) 
74 (63-82) 
74 (63-83) 
75 (62-84) 
77 (64-86) 
69 (50-81) 
856 (59.0) 
3 534 (61.0) 
2 409 (62.9) 
1 512 (62.6) 
1 213 (64.5) 
1 487 (59.5) 
544 (37.5) 
2 168 (37.4) 
1 459 (38.1) 
886 (36.7) 
625 (33.2) 
988 (39.5) 
825 (56.8) 
3 521 (60.8) 
2 388 (62.4) 
1 540 (63.7) 
1 056 (56.1) 
1 827 (73.1) 
101 (7.0) 
324 (5.6) 
204 (5.3) 
131 (5.4) 
75 (4.0) 
120 (4.8) 
4 (3-6) 
5 (3-7) 
5 (3-7) 
5 (3-7) 
5 (3-7) 
4 (3-7) 
Entire cohort 530 215 (100) 69 088 (100) 72 (59-81) 42 179 (59.6) 22 695 (32.8) 29 884 (43.3) 3 057 (4.4) 4 (2-6) 
IQR: interquartile range; N: number; NSAID: nonsteroidal anti-inflammatory drug 
a Denominator is ‘persons’ accessing same number of opioid dispensings 
b Measured in 12 months after the date of initiating or reinitiating strong opioid treatment  
c Any PBS-subsidised opioid: buprenorphine, codeine, fentanyl, hydromorphone, methadone, morphine, oxycodone or tramadol  
d Measured at the date of initiating or reinitiating strong opioid treatment 
e Defined by Rx-Risk tool measured in 12 months prior to the date of initiating or reinitiating strong opioid treatment 
f Excluded medical conditions of pain, pain/inflammation and malignancy as defined by Rx-Risk tool 
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Table 6.4 Separate zero-truncated negative multivariable binomial regression models to examine factors associated with increasing number of 
unique opioid prescribers, dispensing pharmacies or dispensings in 12 months 
 Cohort (N=69 088) Prescribers Pharmacies Dispensings 
N (%) IRR (CI) IRR (CI) IRR (CI) 
Age group (years)a 
18-44 
45-64 
65-84 
≥85 
 
9 735 (14.1) 
13 113 (19.0) 
34 930 (50.6) 
11 310 (16.4) 
 
Ref. 
0.84 (0.81 to 0.88) 
0.76 (0.73 to 0.78) 
0.84 (0.80 to 0.89) 
 
Ref. 
0.78 (0.75 to 0.81) 
0.58 (0.55 to 0.60) 
0.55 (0.52 to 0.58) 
 
Ref. 
1.25 (1.20 to 1.31) 
1.23 (1.19 to 1.30) 
2.39 (2.27 to 2.53) 
Sexa 
Female 
Male 
 
41 241 (59.7) 
27 847 (40.3) 
 
Ref. 
1.13 (1.11 to 1.16) 
 
Ref. 
1.06 (1.04 to 1.09) 
 
Ref. 
1.13 (1.09 to 1.15) 
Residential level of remotenessa 
Major city 
Inner regional 
Outer regional 
Remote/very remote 
 
43 494 (63.0) 
17 846 (25.8) 
7 045 (10.2) 
703 (1.0) 
 
Ref. 
1.04 (1.01 to 1.07) 
1.17 (1.13 to 1.22) 
1.38 (1.23 to 1.55) 
 
Ref. 
0.87 (0.84 to 0.90) 
0.87 (0.84 to 0.91) 
0.83 (0.73 to 0.93) 
 
Ref. 
1.05 (1.01 to 1.08) 
1.09 (1.05 to 1.15) 
1.02 (0.89 to 1.17) 
Relative socioeconomic disadvantage of 
residencea 
Least disadvantage  
Medium disadvantage 
Highest disadvantage 
 
 
21 076 (30.5) 
31 051 (44.9) 
16 961 (24.6) 
 
 
Ref. 
1.04 (1.01 to 1.06) 
1.03 (1.00 to 1.07) 
 
 
Ref. 
0.99 (0.96 to 1.02) 
1.03 (0.99 to 1.07) 
 
 
Ref. 
1.01 (0.98 to 1.04) 
0.97 (0.93 to 1.01) 
History of pain/inflammation (NSAID) 
treatmentb 
No 
Yes 
 
 
46 393 (67.2) 
22 695 (32.8) 
 
 
Ref. 
1.03 (1.01 to 1.06) 
 
 
Ref. 
1.11 (1.07 to 1.13) 
 
 
Ref. 
1.00 (0.97 to 1.03) 
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History of pain (opioid) treatmentb,c 
No 
Yes 
39 204 (56.7) 
29 884 (43.3) 
Ref. 
1.60 (1.57 to 1.65) 
Ref. 
1.73 (1.68 to 1.79) 
Ref. 
2.14 (2.08 to 2.20) 
History of malignancy treatmentb 
No 
Yes 
 
66 031 (95.6) 
3 057 (4.4) 
 
Ref. 
2.05 (1.93 to 2.18) 
 
Ref. 
1.62 (1.52 to 1.72) 
 
Ref. 
1.70 (1.58 to 1.82) 
Number of medical conditionsb,d 
0-2 
3-5 
≥6 
 
22 279 (32.3) 
26 554 (38.4) 
20 255 (29.3) 
 
Ref. 
1.17 (1.14 to 1.21) 
1.32 (1.28 to 1.38) 
 
Ref. 
1.11 (1.07 to 1.15) 
1.16 (1.12 to 1.20) 
 
Ref. 
1.38 (1.34 to 1.43) 
1.63 (1.58 to 1.70) 
CI = 95% confidence interval; IRR = incidence rate ratio; NSAID = nonsteroidal anti-inflammatory drug; Ref. = reference category 
a Measured at the date of initiating or reinitiating strong opioid treatment  
b Defined by Rx-Risk tool measured in 12 months prior to date of initiating or reinitiating strong opioid treatment  
c Strong opioids dispensed prior to ≥90-day period of no strong opioid dispensings  
d Excluded medical conditions of pain/inflammation (NSAID), pain (opioid) and malignancy as defined by the Rx-Risk tool  
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Our descriptive results were largely consistent with the multivariable regression analyses 
(Table 6.4). We found males were 6-13% more likely to exhibit increasing opioid access 
patterns compared to females. Older persons (≥45 years) accessed fewer prescribers and 
pharmacies than younger persons (18-44 years), but obtained more opioid dispensings. 
Persons living in regional or remote areas visited more prescribers, but fewer pharmacies 
than persons living in a major city. There was limited evidence that relative socioeconomic 
disadvantage of residence was associated with any outcome after adjusting for other 
factors.  
 
Across all outcomes, the strongest factors associated with increasing opioid access patterns 
were a history of pain (opioid) or malignancy treatment. We found limited associations 
between a history of pain/inflammation (NSAID) treatment and increasing opioid access 
patterns after adjusting for other factors. For all three outcomes, persons with increasing 
number of medical conditions had higher access patterns than their counterparts with fewer 
medical conditions. Of note, our descriptive analysis demonstrated a decrease in median 
number of medical conditions as number of prescribers or dispensing pharmacies increased; 
controlling for age in the multivariable regression analyses reversed the direction of this 
association.  
 
In all analyses we excluded persons who died in the same month as initiating or reinitiating 
strong opioid treatment (n = 2 606). We conducted a sensitivity analysis to explore the 
impact of this decision by replicating our three zero-truncated negative binomial 
multivariable regression analyses and including these persons. The results for these 
sensitivity analyses were almost identical to our original results for number of prescribers 
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and dispensing pharmacies (Supplementary Table 6.3). However, the incidence risk ratio 
(IRR) of obtaining multiple opioid dispensings increased considerably for persons aged ≥85 
years and persons with a history of malignancy treatment. 
 
6.4 Discussion 
In this cohort, the majority of people initiating or reinitiating strong opioid treatment 
exhibited unremarkable access patterns. Specifically, over two-thirds of the cohort visited 
one or two prescribers or dispensing pharmacies over one year to access their prescription 
opioids. These people obtained two-fifths of all dispensed opioids and had a median of two 
opioid dispensings over one year. 
 
In our systematic review quantifying extramedical use of prescription drugs in 
pharmaceutical claims, only six of the 52 reviewed studies reported the distribution of 
prescription drug access for at least one metric.9 To date, only three studies, all from the US, 
have reported the spectrum of opioid access patterns over one year using pharmaceutical 
claims.21-23 These studies reported 83-92% of persons visited one or two opioid prescribers 
over one year21,22 and 52-98% visited up to two pharmacies.22,23 The difference in 
proportions reflects the cohort definition; studies with a more restrictive inclusion criteria, 
such as 3 months of continuous opioid use prior to index date, generally report lower 
proportions of persons visiting 1-2 prescribers/dispensing pharmacies.  
 
There is considerable variation in the extent of extramedical opioid use reported across 
studies. In our systematic review we found the extent of extramedical opioid use ranged 
from <1% to 63.2%, with similar figures (<1% to 81%) reported in a recent review examining 
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extramedical opioid use in adults with chronic pain.10,24 In our review, estimates were 
dependent on the use of single or combined metrics and thresholds delineating routine use 
from extramedical use. Generally, when extramedical use is defined using higher thresholds 
and/or multiple metrics, the reported level of misuse is lower. In the current study, over 
one-quarter of the cohort exhibited access patterns in the top decile for at least one metric 
(≥4 prescribers, ≥3 pharmacies or ≥20 dispensings). Based on our review of previous 
literature, any one of these access patterns would have been considered extramedical use.9 
 
In our study, 3% of persons exhibited access patterns in the top decile for all three metrics. 
Compared to the entire cohort, these persons were younger (52% aged 18-64 years) and 
obtained a disproportionately large amount of opioid dispensings (14%). These 
characteristics were consistent with previous literature profiling ‘misusers’.25 Compared to 
the entire cohort, persons who exhibited access patterns in the top decile for all three 
metrics, also had a higher proportion of persons with a history of malignancy treatment (7% 
versus 4%) and a higher median number of medical conditions (6 versus 3). Our findings 
were consistent with a recent US Medicare study; as the number of prescribers increased so 
did the proportion of persons dispensed antineoplastic, stimulant, central nervous system, 
neuromuscular and non-opioid analgesic drugs.21 These findings suggest sicker persons have 
increasing opioid access, which may be consistent with routine medical care, rather than 
extramedical use. However, disease severity is difficult to determine based on 
pharmaceutical claims alone; only the treating physician would have all the information 
necessary to assess whether the volume of drugs procured from visiting multiple doctors 
and pharmacies were for legitimate medical or extramedical purposes.  
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Our study had several limitations. As with previous studies included in our systematic 
review, we have focused on access patterns and therefore the potential risk of harm that 
could be attributed to higher patterns of use. These studies which rely solely on dispensing 
claims do not have the capacity to identify harms with normal use, for example excessive 
sedation occurring with initiation. Moreover our cohort was restricted to initiators and 
reinitiators of strong opioid treatment, and thus excluded most long-term strong opioid use. 
We restricted our cohort to concessional beneficiaries (persons receiving a government 
pension) as we have their complete PBS dispensing history. Our data did not capture any 
under-copayment dispensings or private prescriptions which together accounted for 18% of 
opioid use in 2011.26 Further, our data did not capture dispensings for non-PBS-listed 
prescription opioids including dextropropoxyphene and tapentadol nor over-the-counter 
(OTC) codeine (only OTC opioid available in Australia), which accounted for at least 56% of 
all prescription and OTC codeine sales in 2013.27, 28 Therefore, our results underestimate 
total opioid use and access patterns. Moreover, our previous research demonstrated the 
length of the look-back period impacts on the formation of cohorts in new-user study 
designs.29 However, we previously demonstrated the POPPY cohort demographics were 
similar whether we adopted a 3, 6 or 12-month opioid-free period.16 
 
6.5 Conclusions 
Despite the recent push to quantify extramedical opioid use via routinely collected health 
data, this study demonstrated the challenges in delineating routine from extramedical use 
based on pharmaceutical claims alone. Pharmaceutical claims have utility in examining 
population norms of prescription drug use and access patterns, and flagging persons at the 
extreme end of access, for at least one measure, who may warrant further investigation.   
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Supplementary Table 6.1 List of all PBS-subsidised opioid analgesics and Anatomical Therapeutic 
Chemical code 
ATC code Generic drug name  Opioid typea 
N02AE01 Buprenorphine Strong 
R05DA04b (N02AA59, N02AA79) Codeine (combinations) Weaker 
N02AB03 Fentanyl Strong 
N02AA03 Hydromorphone Strong 
N02AC Methadone Strong 
N02AA01 Morphine Strong 
N02AA05 (N02AA55) Oxycodone (combinations) Strong 
N02AX02 Tramadol Weaker 
ATC: Anatomical Therapeutic Chemical  
a Opioid classification based on World Health Organization cancer pain ladder for adults13 
b Codeine dispensed under this ATC code may be dispensed for the indication of cough 
suppression or pain 
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Supplementary Table 6.2 List of Rx-Risk tool defined medical conditions and Anatomical 
Therapeutic Chemical codes 
Medical condition  
(defined by Rx-Risk tool) 
ATC codes 
Alcohol dependence N07BB03-N07BB04; V03AA01 
Allergies R01AC01-R01AD60; R06AD02-R06AX26 
Anticoagulation B01AA03-B01AB06 
Antiplatelet B01AC04-B01AC30 
Anxiety N05BA01-N05BA12 
Arrhythmia C01AA05, C01BA01-C01BD01 
Benign prostate hyperplasia G04CA02-G04CA03, G04CB01 
Bipolar N06AX 
Congestive heart failure C03CA01-C03CC01 
Dementia N06DA02-N06DA04 
Depression N06AA01-N06AG02, N06AX03-N06AX18 
Diabetes A10AA01-A10BG03 
End stage renal disease B03XA01-B03XA02; A11CC01-A11CC04; V03AE02 
Epilepsy N03AA01-N03AX14 
Gastric acid disorder A02BA01-A02BX05 
Glaucoma S01EA01-S01EB03; S01EC03-S01EX 
Gout M04AA01-M04AC01 
Hepatitis C J05AB54 
HIV J05AE-J05AE08; J05AF01-J05AG03; J05AR; J05AX07 
Hyperkalaemia V03AE01 
Hyperlipidaemia C10AA01-C10BX03 
Hypertension C03AA01-C03BA11; C03DA01-CO3AE01; C09BA02-C09BA09; 
C09DA02-C09DA07; C02AB01-C02AC05; C02DB02-C02KX01 
Hypothyroidism H03AA01-H03AA02 
IHD angina C01DA02-C01DA14 
IHD hypertension C07AA01-C07AB03; C07AG01-C08DB01 
Inflammatory bowel disease A07EC01-A07EC04; A07EA01-A07EA02 
Liver failure A06AD11 
Malignancy L01AA01-L01XX31 
Malnutrition B05BA03 
Migraine N02CA01-N02CX01 
Osteoporosis/Paget’s disease M05BA01-M05BB03 
Pain N02AA01-N02AX02 
Pain/inflammation M01AB01-M01AH06 
Pancreatic insufficiency A09AA02 
Parkinson’s disease N04AA01-N04BX02 
Psoriasis D05AA; D05BB01-D05BB02; D05AX02 
Psychotic illness N5AA01-N05AB02; N05AB06-N05AX12 
Reactive airway disease R03AC02-R03DC03 
Smoking cessation N07BA01-N07BA02 
Steroid responsive disease H02AB01-H02AB10 
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Transplant L04AA01-L04AA21 
Tuberculosis J04AB04-J04AK02 
ATC: Anatomical Therapeutic Chemical 
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Supplementary Table 6.3 Sensitivity analysis results: separate zero-truncated negative binomial regression models to examine factors 
associated with increasing number of unique opioid prescribers, dispensing pharmacies or dispensings in 12 months 
 Cohort (N=71 685) Prescribers Pharmacies Dispensings 
N (%) IRR (CI) IRR (CI) IRR (CI) 
Age group (years)a 
18-44 
45-64 
65-84 
≥85 
 
   9 750 (13.6) 
13 197 (18.4) 
35 855 (50.0) 
12 883 (18.0) 
 
Ref. 
0.84 (0.81 to 0.88) 
0.76 (0.73 to 0.79) 
0.89 (0.84 to 0.93) 
 
Ref. 
0.78 (0.75 to 0.81) 
0.58 (0.56 to 0.61) 
0.55 (0.53 to 0.58) 
 
Ref. 
1.26 (1.20 to 1.34) 
1.34 (1.27 to 1.40) 
3.86 (3.60 to 4.10) 
Sexa 
Female 
Male 
 
42 657 (59.5) 
29 028 (40.5) 
 
Ref. 
1.15 (1.12 to 1.17) 
 
Ref. 
1.07 (1.05 to 1.11) 
 
Ref. 
1.21 (1.17 to 1.26) 
Residential level of remotenessa 
Major city 
Inner regional 
Outer regional 
Remote/very remote 
 
43 494 (63.1) 
18 482 (25.8) 
7 257 (10.1) 
728 (1.0) 
 
Ref. 
1.04 (1.01 to 1.07) 
1.17 (1.12 to 1.22) 
1.36 (1.22 to 1.54) 
 
Ref. 
0.88 (0.84 to 0.90) 
0.87 (0.84 to 0.91) 
0.82 (0.72 to 0.93) 
 
Ref. 
1.04 (1.00 to 1.08) 
1.07 (1.02 to 1.14) 
0.98 (0.84 to 1.14) 
Relative socioeconomic disadvantage of 
residencea 
Least disadvantage  
Medium disadvantage 
Highest disadvantage 
 
 
21 735 (30.3) 
32 193 (44.9) 
17 757 (24.8) 
 
 
Ref. 
1.03 (1.01 to 1.06) 
1.04 (1.00 to 1.07) 
 
 
Ref. 
0.99 (0.96 to 1.02) 
1.03 (1.00 to 1.07) 
 
 
Ref. 
1.01 (0.97 to 1.05) 
0.98 (0.94 to 1.03) 
History of pain/inflammation (NSAID) 
treatmentb 
No 
Yes 
 
 
48 727 (68.0) 
22 958 (32.0) 
 
 
Ref. 
1.02 (0.99 to 1.05) 
 
 
Ref. 
1.09 (1.06 to 1.13) 
 
 
Ref. 
0.93 (0.90 to 0.96) 
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History of pain (opioid) treatmentb,c 
No 
Yes 
 
41 196 (57.5) 
30 489 (42.5) 
 
Ref. 
1.60 (1.55 to 1.63) 
 
Ref. 
1.73 (1.68 to 1.77) 
 
Ref. 
2.14 (2.05 to 2.20) 
History of malignancy treatmentb 
No 
Yes 
 
68 445 (95.5) 
3 240 (4.5) 
 
Ref. 
2.14 (2.01 to 2.27) 
 
Ref. 
1.67 (1.55 to 1.77) 
 
Ref. 
2.03 (1.88 to 2.20) 
Number of medical conditionsb,d 
0-2 
3-5 
≥6 
 
22 648 (31.6) 
27 598 (38.5) 
21 439 (29.9) 
 
Ref. 
1.17 (1.14 to 1.21) 
1.34 (1.30 to 1.39) 
 
Ref. 
1.12 (1.08 to 1.15) 
1.16 (1.13 to 1.21) 
 
Ref. 
1.46 (1.40 to 1.52) 
1.86 (1.77 to 1.93) 
CI: 95% confidence interval; IRR: incidence rate ratio; NSAID: nonsteroidal anti-inflammatory drug; Ref.: reference category 
a Measured at date of initiating or reinitiating strong opioid treatment 
b Defined by Rx-Risk tool measured in 12 months prior to date of initiating or reinitiating strong opioid treatment 
c Strong opioids dispensed prior to ≥90-day period of no strong opioid dispensings  
d Excluded medical conditions of pain/inflammation (NSAID), pain (opioid) and malignancy as defined by the Rx-Risk tool 
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Chapter Seven: Looking forward and looking back: the balancing act 
in new drug user designs for pharmacoepidemiological research 
 
In Chapter Six we examined the associations between patient factors and increasing opioid 
access patterns in persons initiating or reinitiating strong opioid treatment. We defined an 
initiation/reinitiation as ≥90 days of no strong opioid dispensings prior to a strong opioid 
dispensing. We used this definition as we previously demonstrated there was little 
difference in the opioid cohort composition based on a longer opioid-free period of 180 or 
365 days. 
 
However, for future pharmacoepidemiology studies it is important to understand the impact 
of the length of the look-back period on results and cohort composition. In this chapter, we 
examine this question for three drug classes: antipsychotics, opioids including codeine 
preparations and opioids excluding codeine preparations.  
 
This chapter is based on the following publication:  
Bianca Blanch, Benjamin Daniels, Melisa Litchfield, Sallie-Anne Pearson. Looking forward 
and looking back: the balancing act in new drug user designs for pharmacoepidemiological 
research. Pharmacoepidemiology and Drug Safety. 2015; 24: 157-158. 
 
Formatting note: To increase the readability of viewing this thesis electronically, we provide 
all figures or tables on the page following its first citation in the text. The key points and 
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abstract are formatted according to the Pharmacoepidemiology and Drug Safety style guide. 
We provide the reference list at the end of this chapter. 
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Key Points 
 There is no ‘one-size-fits-all’ approach to new-user study designs. 
 Length of the look-back period will depend on the prescription drug and outcome of 
interest.  
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To the Editor, 
 
It has long been known that the length of a look-back period to determine new versus 
previous users of a specific drug can introduce misclassification and bias study findings. In a 
large cohort of Danish children dispensed asthma drugs and antibiotics, Riis et al. recently 
showed that new user designs using look-back periods of 2 years can introduce severe 
misclassification.1  
 
We are currently undertaking a program of research in Australia examining the use and 
outcomes associated with prescription antipsychotic and opioid analgesics. We have been 
developing our study methodology based on different look-back periods. To add further 
evidence to the Riis et al. study, we detail our experience in quantifying the effect of 10 
look-back periods on the misclassification of new users of antipsychotics and opioid 
analgesics (with and without codeine preparations) in Australian adults.  
 
Australia has a publically funded universal healthcare system entitling all citizens and 
permanent residents to a range of subsidised health services including prescription drugs via 
the Pharmaceutical Benefits Scheme (PBS).  
 
The Australian Government Department of Human Services (DHS) established a 
standardised dataset of PBS dispensing claims for a random 10% sample of Australians in 
March 2005 (MI2593 and MI2779). We have a contract with DHS for use of these data for 
pharmacoepidemiological research with quarterly data updates. A record is created in this 
dataset when an individual receives government subsidy for a PBS-listed drug. An individual 
224 
 
is eligible for subsidy when the drug is priced above the patient copayment amount. 
Australia has a two-tiered copayment system meaning that low-cost PBS-listed drugs 
dispensed to individuals with the highest copayment (general beneficiaries) are not 
captured in this dataset. However, all prescription drugs are priced above the concessional 
beneficiary copayment meaning we have complete ascertainment of all PBS-listed drugs 
dispensings for this patient group. We focus our analyses on the latter group.   
 
The drug classes of interest include antipsychotics (ATC code: N05A) and opioid analgesics 
(ATC codes: N02A, R05DA04, N07BC [methadone for the indication of pain alone]).  
 
Our study population included persons aged ≥18 years at 1 January 2005 and concessional 
beneficiaries for the entire period between 1 July 2005 and 30 June 2014. For each drug 
class of interest, we categorised persons as true new users (dispensing between 1 July 2012 
and 30 June 2014 and no dispensings between 1 July 2005 and 30 June 2012) or true prior 
users (dispensing between 1 July 2012 and 30 June 2014 and a dispensing between 1 July 
2005 and 30 June 2012). This project was approved by the Population and Health Services 
Research Ethics Committee (2013/11/494). 
 
We calculated the relative misclassification (RM) based on 10 look-back periods: 1, 3 and 6 
months and annual look-back periods from 1 to 7 years, defined as the time period prior to 
each individual’s index dispensing. We calculated the RM of new users by dividing the 
number of defined new users (dispensing between 1 July 2012 and 30 June 2014 and no 
dispensings during the look-back period of interest) by the number of true new users. We 
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calculated RM and 95% confidence intervals (using bootstrap methods) for each look-back 
period.  
 
We identified 24 375 antipsychotic users between 1 July 2012 to 30 June 2014. RM 
decreased from 2.51 at 1 month to 1.01 at 7 years. We identified 132 153 opioid users 
including codeine preparations and 80 333 opioid users excluding codeine preparations. RM 
decreased from 3.61 at 1 month to 1.08 at 7 years and 2.23 at 1 month to 1.04 at 7 years, 
respectively (Table 7.1). 
 
Consistent with the findings of Riis et al, our study shows that varying look-back periods 
impact on the RM of new users1 and that RM is higher for drugs used intermittently (opioids 
are likely to be used intermittently). Opioid users excluding codeine preparations had a 
median of three dispensings (interquartile range [IQR]: 1-14) in two years compared with 10 
antipsychotic dispensings (IQR: 3-23). The RM for opioids in our analysis was higher than 
antipsychotics across all look-back periods longer than 1 month. Within opioids, we have 
demonstrated that including codeine preparations increases the RM.  
 
We have recently undertaken a systematic review of all Australian studies using PBS data for 
pharmacoepidemiological research.2 Seven studies investigating antipsychotics or opioid 
analgesics employed a new user design, and all used a look-back period of 12 months. Based 
on our findings, the potential RM for the antipsychotic or opioid studies were 1.31 or 2.72, 
respectively. 
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Table 7.1 Relative misclassification for new adult antipsychotic and opioid analgesic users for each look-back period of interest  
 
Antipsychotics 
N =  24 375 
Opioid analgesics  
(including codeine) 
N = 132 153 
Opioid analgesics  
(excluding codeine) 
N = 80 333 
Female (N, %) 13 207 54.2 79 591 60.2 49 525 61.7 
Age at 1 July 2012 (median, IQR) 61 44-80 68 50-78 72 57-80 
Dispensings (median, IQR)a 10 3-23 2 1-9 3 1-14 
True new users (N, %) 7 774 31.9 32 529 24.6 30 831 38.4 
Prior users (N, %) 16 601 68.1 99 624 75.4 49 502 61.6 
Look-back periodb New 
users (N) 
RM (95% CI) New 
users (N) 
RM (95% CI) New 
users (N) 
RM (95% CI) 
0 days 24 375 3.14 - 132 153 4.06 - 80 333 2.61 - 
1 month  19 481 2.51 (2.48-2.53) 117 459 3.61 (3.60-3.62) 68 599 2.23 (2.22-2.23) 
3 months  12 973 1.67 (1.64-1.70) 106 217 3.27 (3.26-3.27) 62 042 2.01 (2.01-2.02) 
6 months  11 147 1.43 (1.41-1.46) 99 364 3.05 (3.05-3.06) 59 210 1.92 (1.91-1.93) 
12 months  10 194 1.31 (1.29-1.33) 88 537 2.72 (2.71-2.73) 54 958 1.78 (1.77-1.79) 
2 years  9 281 1.19 (1.17-1.22) 70 800 2.18 (2.17-2.19) 47 738 1.55 (1.54-1.56) 
3 years  8 735 1.12 (1.10-1.14) 57 765 1.78 (1.77-1.79) 42 151 1.37 (1.36-1.38) 
4 years  8 423 1.08 (1.06-1.10) 49 390 1.52 (1.51-1.53) 38 472 1.25 (1.24-1.26) 
5 years  8 174 1.05 (1.03-1.07) 43 327 1.33 (1.32-1.34) 35 802 1.16 (1.15-1.17) 
6 years  8 013 1.03 (1.01-1.05) 38 783 1.19 (1.18-1.20) 33 723 1.09 (1.09-1.10) 
7 years  7 883 1.01 (0.99-1.03) 35 229 1.08 (1.07-1.09) 32 129 1.04 (1.03-1.05) 
RM: relative misclassification; 95% CI: 95% confidence interval 
a Dispensings between 1 July 2012 and 30 June 2014 
b Look-back period: time period prior to each individual’s index dispensing during the observation period 
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However, our study demonstrates that there is no ‘one-size-fits-all’ approach to new 
user study designs, and the length of the look-back period will depend on the 
prescription drug and outcome of interest. Like Riis et al., we encourage researchers 
to undertake sensitivity analyses to determine the influence of the look-back period 
on study outcomes. Clearly, new user pharmacoepidemiological research studies 
should use lengthy look-back periods. Ideally, dispensing claims linked with other 
routinely collected health data should be available from birth to minimise RM. Yet in 
reality, researchers in most jurisdictions do not have the luxury of the whole-of-
population, linked data available in Scandinavian countries. Therefore, pragmatic 
considerations play into decisions about look-back periods. It is a balancing act – the 
longer the look-back period, the shorter the look-forward period. We encourage 
more studies, like Riis et al., to shed light on this important but under-researched 
aspect of potential misclassification bias in pharmacoepidemiological research. 
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Chapter Eight: Discussion 
The work outlined in this thesis provides the foundation to better understand the 
capacity of pharmaceutical claims to identify and quantify prescription drug ‘misuse’. 
In this concluding chapter we discuss the implications of our study findings and the 
potential of our research to inform evidence-based strategies to reduce prescription 
drug misuse and related harms in the future. 
 
To increase the readability of viewing this thesis electronically, we provide all figures 
or tables on the page following its first citation in the text. We provide the reference 
list at the end of this chapter. 
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8.1 Key findings and future research directions 
8.1.1 Limitations of the traditional threshold approach to quantify prescription drug 
misuse 
Our research demonstrates the possibilities and challenges of quantifying 
prescription drug misuse in pharmaceutical claims. One of the challenges of using 
pharmaceutical claims alone to quantify misuse is the nature of these data; they 
contain limited clinical information and a finite set of variables. To date, the global 
literature has predominantly utilised specific thresholds based on access patterns to 
delineate appropriate use from potential misuse. However, these thresholds are 
largely based on expert consensus or previous literature and most have not been 
validated.  
 
In our research we used alternative methodologies to the threshold approach. We 
examined the full spectrum of prescription drug access patterns and benchmarked 
access across drug classes with known and no known abuse potential, to establish 
how an approach of this kind may better inform the primary aims of our work. We 
demonstrated access patterns for individual drug classes were remarkably similar 
across two jurisdictions with universal healthcare arrangements. However, there 
were marked differences in access patterns in the higher centiles between 
prescription drug classes with high and no known abuse potential. These differences 
may identify access patterns associated with individual or societal harm. 
 
Furthermore, we examined the factors associated with increasing opioid access 
patterns across three metrics used commonly to define misuse. This approach 
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clearly demonstrated the limitations of the threshold methodology in quantifying 
prescription drug misuse based on pharmaceutical claims, as it is likely to identify 
persons with high levels of comorbid and/or chronic disease who may be accessing 
and taking opioids appropriately, as well as a group of people who are likely to be 
misusing these drugs. At best, the traditional threshold method could be used as a 
marker of a potential problem; this approach does not have the capacity to 
accurately quantify misuse.  
 
8.1.2 Pharmaceutical claims in quantifying misuse: limitations and future potential 
Given pharmaceutical claims are collected for the purpose of administering 
prescription drug subsidy programs it is highly unlikely they will ever contain all the 
information necessary to inform this important research, clinical and policy agenda. 
Information currently missing from pharmaceutical claims includes the medical 
indication for use, and, specifically in Australian data, prescribed daily dose and 
treatment duration. Moreover, until recently PBS claims did not contain all PBS-
listed drugs dispensed in Australia, only those where the dispensing attracted a 
Commonwealth subsidy.  
 
The potential of routinely collected data to inform efforts to quantify and ultimately 
curb prescription drug misuse are likely to be realised when pharmaceutical data are 
linked to other routinely collected health outcome data to establish the association 
between prescription drug access patterns and harm.   
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Australia is in a unique position to lead this global effort due to its universal 
healthcare system, large stores of routinely collected health data and capacity for 
linkage across disparate data collections. However, until recently data linkage efforts 
have been hampered due to legislative barriers, privacy concerns and the 
fragmented nature of health data collections.1 Specifically, hospital data (including 
hospital admissions and emergency department [ED] presentations) and registries 
(cancer notifications and death) are under the custodianship of individual Australian 
States and Territories, whereas community health service data and PBS dispensing 
claims are under the custodianship of the Commonwealth.  
 
Despite the establishment of Commonwealth-approved data integrating authorities, 
such as the Australian Institute of Health and Welfare,2 to link population-level cross-
jurisdictional data, linkages are very costly, resource intensive and time consuming. 
Moreover, national prescription drug use and outcomes studies would require 
approval across nine jurisdictions, from at least 10 human research ethics 
committees (HRECs) and more than 30 data custodians. Not surprisingly, Australia’s 
research output in pharmacoepidemiological studies is modest relative to other 
jurisdictions with universal healthcare systems such as the Scandinavian countries.1 
Due to this challenging data linkage environment, researchers currently face the 
trade-off between accessing cross-jurisdictional data, that is likely to take a 
minimum of two years to obtain all relevant HREC approvals and these data may cost 
in excess of AU$100 000 dollars; or, access whole-of-population data through the 
lens of one healthcare payer, as is the case with this thesis.  
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8.2 Examining drug access patterns and harm  
A potential compromise, or first step, to explore drug use and outcomes in Australia 
is to establish a cross-jurisdictional linkage based on residents living in New South 
Wales (NSW) and the Australian Capital Territory (ACT). NSW is the most populous 
Australian state (7.5 million people), and the ACT (400,000 people) is bordered 
entirely by NSW. Due to the geographic location of the ACT there is likely cross-
border health service utilisation by Australian residents living close to the State 
border.3 A population of almost 8 million people would yield sufficient power to 
examine specific prescription drug exposures and rare outcomes. Importantly, this 
approach would substantially reduce the administrative burden in accessing these 
data; for example a linkage of this kind would require approval from only three 
HRECs. Below we detail the necessary data infrastructure, using prescription opioids 
as the case example, to deliver this program.  
 
8.2.1 Data linkage and datasets 
To investigate the associations between prescription drug use, access patterns and 
harm one would establish a cohort of prescription opioid exposed persons 
ascertained through PBS claims. These claims could be linked to the following State-
based datasets: prescription opioid dispensings to treat opiate dependence (Section 
100 – Highly Specialised Drugs Program), hospital separations, ED presentations, and 
mortality data (fact and cause of death). There may also be merit in linking State-
based cancer notification data to identify persons who are likely to be treated for 
cancer rather than non-cancer pain. These State collections could be linked to 
Medicare Benefits Schedule (MBS) data. We provide a data summary in Table 8.1.
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 Table 8.1. Summary of other routinely collected health datasets available to link to Pharmaceutical Benefits Scheme dispensing data 
Data Summary of captured data Use 
State-based data collection  
Section 100 – Highly 
Specialised Drugs 
Program (S100 
HSDP) 
State-collected data that records dispensing information for drugs prescribed for the treatment of 
chronic conditions which, because of their clinical use or other special features, are restricted to 
supply through public or private hospitals having access to appropriate specialist facilities.4 
Opioids, such as methadone and buprenorphine, dispensed for the indication of opiate 
dependence are classified as highly specialised drugs. 
Drug exposure and 
outcome/harm 
Hospital separations State-collected data that records all hospital separations and services/procedures provided to 
admitted patient in public hospitals, public psychiatric hospitals, public multi-purpose services, 
private hospitals and private day procedure centres.5 
Outcome/harm 
Emergency 
department 
presentations 
State-collected data that records information for emergency department presentations in public 
hospitals.5 
Outcome/harm 
Mortality data State-collected data that provides information regarding death from the Registry of Births, Deaths 
and Marriages, and the Australian Bureau of Statistics Cause of Death Unit Record File.5 
Outcome/harm 
Cancer notification 
data 
State-collected data that details health information for a persons index cancer diagnosis.5 Outcome/harm 
National data collection  
Medicare Benefits 
Scheme (MBS) data 
Nationally-collected dataset that captures Medicare services subsidised by the Australian 
Government.6 The Health Insurance Act 1973 stipulates that Medicare benefits are payable for a 
professional service, define as a clinically relevant service listed on the MBS such as pathology 
tests and psychological consultations.6 
Drug exposure and 
outcome/harm 
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Importantly, linking any of these datasets with PBS claims would provide the opportunity to 
examine the nuances of prescription opioid use and harms, validate measures of ‘misuse’ 
developed through pharmaceutical claims and examine trajectories likely to lead to misuse 
or other harms. To date, only one Australian study has linked a cohort of young adults who 
experienced a heroin overdose death with their MBS and PBS claims. They found as year of 
death approached the cohort had considerably higher healthcare interactions.7 However, 
this study focused on illicit opioids, no Australian studies has undertaken a cross-
jurisdictional linkage to examine prescription opioid use and outcomes in the general 
population. Consequently, there are no published studies using person-level linked data 
examining individual patterns of prescription opioid use and outcomes. 
 
Internationally, multiple studies have  linked pharmaceutical claims with outcomes data,7-24 
the majority of which examined associations between patient and clinical factors, and 
negative outcomes including overdose, diagnosis of opioid misuse or death.7-24 Patient 
factors associated with negative outcomes include male sex; younger age;18,21,23,24 and, 
previous diagnoses such as substance abuse or depression; 9,11,22,24 Clinical factors 
associated with these outcomes include increasing opioid dose;8,9,11,12,14-16,20,21,24 dispensing 
of specific opioids  or formulations, such as buprenorphine or long-acting opioids 
respectively;11,13,19,21,22 dispensing of other classes of prescription drugs such as 
benzodiazepines;12,17,20,21,23 and, opioid access patterns.8,17,21,22,24 Consistent with our 
findings throughout this thesis, these studies found a minority of patients accessed multiple 
prescribers or pharmacies, but as the number of prescribers, pharmacies or dispensings 
increased so did the risk of a negative outcome.  
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The limitations of these studies mirror those we identified in our systematic review detailed 
in Chapter Two. Opioid cohort definitions were heterogeneous across studies, ranging from 
one opioid dispensing to ≥3 months of continuous opioid use. We demonstrated throughout 
this thesis that cohort definitions impact cohort size, demographics and/or opioid access 
patterns, which limits the opportunity for comparisons across studies. The definition of the 
outcomes of interest also varied across studies, which may also impact on study findings. No 
studies examined whole-of-population, national data. The majority of studies were set in 
the US (13 studies; 72%)8-12,14,15,17,19-22,24; 10 studies (56%) included a particular patient 
population such as veterans; Medicare/ Medicaid enrolees or privately insured persons,9-
11,14,15,17,19,20,22,24 of these, six studies used national data.9,10,17,19,20,22 As previously 
highlighted in this thesis, relying on death certificates to identify persons with an opioid-
related death will likely result in under ascertainment of cases as the cause of death may be 
recorded as due to another related cause such as respiratory depression, particularly in 
older persons. Despite these limitations, these studies demonstrate the evidence-base in 
this field is increasing regarding prescription opioid use and outcomes and we are beginning 
to identify high-risk patient groups, as well as assess the effectiveness of strategies and 
health policies to reduce prescription drug misuse.  
 
The evidence-base in this field would be strengthened if studies from different jurisdictions 
examine prescription drug access patterns. By adopting a similar methodology, we can 
conduct comparisons between jurisdictions to examine common prescription drug access 
patterns. Where there are differences in access patterns across jurisdictions, we have the 
opportunity to investigate factors that facilitate and/or act as a barrier to prescription drug 
access/misuse, which may include healthcare arrangements, prescribing patterns and health 
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policy. For example, few Scandinavian studies have examined prescription opioid misuse or 
‘shopping’ behaviours as they are rare occurrences.25,26 Consequently, there may be limited 
perceived public health benefit to examine prescription drug access patterns in these 
jurisdictions.  
 
However, from a global public health perspective, curbing prescription drug misuse is a 
priority so understanding why there is a lack of opioid misuse in these jurisdictions warrants 
further investigation. In Australia, we have a universal healthcare provider and a data 
linkage project provides the opportunity to link national pharmaceutical claims, via the PBS, 
with outcomes data for at least one State/Territory. To understand and define prescription 
drug misuse, we must first understand the norms of prescription drug access. 
 
8.3 Gaps in Pharmaceutical Benefits Scheme data 
As detailed previously, PBS data were established for the primary purpose of administering 
payments for PBS-listed prescription drug dispensings. Consequently, the variables 
contained within these collections are those required to administer the program. In this 
section, we outline the PBS data gaps that, if filled, would strengthen these data and 
enhance routine monitoring and research efforts. 
Traditionally, only dispensed drugs attracting a government subsidy form part of the PBS 
dataset, which is managed by the Australian Government Department of Human Services 
(DHS). However, in 2012, the Pharmacy Guild Survey agreement was renegotiated whereby 
PBS-listed drugs that did not attract a government subsidy (e.g. under-copayment drugs) 
were also provided to DHS in unit record form.27 This addition led to more complete 
pharmaceutical data collection, for example, between 2014-2015 over one-quarter of all 
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drug dispensings in Australia were for under-copayment drugs.28 While mechanisms to 
access under-copayment data are under development, routine access for approved research 
studies will be available in the near future. 
 
The Public Hospital Pharmaceutical Reforms allow participating hospitals to provide 
discharging inpatients and outpatients with PBS-subsidised drugs. 29 These Reforms were 
introduced in Victoria (2001), Queensland (2002), Western Australia (2002), Northern 
Territory (2007), South Australia (2008) and Tasmania (2010). As no agreement currently 
exists between the NSW or ACT public hospitals, these States in-hospital drug dispensings 
are not included in the PBS collection.  
 
Private dispensings occur when a prescription drug is either: not PBS-listed, or PBS-listed but 
prescribed for an indication that is not PBS-approved. In 2011, almost 7% of all opioids were 
dispensed via a private prescription but the proportion of private dispensings varied by 
drug.30 It is reasonable to assume the proportion of dispensings obtained via private 
prescription will vary across drug class and over time. As detailed previously, due to the 
Pharmacy Guild Survey ceasing in 2012, there is no unit-record data collection of private 
prescriptions.  
 
We also recommend other information available to dispensing pharmacists should be 
captured in these data. The prescribed daily dose (PDD) is the amount of drug prescribed 
per day to the patient to treat the relevant medical condition. Despite this information 
being detailed on prescriptions and collected by pharmacists to print on the packaging of 
the dispensed drug, this information is not recorded in PBS claims. Furthermore, the 
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quantity field in PBS data refers to the total amount of the drug dispensed to the patient 
rather than the amount recommended for treatment. For example, 5 mg tablets of 
oxycodone are currently dispensed in a pack size of 20 tablets; a patient may require four 
tablets per day therefore one pack would be dispensed whether the treatment was for two 
or five days. Due to the absence of these two data points, Australian researchers are 
required to create proxies for important exposures and/or outcomes of interest such as 
duration of treatment, discontinuation of therapy and delineating switching behaviour from 
concomitant therapy. 
 
While these enhancements would address some important data gaps, even with these 
additions, the PBS dataset alone is not sufficient to fully understand access patterns that 
place people at most risk of harm.  
 
8.4 Implications for policy and practice 
In 2014, the US Food and Drug Administration (FDA) committed publically to curbing the 
abuse and misuse of prescription opioids while still retaining access for persons requiring 
these drugs to manage pain. As part of the declaration, they endorsed the use of routinely 
collected data to define and quantify prescription opioid misuse.31 Initiatives such as 
prescription drug monitoring programs (PDMPs) have been developed in response to the 
escalating use and harm associated with prescription drugs, particularly opioids. PDMPs 
allow a prescriber or pharmacist to examine an individual’s dispensing history to determine 
whether they have obtained excessive, and potentially harmful, amounts of prescription 
drugs.  Of note, three of the 18 studies (17%) linking pharmaceutical claims with outcomes 
data used PDMP data.8,12,21 PDMP data may prove to be a vital resource in examining 
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associations between prescription drug dispensings and outcomes, particularly in the US, as 
these data capture all prescription drug dispensings for controlled drugs, regardless of the 
patient’s age or health insurance status. 
 
PDMPs have been implemented in almost every US State.32 The effectiveness of PDMPs in 
reducing prescription rates for controlled substances, misuse or harms are unclear due to 
the nuances of each system.43-48 In an effort to harmonise PDMP data collections across the 
US, the Drug Enforcement Agency created a list of the ideal features of a PDMP (Table 
8.2).49 An essential feature of every PDMP should be its capacity to implement a red flag, to 
identify persons exhibiting access patterns associated with harms. To achieve this goal, a 
close collaboration between researchers and policy makers is required. 
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Table 8.2. US Drug Enforcement Agency list of features in an ideal prescription drug 
monitoring program49 
Features of an ideal prescription drug monitoring program 
Ease of access 
Standardised content 
Real-time updates 
Mandatory pharmacy reporting 
Monitoring of concerning prescription drugs (Schedules 2-5)a 
Interstate accessibility 
Confidentiality and security 
Support for public health initiatives 
Capability for strictly monitored access by non-prescribers 
a Schedules 2-5 in the US equates to at least Schedules 4 (prescription only drugs) and 8 (controlled 
drugs) in Australia. 
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Pharmaceutical claims are the foundation to examine the association between drug 
exposure, access and harms. In its basic form, pharmaceutical claims alone provide 
researchers the opportunity to examine population norms of prescription drug access. 
When linked with outcomes data, such as those described in Table 8.1, researchers have the 
opportunity to examine associations between drug exposure, access and harms. An 
evidence-based metric, that is a measure demonstrated to be associated with harm, should 
then be translated into the PDMP as a red flag, indicating to the prescriber that their 
patient’s access patterns are potentially harmful (Figure 8.1). 
 
This approach allows prescribers the opportunity to identify high-risk individuals, discuss 
their prescription drug use and potentially stop harms from occurring. Researchers should 
routinely re-examine pharmaceutical claims data to determine if access patterns shift due to 
real world events such as prescription drug access policies, listing new prescription drugs on 
the formulary and/or changes in the illicit drug supply. 
 
8.4.1 Australian prescription drug monitoring programs 
As of November 2016, Australia has two functioning PDMPs, the national Prescription 
Shopping Programme (PSP) and the Tasmanian Drugs and Poisons Information System 
Online Remote Access (DORA).  
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Figure 8.1 Implementing evidence-based metrics in prescription drug monitoring programs 
to identify potentially harmful access patterns 
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The PSP is a national program aiming to identify persons acquiring more prescription drugs 
than medically required.50 However, the PSP uses the traditional threshold approach 
utilising metrics that have not been validated to identify ‘shoppers’. Based on the results of 
our systematic review, the PSP threshold to identify ‘shoppers’ are extremely high, within 3 
months a person must: 1) visit ≥6 prescribers; 2) obtain ≥25 target pharmaceutical benefits 
(dispensings); or 3) obtain any ≥50 pharmaceutical benefits (dispensings). As these 
behaviours are extreme, this definition may be more likely to target diversion rather than 
misuse, which is supported by the fact that prescription drugs with no known abuse 
potential are included in the target pharmaceuticals (criteria two).  
 
Two limitations of the PSP include the data being retrospective and reactive. For example, if 
a prescriber suspects their patient of being a ‘shopper’ the prescriber must contact the PSP 
information service to confirm their suspicion. If they are correct PSP administrators send 
the prescriber their patient’s dispensing history current to the last 24 hours, which does not 
requiring the patient’s consent. If the prescriber is incorrect they are not able to obtain their 
patient’s dispensing history, unless their patient provides consent. As PSP information is not 
available in real-time it hinders a prescriber’s ability to discuss a patient’s potentially 
harmful access patterns, as the necessary dispensing history cannot be obtained within the 
time constraints of a clinical consultation. 
 
On the other hand, DORA is a state-based system operating in Tasmania and allows 
prescribers and pharmacists real-time access to a patient’s dispensing history for 
prescription drugs with high abuse potential (known as Schedule 8 controlled drugs) which 
includes opioids and alprazolam.51 However, as there has been limited peer-reviewed 
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literature examining the impact of PDMPs, their effect on prescription drug use, misuse or 
diversion is largely unknown. 
 
In the future, Australia may adopt a national PDMP allowing prescribers and pharmacists’ 
real-time access to patient dispensing histories. In the short term, researchers should 
examine access patterns for prescription drugs and associations between access and harms. 
Eventually, this information could be translated into a PDMP as a red flag to better target 
populations at risk for prescription drug related harms. This proposal is challenging and 
would require co-ordination at the Commonwealth level, but would provide the opportunity 
for Australia to be world leaders in examining norms of prescription drug use and 
quantifying potential misuse.    
 
8.5 Conclusions 
There is widespread global concern about the increase in prescription drug use, misuse and 
harm, particularly in relation to opioid analgesics. Regulatory bodies, third party payers and 
clinicians are all attempting to balance the provision of safe and effective treatment to 
those in need while restricting access to those who will derive no benefit or potentially 
experience harm. This is a complex problem requiring multi-faceted solutions that need to 
be nuanced to account for local health care delivery models and patient and prescriber 
behaviour. 
 
Leveraging from large-scale data to conduct post-market surveillance studies of prescription 
drug access and associated harms forms one important component to drive evidence-based 
policy responses. However, research of this kind is still relatively under-developed and 
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methods are far from harmonised. In Australia, our federated model has particularly 
impeded this effort, where essential data to undertake this work lies in different 
jurisdictions. To date, the evidence-base relating to prescription drug access patterns and 
associated benefits and harms is grossly inadequate to drive evidence-based interventions.   
 
While the world has become increasingly digitised and we generate data about every aspect 
of our lives, it is clear, particularly in Australia, that we are still not making best use of the 
health information that we currently have to provide timely and robust evidence for policy 
and clinical decisions. This is an important and fundamental step to ensure individual and 
societal benefits for the very large and ever-increasing global investment in prescription 
drugs. 
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Supplementary Material 2.1 Detailed search strategies executed in systematic review 
1. MEDLINE Search Strategy (N=5,136)a 
1. Prescription drug 
or substance abuse 
related term 
2. Epidemiology and 
related methods term 
3. Routinely 
collected data 
4. A prescription 
drug misuse-related 
keyword 
Central nervous 
system agentsb 
Pharmacoepidemiology Pharmacovigilance Addic* 
Benzodiazepines Epidemiology Insurance, health Abus* 
Substance related 
disorders 
Product surveillance, 
postmarketing 
Universal coverage Misus* 
Substance abuse 
detection 
Epidemiological 
methods 
National health 
programs 
Devian* 
Polypharmacy Physician’s practice 
patterns 
Health benefit plans, 
employees 
Aberran* 
Pharmaceutical 
services 
Drug utilization Insurance, health, 
reimbursement 
Depend* 
Prescription drug 
misuse 
Health services Centers for 
Medicare and 
Medicaid Services 
Nonmed* 
Prescription drugs Health services 
accessibility 
Medicaid Diver* 
Drug prescriptions Public health Databases, factual Seek* 
 Population surveillance Insurance coverage Inapprop* 
 Cohort studies Insurance benefits Problem* 
 Retrospective studies Single-payer system Illeg* 
 Health services misuse Reimbursement, 
incentive 
Poison* 
  Registries Selfmed* 
  Pharmacies Inject* 
  Drug and narcotic 
control 
Suicid* 
  Drug monitoring Repeat* 
  Keywords: 
Claim* or reimburs* 
Withdraw* 
   Harm* 
   Unintent* 
   Recreat* 
   Shop* 
   Hopp* 
   Overlap* 
a For this search strategy: the search terms utilised in each column were combined with ‘OR’; the terms between 
columns were combined with ‘AND’. 
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b The subject heading ‘central nervous system agents’ captures the majority of drug classes associated with 
misuse. For each search strategy we list any drug class(es) (as subject heading[s]) not captured by ‘central nervous 
system agents’.  
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2. EMBASE Search Strategy (N=6,160) a 
1. Prescription drug 
or substance abuse 
related term 
2. Epidemiology and 
related methods 
term 
3. Routinely collected 
data 
4. A prescription 
drug misuse-related 
keyword 
Central nervous 
system agents 
Epidemiology Government Addic* 
Benzodiazepine Postmarketing 
surveillance  
Insurance Abus* 
Psychotropic agent Retrospective study Factual database Misus* 
Central stimulant 
agent 
Drug utilization Reimbursement Devian* 
Drug dependence Health care facility Drug control Aberran* 
Prescription Health care Register Depend* 
Polypharmacy Health service  Nonmed* 
Prescription drug Drug surveillance 
program 
 Diver* 
Pharmaceutics Public health  Seek* 
Narcotic analgesic 
agent 
Cohort analysis  Inapprop* 
   Problem* 
   Illeg* 
   Poison* 
   Selfmed* 
   Inject* 
   Suicid* 
   Repeat* 
   Withdraw* 
   Harm* 
   Unintent* 
   Recreat* 
   Shop* 
   Hopp* 
   Overlap* 
a For this search strategy: the search terms utilised in each column were combined with ‘OR’; the terms between 
columns were combined with ‘AND’. 
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3. CINAHL Search Strategy (N=471) a 
1. Prescription drug 
or substance abuse 
related term 
2. Epidemiology and 
related methods 
term 
3. Routinely collected 
data 
4. A prescription 
drug misuse-related 
keyword 
Central nervous 
system agents 
Epidemiology Insurance, 
pharmaceutical 
services 
Addic* 
Substance use 
disorders 
Epidemiological 
research 
Insurance, health 
reimbursement 
Abus* 
Substance abuse 
detection 
Disease surveillance  Insurance, health Misus* 
Polypharmacy Population 
surveillance 
Insurance benefits Devian* 
Drug dependence Product surveillance Insurance coverage Aberran* 
Prescriptions, drug Drug utilization Resource databases, 
health 
Depend* 
Drugs, prescription Health resource 
utilization 
Databases, health Nonmed* 
 Practice patterns Medicaid Diver* 
 Prescribing patterns United States 
Centers for Medicare 
and Medicaid 
services 
Seek* 
 Pharmacy service Medicare Inapprop* 
 Pharmacy and 
pharmacology 
Insurance, Medigap Problem* 
 Public health Pharmacovigilance Illeg* 
 Retrospective design Student health 
services 
Poison* 
 Health services 
misuse 
Reimbursement, 
incentive 
Selfmed* 
 Inappropriate 
prescribing 
Drug monitoring Inject* 
  Key words:  
Claim* or 
reimburse* 
Suicid* 
   Repeat* 
   Withdraw* 
   Harm* 
   Unintent* 
   Recreat* 
   Shop* 
   Hopp* 
   Overlap* 
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a For this search strategy: the search terms utilised in each column were combined with ‘OR’; the terms between 
columns were combined with ‘AND’.  
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4. MEDLINE In Process Search Strategy (N=896)a 
1. Prescription drug 
or substance abuse 
related term 
2. Epidemiology and 
related methods 
term 
3. Routinely collected 
data 
4. A prescription 
drug misuse-related 
keyword 
Benzodiazepine* Epidemiol* Monitor* Addic* 
Prescri* Pharmacoepi*  Reimburs* Abus* 
Analgesic* Cohort* Claim* Misus* 
Opioid* Retro* Benefit* Devian* 
Medication* Population* Data* Aberran* 
Stimulant*   Depend* 
Antidepressant*   Nonmed* 
Anipsychotic*   Diver* 
Polypharmacy*   Seek* 
   Inapprop* 
   Problem* 
   Illeg* 
   Poison* 
   Selfmed* 
   Inject* 
   Suicid* 
   Repeat* 
   Withdraw* 
   Harm* 
   Unintent* 
   Recreat* 
   Shop* 
   Hopp* 
   Overlap* 
a For this search strategy: the search terms utilised in each column were combined with ‘OR’; the terms between 
columns were combined with ‘AND’.  
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5. Google Scholar Search Strategy (N=600)a 
“Prescription drug” + excess 
“Prescription drug” + misuse 
“Prescription drug” + abuse 
a Reviewed first 200 results per search 
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Supplementary Material 2.2 5-item eligibility criteria tool 
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Supplementary Material 2.4 A Measurement Tool to Assess Systematic Reviews (AMSTAR) checklist and Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) checklist 
Supplementary Material 2.4A: A Measurement Tool to Assess Systematic Reviews (AMSTAR) checklist 
Section/topic # Checklist item Reported on 
page # 
Comments 
INTRODUCTION    
Was an “a priori” 
design provided? 
1 The research question and inclusion criteria should be established before the conduct of the 
review. 
58  
METHODS    
Was there 
duplicate study 
selection and data 
extraction? 
2 There should be at least two independent data extractors and a consensus 
procedure for disagreements should be in place. 
 
59  
Was a 
comprehensive 
literature search 
performed? 
 
3 At least two electronic sources should be searched. The report must include years 
and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH 
terms must be stated, and where feasible, the search strategy should be provided. 
All searches should be supplemented by consulting current contents, reviews, 
textbooks, specialised registers, or experts in the particular field of study, and by 
reviewing the references in the studies found. 
59, SM 1  
Was the status of 
publication (i.e., 
grey literature) 
used as an 
inclusion 
criterion? 
4 The authors should state that they searched for reports regardless of their 
publication type. The authors should state whether or not they excluded any reports 
(from the systematic review), based on their publication status, language etc. 
 
58, 75  
Were the methods 
used to combine 
the findings of 
studies 
5 For the pooled results, a test should be done to ensure the studies were combinable, 
to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2). If 
heterogeneity exists, a random effects model should be used and/or the clinical 
X Not a meta- 
analysis: 
qualitative 
synthesis 
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appropriate? appropriateness of combining should be taken into consideration (i.e., is it sensible 
to combine?). 
RESULTS    
Were the 
characteristics of 
the included 
studies provided? 
6 In an aggregated form, such as a table, data from the original studies should be 
provided on the participants, interventions, and outcomes. The ranges of 
characteristics in all the studies analysed, e.g., age, race, sex, relevant socioeconomic 
data, disease status, duration, severity, or other diseases should be reported. 
Tables 2.1 
and 2.2 
 
Was the scientific 
quality of the 
included studies 
assessed and 
documented? 
7 ‘‘A priori’’ methods of assessment should be provided (e.g., for effectiveness studies 
if the author(s) chose to include only randomised, double-blind, placebo-controlled 
studies, or allocation concealment as inclusion criteria); for other types of studies, 
alternative items will be relevant. 
73  
Was the scientific 
quality of the 
included studies 
used 
appropriately in 
formulating 
conclusions? 
8 The results of the methodological rigor and scientific quality should be considered in 
the analysis and the conclusions of the review, and explicitly stated in formulating 
recommendations. 
 
X Not a meta- 
analysis: 
qualitative 
synthesis 
Was the 
likelihood of 
publication bias 
assessed? 
9 An assessment of publication bias should include a combination of graphical aids 
(e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression 
test). 
 
X Not a meta- 
analysis: 
qualitative 
synthesis 
FUNDING    
Was the conflict 
of interest 
included? 
10 Potential sources of support should be clearly acknowledged in both the systematic 
review and the included studies. 
 
73, Table 
2.1, 257-258 
 
APPENDIX    
Was a list of 
studies (included 
and excluded) 
provided? 
11 A list of included and excluded studies should be provided. 
 
SM 5 and 6   
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Section/topic  # Checklist item  Reported 
on page # 
Comments 
TITLE    
Title  1 Identify the report as a systematic review, meta-analysis, or both.  53  
ABSTRACT    
Structured 
summary  
2 Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number.  
55-56 No 
registration 
number 
INTRODUCTION    
Rationale  3 Describe the rationale for the review in the context of what is already known.  57-58  
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
58  
METHODS    
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.  
X No 
registered 
protocol  
Eligibility 
criteria  
6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
58  
Information 
sources  
7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors 
to identify additional studies) in the search and date last searched.  
59  
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that 
it could be repeated.  
SM 1  
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, 
if applicable, included in the meta-analysis).  
58-59  
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) 
and any processes for obtaining and confirming data from investigators.  
59-61, SM 
2 and 3 
 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
59-61, SM 
3 
 
Supplementary Material 2.4B: Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist 
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Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  
X Not a meta- 
analysis: 
qualitative 
synthesis 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified.  
X Not a meta- 
analysis: 
qualitative 
synthesis 
RESULTS    
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons 
for exclusions at each stage, ideally with a flow diagram.  
62, Figure 
2.1 
 
Study 
characteristics  
18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-
up period) and provide the citations.  
SM 7  
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 
12).  
X Not a meta- 
analysis: 
qualitative 
synthesis 
Results of 
individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data 
for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
SM 7 Not a meta- 
analysis: 
qualitative 
synthesis 
Synthesis of 
results  
21 Present the main results of the review. If meta-analyses are done, include for each, confidence 
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Supplementary Material 2.7. Summary of included studies (N=52)a 
First Author 
Year of 
Publication 
Setting 
(Observation 
period)b 
Aim(s)c  
(Drug 
class[es] of 
interest) 
 
Cohort(s) detailsc 
 
Measures of prescription drug misuse 
with a defined threshold 
(time period of assessment)d 
Other findings relevant to prescription drug misuse  
(time period of assessment) 
Bachs1 
2008 
Norway 
(2006)  
Describe 
‘high users’ 
concomitant 
drug use 
(opioid). 
A) Cohort 
(N=386,836): ≥1 
codeine dispensing. 
Excluded if: cancer 
patient; incomplete 
patient identifiers; or, 
use in hospitals, 
nursing homes or 
physician’s office. 
1) Moderate/high codeine user (≥120 
DDD): highest 10% of codeine users 
(12 months) 
A) 10.7% (n=41,459) 
2) High drug-user: dispensed ≥100 
DDD of BZD and/or ≥15 DDD of 
carisoprodol (12 months) 
A) 50.1% (n=193,804); 41.9% 
(n=162,084) dispensed high amount of 
BZD or carisoprodol; 8.2% (n=31,720) 
dispensed high amounts of BZD and 
carisoprodol.  
*Moderate/high codeine 
use and concurrent high 
use of BZD (≥100 DDD) or 
carisoprodol (≥15 DDD) by 
sex:  
Female: 6.9%-8.1%  
Male: 4.0%-5.7%  
*From 10 years of age, 
females had higher rates 
of codeine utilisation than 
males.  
*In other codeine users 
(<120 DDD in 12 
months): 9.6% received 
high amounts of BZD 
(≥100 DDD), carisoprodol 
(≥15 DDD) or both. 
*8% of Norwegian 
population was 
dispensed a codeine 
analgesic in 2006. 
Bellanger2 
2013 
France 
(Jul-Dec 
2005) 
Identify users 
as over- or 
normal-drug-
users and 
identify 
characteristic
s associated 
with 
overconsump
tion (AD and 
A) Tianeptine 
(N=7,263): ≥2 
tianeptine 
dispensings.  
B) Zolpidem 
(N=33,584): ≥2 
zolpidem dispensings. 
1) Doctor shopper: ≥4 prescribers (6 
months) 
A) 0.4% (n=32) 
B) 0.9% (n=300) 
2) Pharmacy shopper: ≥4 dispensing 
pharmacies (6 months) 
A) 1.1% (n=78) 
B) 1.3% (n=438) 
3) Excessive user: excessive use 
threshold derived from Peaks Over 
*Overconsumption risk 
factors for tianeptine and 
zolpidem: younger age, 
pharmacy shopping 
behaviour, consumption of 
≥1 anxiolytic drug and R 
ratio >1 (>1 dispensing per 
28 days). 
*Treatment by a 
psychiatrist increased the 
*Pharmacy shopping 
increased odds of 
overconsumption by: 
168.5% for tianeptine 
and 518% for zolpidem 
users.  
*The classification rate of 
POT model:  
Sensitivity: 
A) 83%; B) 90% 
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Z-drug).  Threshold (POT) model (6 months) 
Threshold value: proportion (%) of 
cohort exceeding threshold 
A) 1.1: 7.2% (n=524) 
B) 2.0: 0.9% (n=318) 
odds of overconsumption 
for tianeptine by 63%; and 
for zolpidem decreased 
the odds of 
overconsumption by 
35.6%. 
 
Specificity:  
A) 81%; B) 84%  
Correctly identified:  
A) 81%; B) 85% 
Bramness3 
2007 
Norway 
(2004) 
Explore 
abuse 
potential of 
carisoprodol 
(other 
sedative). 
 
A) Cohort (N=83,713): 
≥18 years; ≥1 
carisoprodol 
dispensing. Excluded if 
use in a hospital, 
nursing home or 
physician’s office; 
incomplete 
doctor/user 
identifiers.  
1) Carisoprodol abuser (CA): ≥2 
DDD/day in any prescription (not 
further specified); dispensed <100 
DDD of opioids, and dispensed <100 
DDD of BZD (12 months)  
A) 1.0% (n=815)  
2) BZD abuser/anxiety patient (BA): 
dispensed ≥100 DDD of BZD and <100 
DDD of opioids (12 months)  
A) 7.8% (n=6,546) 
3) Opioid abuser/pain patient (OA): 
dispensed ≥100 DDD of opioids (12 
months)  
A) 13.6% (n=11,382) 
4) High carisoprodol user: dispensed 
>15 DDD of carisoprodol  (12 months) 
A) 32.2% (n=26,914) 
5) Doctor shopper: ≥4 prescribers 
(time period not reported) 
A) 0.5% (n=429) 
•In user groups defined above, doctor 
shopper: ≥4 prescribers (time period 
not reported) 
*Number of prescribers 
(time period not reported) 
A) 1 prescriber: 88.8% 
(n=74,305) 
2 prescribers: 9.1% 
(n=7,602) 
3 prescribers: 1.6% 
(n=1,377) 
≥4 prescribers: 0.5% 
(n=429) 
*Prescribed drug by a high 
volume prescriber: highest 
1% of prescribers in drug 
volume (12 months) 
A) 9.4% (n=7,834) 
CA: 10.8% (n=88) 
BA: 25.3% (n=1,657) 
OA: 28.3% (n=3,223) 
*OAs received 48% of total 
amount of carisoprodol 
dispensed in 2004. 
*Most carisoprodol was 
dispensed to users with 
greater than 
recommended use who 
were also dispensed 
large amounts of BZDs 
and opioids.  
*Use of ≥4 prescribers 
and prescription from a 
high volume prescriber 
were more prevalent for 
drugs with abuse 
potential, i.e. BZDs and 
opioids. 
*High prescribers 
prescribed ‘almost 20%’ 
of drugs with abuse 
potential, i.e. BZDs and 
opioids. 
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CA: 4.5% (n=37) 
BA: 1.1% (n=69) 
OA: 2.0% (n=228) 
Bramness4 
2010 
Norway 
(2004) 
Explore 
whether total 
carisoprodol 
(other 
sedative) 
consumption 
relates to 
prevalence of 
excessive 
carisoprodol 
use. 
A) Cohort (N=84,319): 
≥18 years; ≥1 
carisoprodol 
dispensings from a 
pharmacy. Excluded if 
dispensed from an 
institution (not further 
defined). 
1) Excessive carisoprodol user: 
dispensed >15 DDD of carisoprodol; 
used >2 times MRDD (time period not 
specified); ≥2 carisoprodol 
dispensings; dispensed <100 DDD of 
BZD, and dispensed <100 DDD of 
opioids (12 months)  
A) 1.0% (n=815) 
2) Highest 1% of carisoprodol users 
(dispensed ≥480 DDD of carisoprodol) 
(12 months) 
A) 1.1% (n=896) 
3) Extreme carisoprodol user: 
dispensed >1000 DDD of carisoprodol 
(12 months) 
A) 0.2% (n=158) 
4) Proportion of carisoprodol 
dispensed to each misuse cohort (12 
months) 
Excessive user: 4.5% 
Highest 1%: 18.7% 
Extreme user: 6.1% 
*Correlation between 
misuse cohort  and total 
carisoprodol consumption 
(12 months) 
Excessive user: 0.74 
Highest 1%: 0.81 
Extreme user: 0.61 
*Correlation between 
misuse cohort and mean 
dose (12 months)  
Excessive user: 0.67 
Highest 1%: 0.70 
Extreme user: 0.55 
*An increase in amount of 
carisoprodol sold resulted 
in an increase in the 
number of people 
identified in the extreme 
user group. 
*Proportion overlap 
between misuse cohorts 
(12 months) 
Excessive user: not 
reported. 
Highest 1%: 20% were in 
extreme group; 7% were 
excessive users.  
Extreme user: 4% were 
excessive users. 
*45%-64% of variation in 
prevalence of excessive 
use was explained by the 
total sales of 
carisoprodol. 
Cepeda5 
2012 
US 
(2008 to 18 
months after 
Compare 
rates of 
overlapping 
opioid 
prescriptions 
Cohort: dispensed ≥1 
drug of interest; 3 
months of data 
supplied pre-index 
prescription; 
1) ≥1 days of overlapping 
prescriptions: written by ≥2 
prescribers (18 months) 
A) 13.1% (n=3,297,891) 
B) 9.8% (n=843,654) 
*Median days’ drug supply 
(18 months) 
A) Opioid: 10 
B) BZD: 30 
C) Diuretic: 30 
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index drug 
dispensing) 
and multiple 
dispensing 
pharmacies 
with BZD 
(abuse 
potential) 
and diuretic 
(‘no abuse 
potential’) 
users and 
propose a 
definition for 
shopping 
behaviour 
that 
differentiates 
between drug 
classes.  
dispensing 
pharmacy(ies) 
supplied data over 
entire observation 
period. 
A) Opioid 
(N=25,161,024): 
dispensed ≥1 opioid. 
B) BZD (N=8,595,179): 
dispensed ≥1 BZD. 
C) Diuretic 
(N=8,433,456):  
dispensed ≥1 diuretic. 
C) 13.9% (n=1,168,462) 
•In persons with ≥1 days of 
overlapping prescriptions: ≥3 
prescribers (18 months) 
Opioid: 5.4% (n=176,731) 
BZD: 2.5% (n=20,928) 
Diuretic: 3.2% (n=37,164) 
•In persons with ≥1 days of 
overlapping prescriptions: ≥2 
dispensing pharmacies (18 months) 
Opioid: 21.3% (n=700,840) 
BZD: 17.7% (n=149,036) 
Diuretic: 8.3% (n=97,004) 
•In persons with ≥1 days of 
overlapping prescriptions: ≥3 
dispensing pharmacies (18 months) 
Opioid: 1.3% (n=44,071) 
BZD: 1.0% (n=8,167) 
Diuretic: 0.2% (n=2,431) 
2) ≥4 days of overlapping prescriptions 
(18 months) 
A) 7.7% (n=1,937,130) 
B) 6.8% (n=587,241) 
C) 11.1% (n=936,922) 
3) ≥1 overlapping prescriptions and ≥3 
dispensing pharmacies (18 months) 
A) 0.2% (n=44,071) 
B) 0.1% (n=8,167) 
C) 0.03% (n=2,431) 
*Overlapping prescriptions 
were more common in 
persons with history of 
exposure (H) to drug, than 
naïve users (N). 
Opioid: 38.3% (H); 8.5% 
(N) 
BZD: 19.5% (H); 6.0% (N) 
Diuretics: 17.5% (H); 
10.8% (N). 
*Opioid cohort: persons 
aged 25-64 exhibited 
shopping behaviour (≥2 
overlapping prescriptions, 
≥2 prescribers and ≥3 
dispensing pharmacies) 
more commonly (0.3%) 
than older users aged ≥65 
years (0.1%); prior opioid 
users exhibited shopping 
behaviour more 
commonly (0.8%) than 
opioid-naïve users (0.1%). 
 
Cepeda6 2012 Report A) Patients 1) Opioid shopper: ≥1 days *Prescribers with opioid *Prescriber 
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US 
(2008 to 18 
months after 
index drug 
dispensing) 
prevalence of 
opioid 
shopping, 
heavy opioid 
shopping 
behaviour, 
and 
prescriber 
characteristic
s associated 
with 
shopping.  
(N=217,851): ≥1 
opioid dispensings; 3 
months of data pre-
index prescription; 
dispensing 
pharmacy(ies) 
supplied data for 
entire observation 
period. 
B) Prescribers 
(N=858,290): 
prescribers with ≥1 
opioid shopper as a 
patient.  
overlapping opioid prescriptions, ≥2 
prescribers and ≥3 dispensing 
pharmacies (1 shopping episode) (18 
months) 
A) The extent of drug-users defined as 
an opioid shopper not reported 
shoppers as patients (18 
months)  
B) 13.2% (n=113,034); 
86.8% of prescribers had 
no shoppers as patients. 
*Prescribers with heavy 
shoppers (≥5 shopping 
episodes) as patients (18 
months)  
B) 1.7% (n=14,699); 98.3% 
of prescribers had no 
heavy shoppers as 
patients. 
 
characteristics associated 
with opioid shoppers: 
number of patients 
prescribed an opioid (18-
35 users [OR 4.05], 916-
1831 [OR 620.13]); male 
(OR 1.06); aged 70-79 
(OR 2.01). 
*25% of prescribers, 
prescribed opioids to ≥66 
patients, accounting for 
82% of shoppers. 
*Prescriber specialties 
most associated with 
opioid shoppers as 
patients: pain, addiction 
and emergency drug. 
Cepeda7 
2013 
US 
(2008 to 18 
months after 
index drug 
dispensing) 
Assess 
prevalence of 
shopping 
behaviour in 
opioid users; 
how soon 
shopping 
behaviour 
occurs after 
initial opioid 
exposure; 
number of 
events per 
A) Cohort 
(N=25,161,024): ≥1 
opioid dispensings; 3 
months of data pre-
index prescription; 
dispensing 
pharmacy(ies) 
supplied data over 
entire observation 
period. 
1) Opioid shopper: ≥1 days 
overlapping opioid prescriptions, ≥2 
prescribers and ≥3 dispensing 
pharmacies (1 shopping episode) (18 
months) 
A) 0.3% (n=75,215) of users accounted 
for 205,932 shopping episodes. 
•In opioid shoppers, proportion of 
heavy shoppers: ≥6 shopping episodes 
(18 months)  
Opioid shoppers: 9.5% (n=7,157) of 
users accounted for 44.2% (n=90,997) 
of shopping episodes 
*In opioid shoppers, 
number of dispensing 
pharmacies (18 months) 
3 pharmacies: 72.7% 
(n=54,658) 
4 pharmacies: 13.9% 
(n=10,460) 
5 pharmacies: 6.8% 
(n=5,080) 
6 pharmacies: 3.2% 
(n=2,439) 
≥7 pharmacies: 3.4% 
(n=2,578) 
*Shoppers (44.9%) more 
frequently paid in cash 
than non-shoppers 
(18.5%). 
*In shoppers, the most 
utilised opioids: schedule 
II and III (32.7%); 
combination formulation 
(30.7%); and IR and ER 
(25.2%) 
*Median of 234 days to 
first shopping event 
*Mean 2.7 shopping 
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shopper; 
preferred 
opioids; and 
method of 
payment. 
 *In opioid shoppers, 
number of prescribers (18 
months) 
2 prescribers: 48.1% 
(n=36,178) 
3 prescribers: 31.6% 
(n=23,790) 
4 prescribers: 9.3% 
(n=6,967) 
5 prescribers: 4.5% 
(n=3,357) 
≥6 prescribers: 6.6% 
(n=4,923) 
episodes per shopper 
*91.7% of subjects with a 
shopping behaviour were 
aged 19-64 years. 
*Prior opioid users were 
13.7 times more likely to 
exhibit shopping 
behaviour (1.4% vs. 
0.1%) than opioid-naïve 
users. 
Cepeda8 
2013 
US 
(2009 to 12 
months after 
index drug 
dispensing) 
Compare risk 
of shopping 
behaviour 
between 
tapentadol 
immediate 
release (IR) 
and 
oxycodone IR 
(opioid). 
 
 
Cohort: ≥1 tapentadol 
or oxycodone 
dispensing; no opioid 
dispensed in 3 months 
pre-index 
prescription. 
Excluded: dispensed 
any other opioid 3 
days from index date. 
A) Tapentadol IR 
(N=42,940) 
B) Oxycodone IR 
(N=112,821)  
Cohorts were 
matched 1:4 ratio on 
month of initial 
exposure, age, 
1) Opioid shopper: ≥1 days 
overlapping opioid prescriptions, ≥2 
prescribers and ≥3 dispensing 
pharmacies (1 shopping episode) (12 
months) 
A) 0.2% (n=88) 
B) 0.9% (n=967) 
2) Heavy shopper: ≥5 shopping 
episodes (12 months) 
A) 0.01% (n=4) 
B) 0.07% (n=80) 
•In opioid shoppers, proportion of 
heavy shoppers (12 months) 
Tapentadol: 4.5% (n=4) 
Oxycodone: 8.3% (n=80) 
 
*Oxycodone users had a 
higher risk of shopping 
(3.5 times higher) and 
heavy shopping behaviour 
(OR 6.9) than tapentadol 
users. 
*Mean (SD) shopping 
episodes per person (12 
months) 
A) 0.004 (0.1) 
B) 0.02 (0.3) 
*In opioid shoppers, mean 
(SD) shopping episodes per 
shopper (12 months) 
Tapentadol: 1.8 (1.9) 
Oxycodone: 2.1 (2.6) 
 
*Shopping events 
exclusively for opioid of 
interest (12 months) 
Tapentadol: 0.6% 
Oxycodone: 28% 
-Mean (SD) days to 
shopping event (12 
months) 
Tapentadol: 180.0 
(104.6) 
Oxycodone: 156.1 
(100.9) 
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geographic area of 
pharmacy, prescriber 
specialty. 
  
Cepeda9 
2013 
US 
(2008 to 18 
months after 
index drug 
dispensing) 
Compare 
distance 
travelled to 
fill opioid 
prescriptions 
for shoppers 
and non-
shoppers. 
 
A) Cohort 
(N=10,910,451): ≥3 
opioid dispensings; 18 
months of data post-
index prescription. 
1) Opioid shopper: ≥1 days 
overlapping opioid prescriptions, ≥2 
prescribers and ≥3 dispensing 
pharmacies (1 shopping episode) (18 
months) 
A) 0.7% (n=75,215); accounted for 
8.6% of all dispensed opioids 
2) Proportion of heavy shoppers: ≥5 
shopping episodes (18 months) 
A) 0.1% (n=9,435) 
 
*Median miles [km] 
travelled to fill opioid 
prescriptions (18 months) 
Non-shoppers: 0 [0 km] 
Shoppers: 83.8 [134.9 km] 
Heavy shoppers: 199.5 
[321.1 km] 
*Median opioid 
dispensings 
Non-shoppers: 6 
Shoppers: 39 
Heavy shoppers: 390 
*Proportion of users with 
opioid dispensings from 
≥2 states (18 months)  
Non-shoppers: 4.2% 
Shoppers: 19.3% 
Heavy shoppers: 22.4% 
 
Dormuth10 
2012 
Canada 
(1993-1997) 
Determine if 
implementing 
a real-time 
centralised 
prescription 
network 
(RTCP) 
reduced rate 
of potentially 
inappropriate 
BZDs and 
opioid 
dispensings. 
Cohort: ≥1 opioid (O) 
or BZD dispensings for 
≥30 tablets 
A) O – Social 
assistance 
(N=86,704): users 
receive social 
assistance 
B) BZD – Social 
assistance 
(N=47,983): users 
receive social 
assistance  
C) O – aged ≥65 years 
(N=199,497)  
1) Proportion of inappropriate 
dispensings: ≥2 prescribers and ≥2 
dispensing pharmacies for ≥30 tablet 
dispensings (7 days)  
A) 3.2% (n dispensings not reported) 
B) 1.2% (n dispensings not reported) 
C) 0.2% (n dispensings not reported) 
D) 0.6% (n dispensings not reported) 
 
*Relative change in 
inappropriate dispensings: 
post RTCP implementation 
(30 months) 
A) -32.8%  
B) -48.6% 
C) -40.1% 
D) -42.4% 
*Absolute change in 
inappropriate dispensings 
per month 
A) -1.1%  
B) -0.5% 
C) -0.3% 
D) -0.1% 
*RTCP implementation 
associated with large, 
immediate and sustained 
reductions in 
inappropriate opioid and 
BZD dispensings. 
*Inappropriate NSAIDs 
use (comparator drug) 
was infrequent and did 
not change during this 
time period. 
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D) BZD – aged ≥65 
years (N=150,699) 
Feroni11 
2005 
France 
(Oct 2001- 
Nov 2002) 
Investigate 
GPs attitudes 
towards 
buprenorphin
e 
maintenance 
treatment 
(BMT) and 
their BMT 
patients’ 
propensity to 
doctor shop 
(opioid). 
A) Cohort (N not 
reported): BMT 
patients of 345 GPs 
who participated in a 
random telephone 
survey. All GP’s BMT 
patients’ data then 
matched to health 
insurance data. 
No threshold of misuse defined. *On average, BMT users 
access 3.1 prescribers in 
12 months (range: 1-13). 
*Doctor shopping was 
lower for persons starting 
BMT on ≥8 mg/day, than 
those who were 
prescribed <8 mg/day. 
*Patients whose doctors 
always or often 
collaborate with a 
specialised network/care 
center had a higher 
number of prescriptions. 
*Doctor shopping 
correlated with high 
mean prescriptions per 
user and shorter average 
duration of BMT. 
*Socioeconomic 
characteristics strongly 
associated with doctor 
shopping: more 
physicians per km2; 
fewer people per 
household; higher 
unemployment or blue 
collar workers. 
Frauger12 
2009 
France 
(2001 and 
2006) 
Estimate 
clonazepam 
(BZD) deviant 
behaviour, 
trends in 
deviant 
behaviour 
and 
characteristic
s of deviants. 
 
A) Cohort (N=26,480): 
≥1 clonazepam 
dispensings.  
 
1) Deviant group: defined by cluster 
analysis profiling individuals by 
number of: dispensing pharmacies; 
prescribers; dispensings, and total 
quantity dispensed (9 months) 
A) Deviant user: 1.1% (n=292) 
‘More deviant’ user: 0.07% (n=19) 
 
*Mean (SD) dispensing 
pharmacies (9 months)  
Deviant: 6.4 (2.8) 
More deviant: 16.6 (4.3) 
All other persons: 1.4 (0.7) 
*Mean (SD) prescribers (9 
months) 
Deviant: 4.6 (2.2);  
More deviant: 11.6 (3.7) 
All other persons: 1.5 (0.8) 
*Mean (SD) dispensing 
episodes (9 months) 
Deviant: 21.1 (8.3) 
More deviant: 65.0 (31.4) 
*Deviant group 
characteristics: younger, 
male and associated with 
higher: use of BZDs and 
buprenorphine; number 
of prescribers, dispensing 
pharmacies, deliveries 
and total DDD dispensed. 
*The prevalence of 
deviant behaviour 
increased from 0.9% in 
2001 to 1.4% in 2006. 
*Proportion of 
clonazepam dispensed to 
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All other persons: 6.0 (3.0) 
*Mean (SD) sum of DDD 
dispensed (9 months) 
Deviant: 392.1 (200.3) 
More deviant: 
1379.7(1014.1) 
All other persons: 54.6 
(51.3) 
deviant group increased 
from 7.8% (2001) to 9.5% 
(2009).  
Frauger13 
2011 
France 
(2005-2008) 
Describe 
patterns of 
methyl-
phenidate 
(CNS 
stimulant) 
use and rates 
of abuse and 
diversion.  
 
A) Cohort (N=3,574): 
≥1 methylphenidate 
dispensings. 
1) Deviant group: defined by cluster 
analysis profiling individuals by 
number of: dispensing pharmacies; 
prescribers; dispensings, and total 
quantity dispensed (9 months) 
A) 1.1% (n=40) 
 
*Mean (SD) dispensing 
pharmacies (9 months) 
Deviant: 11.0 (4.9) 
All other persons: 1.3 (0.6) 
*Mean (SD) prescribers (9 
months) 
Deviant: 12.0 (4.4);  
All other persons: 1.8 (0.9) 
*Mean (SD) dispensing 
episodes (9 months) 
Deviant: 41.9 (14.7) 
All other persons: 6.4 (4.5)  
 
*Mean (SD) sum of DDD 
dispensed (9 months) 
Deviant: 1707.6 (585.3) 
All other persons: 170.5 
(150.6) 
*Proportion of deviant 
behaviour increased over 
study period, peak of 
2.0% in 2007. 
*Deviant group 
characteristics: higher 
utilisation rates of BZD, 
AD, antipsychotic or 
opioid maintenance 
therapy. 
Fredheim14 
2009 
Norway 
(2004-2006) 
Identify 
‘problematic’ 
codeine 
(opioid) 
prescription 
patterns. 
 
A) Naïve users 
(N=222,929): ≥1 
codeine dispensings in 
2005. Excluded: 
prescriptions with 
incomplete identifiers 
or prescribed for 
1) High user: dispensed >365 DDD of 
codeine (12 months) 
A) 0.03% (n=64) 
B) 5.8% (n=9,384) 
•In high users: dispensed >100 DDD of 
BZDs (12 months) 
Naïve users: 29.7% (n=19) 
*Persons with >730 DDD 
per year of codeine 
frequently co-medicated 
with other drugs including 
BZDs (66%) and 
carisoprodol (45%). 
*0.5% of persons 
 
 302 
 
cancer.  
B) Old users 
(N=162,261): A) and 
≥1 codeine 
dispensings in 2004. 
Old users: 50.5% (n=4,738) 
•In high users: dispensed >15 DDD of 
carisoprodol (12 months) 
Naïve users: 18.8% (n=12) 
Old users: 30.2% (n=2,838) 
•In high users: dispensed >730 DDD of 
codeine (12 months) 
Naïve users: 1.6% (n=1) 
Old users: 19.0% (n=1,786) 
prescribed codeine 
developed serious 
problematic use. 
 
Gilson15 
2012 
US 
(2000-2006) 
 
Investigate if 
changes to 
prescription 
monitoring 
program 
influences:  
i) prescribing 
rate for nine 
schedule II 
long- (LA) or 
short-acting 
(SA) opioids, 
or  
ii) incidence 
of multiple 
provider 
episodes 
(MPEs). 
A) Cohort (N not 
reported): 
inclusion/exclusion 
criteria not specified.  
Prescription level data 
(N=15,506,651) 
1) Prescriptions involved in MPEs: ≥2 
prescribers for same opioid and ≥2 
dispensing pharmacies (30 days) 
9.6% (n prescriptions=1,488,639) 
*Prescriptions dispensed 
involving MPEs (time 
period not reported) 
SA hydromorphone: 15.2% 
SA fentanyl: 11.4% 
SA oxycodone: 10.9% 
SA morphine: 10.0% 
LA oxycodone: 8.7% 
Methadone: 8.6% 
LA morphine: 8.5% 
LA fentanyl: 8.1% 
Meperidine: 7.0% 
*Policy change increased 
rate of MPEs involving all 
opioids. 
*Replacing triplicate 
forms with a secure 
tamper resistant form 
increased prescribing 
rates for SA 
hydromorphone, 
meperidine, SA 
oxycodone. Prescribing 
rates unchanged for SA 
or LA fentanyl, 
methadone, SA or LA 
morphine and LA 
oxycodone. 
Gjerden16 
2009 
Norway 
Investigate 
use and 
potential 
Cohort (N=73,964): 
aged 18-69  
A) (N=70,937) 
1) Proportion of drug volume 
consumed by highest 1% of users: a 
figure >15% is a strong signal for drug 
*Maximum number of 
BZD-prescribers (12 
months) 
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(2004) abuse of 
antiparkinson 
(AP) drugs. 
Dispensed any 
antipsychotic drug  
B) (N=2,771) 
Dispensed 
dopaminergic or 
anticholinergic AP 
drug reimbursed for 
Parkinson’s disease  
C) (N=213) Dispensed 
antipsychotic and 
evidence of 
Parkinson’s disease 
D) (N=43) Dispensed 
anticholinergic drug, 
not dispensed an 
antipsychotic, no 
evidence of 
Parkinson's disease. 
Excluded if: dispensed 
benzhexol, 
procyclidine or 
trihexyphenidyl. 
abuse (12 months) 
Biperiden: 6.2% 
BZDs: 16.5% 
Orphenadrine: 5.4% 
2) Doctor shopper: ≥3 prescribers for 
BZD tranquilizers (12 months) 
No meaningful data derived. 
 
A) 8 
B) 5 
C) 3 
D) 6 
*Antipsychotic drug-users 
accounted for 94% of 
anticholinergic use, 
compared to 4.3% of 
antipsychotic drug-users 
with Parkinson's disease.  
*BZD use more frequent in 
antipsychotic drug-users 
than antipsychotic drug-
users with Parkinson's 
disease.  
*Cohort D had highest rate 
of BZD concomitant use. 
Goodman17 
2005 
US 
(Jun 2000-Jul 
2002) 
Determine if 
a prescription 
review could 
identify cases 
of possible 
oxycodone 
ER abuse 
(opioid). 
A) Cohort (N not 
reported): ≥1 
oxycodone ER 
dispensing from a 
Veteran’s Affairs (VA) 
facility.  
Case level data 
(N cases = 60,955) 
Proportion of cases meeting criteria.  
1) Dispensed large quantity: ≥480 
tablets per prescription (20 months) 
A) 5% (n=4 cases) 
2) Multiple sites: prescription for same 
drug filled ≥10 days early from ≥2 
facilities (25 months) 
A) 24% (n=41 cases) 
*Cases involving 
past/present substance 
abuse diagnosis per 
measure of misuse (time 
period not reported) 
Dispensed large quantity: 
3% (n=2 cases) 
Multiple sites: 5% (n=8 
*Multiple VISNs: doctor 
aberrant prescribing not 
defined (10 months) 
2% 
*The prevalence of 
aberrant drug-related 
behaviour of multiple 
sites or multiple VISNs 
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  3) Multiple Veterans Integrated 
Service Networks (VISNs): prescription 
for same drug filled ≥10 days early 
from ≥2 VISNs (10 months) 
A) 15% (n=6 cases) 
4) High usage: ≥480 tablets per 
prescriptions, high dosage (320 mg 
daily), or frequent dosing intervals 
(every 4-6 hours): extent of misuse 
not reported  
5) Early refills: ≥2 consecutive early 
refills from ≥2 providers: extent of 
misuse not reported 
6) Large total quantity: ≥480 tablets 
total per month: extent of misuse not 
reported 
cases) 
Multiple VISNs: 5% (n=2 
cases) 
 
Doctor’s aberrant 
prescribing pattern as 
indicator. 
*Doctors prescribed large 
quantity: ≥480 tablets per 
prescription (20 months) 
12% (n=10 cases) 
*Multiple sites: doctor 
aberrant prescribing not 
defined (25 months) 
2% (n=3 cases) 
 
decreased over the 
review periods. 
 
Hall18 
2008 
US 
(2006) 
 
Evaluate 
characteristic
s of persons 
dying from 
unintentional 
pharmaceutic
al overdose 
(controlled 
substances), 
types of 
drugs 
involved and 
the role of 
drug abuse in 
A) Cohort (N=295): 
died of unintentional 
drug poisoning 
according to death 
certificate in 2006. 
Excluded: no autopsy 
performed; toxicology 
tests not performed 
by Office of Medical 
Examiner; overdose 
due exclusively to 
illicit drugs, over the 
counter products 
and/or alcohol. 
1) Doctor shopper: ≥5 prescribers of 
controlled substances (12 months) 
A) 21.4% (n=63) 
 
*Diverters: 
pharmaceuticals used 
without a prescription 
record (12 months) 
A) 63.1% (n=186) 
*Diverter and doctor 
shopper (12 months) 
A) 8.1% (n=24) 
*Deaths involving specific 
drug classes (12 months) 
Opioid analgesic: 93.2% 
Psychotherapeutic: 48.8% 
Other prescription drug 
(butalbital, carisoprodol, 
*Unintentional overdose 
death rate: 16.2/100,000 
*Doctor shopping 
associated with: being 
female (OR 2.2); aged 35-
44 years (OR 2.0); 
previous overdose (OR 
2.8). 
*Diversion behaviour 
associated with: 18-24 
age group (OR 12.1) 
never marrying (OR 2.8); 
history of substance 
abuse (OR 1.8); non-
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deaths.  
 
cyclobenzaprine, 
diltiazem, phenytoin, 
promethazine): 11.2% 
medical route of 
pharmaceutical 
administration (OR 1.9) 
or illicit drug use (OR 
2.1). 
Han19 
2012 
US 
(2005-2007) 
 
Examine 
effect of 
individual 
and county 
related 
factors on 
use of 
multiple 
prescribers 
and/or 
pharmacies 
for 
prescription 
opioids. 
A) Cohort 
(N=1,057,012): ≥1 
opioid dispensings per 
year (2005 to 2007). 
Excluded if: 
incomplete/ 
implausible 
prescription; 
commercial 
transaction; non-
standard route of 
administration for 
chronic pain users; 
drug use by age group 
not associated with 
chronic pain or 
obtaining drugs 
through office 
interactions. 
No threshold of misuse defined. *Number of prescribers 
(12 months) 
A) Mean (range): 2.1 (1-
158)  
1 prescriber: 50.7% 
(n=536,408) 
2-5 prescribers: 45.1% 
(n=476,843) 
≥6 prescribers: 4.1% 
(n=43,761) 
*Number of dispensing 
pharmacies (12 months) 
B) Mean (range): 1.8 (1-
100) 
1 pharmacy: 59.0% 
(n=623,357) 
2-5 pharmacies: 38.9% 
(n=411,704) 
≥6 pharmacies: 2.1% 
(n=21,951) 
*Higher number of 
prescribers and dispensing 
pharmacies associated 
with: younger age (18-74), 
being female, living in a 
*Physician availability 
was the most robust 
predictor, i.e. as number 
of physicians increased 
so did number of 
prescribers and 
dispensing pharmacies.  
*Individuals who use 
both schedule II and III 
opioids visited multiple 
prescribers and multiple 
pharmacies more often 
than those who used 
opioids from a single 
schedule. 
*Higher use of multiple 
prescribers and 
pharmacies associated 
with: ethnicity, 
educational attainment, 
median household 
income and physician 
availability. 
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county with more licensed 
physicians and surgeons.  
Hartz20 
2009 
Norway 
(2004-2007) 
 
Examine 
association 
between 
disability 
pensioners 
using BZD 
and aspects 
of 
problematic 
use. 
A) Cohort (N=19,520): 
aged ≤61 years; ≥1 
BZD dispensing; 
health survey data 
linked to national 
prescription database. 
Excluded if: 
reimbursed for cancer 
drugs; died/emigrated 
prior to 2004; BZD 
user at survey 
baseline; wrote trade 
names for BZD in 
survey; missing 
disability status. 
1) Long term user: dispensed ≥1 BZD 
each year between 2004 and 2007 (48 
months) 
A) 2.2% (n=425) 
 
*In long term users, 
median BZD use was 
higher in disability 
pensioners (50 DDD) than 
non-disability pensioners 
(20 DDD).  
*When controlling for 
other factors, long term 
use of BZD is more 
prevalent in disability 
pensioners than non-
disability pensioners (OR 
2.5).  
 
*Predictors of long-term 
BZD use: being female 
and increasing age. 
*Use of BZD and other 
potentially addictive 
drugs (z-drugs, opioids 
and carisoprodol) 
increased over the 4 
years.  
 
Hoffman21 
2003 
US 
(1998-Mar 
2000) 
Evaluate 
effectiveness 
of physician 
alert to 
reduce 
patients’ 
excessive use 
of 
prescription 
drugs and 
decrease 
costs to the 
third party 
A) Control (n=89): ≥1 
alert. 
B) Excessive users 
(n=94): letter sent to 
physician; user has ≥3 
alerts in 3 months 
(alerts relate to 
number of 
prescribers, 
pharmacies and 
volume of drug 
dispensed); no 
concurrent 
1) Recurrent excessive users: ≥2 letters 
sent out to physician (6 months) 
B) 29.8% (n=28) 
 
*Number of prescribers (3 
months) 
Pre-intervention mean 
(SD) to post-intervention 
mean (SD) [% change] 
A) 5.3 (2.4) to 1.4 (2.4)  
[-22.0%]  
B) 6.4 (3.6) to 2.2 (3.3)  
[-28.0%] 
*Number of prescriptions 
(1 month) 
A) 13.4 (3.5) to 3.7 (4.7)  
[-28.4%] 
*Prescription drug cost (1 
month) 
A) $460.15 ($335.00) to 
$39.07 ($331.00) [-
17.9%] 
B) $480.28 ($393.00) to 
$118.38 ($296.00) [-
23.1%] 
*Medical cost (12 
months) 
A) $8811.90 to $970 [not 
reported] 
B) $9115.96 to $1413.00 
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payer 
(controlled 
substances 
schedule II to 
IV). 
 
prescription drug use 
indicative of cancer, 
HIV infection or renal 
failure. Excluded if: 
Medicare user; <6 of 
collected data. 
Cohorts matched on 
total number of 
prescriptions and 
number of 
prescriptions with 
abuse potential. 
B) 13.7 (6.4) to 5.0 (4.4) 
[38.1%] 
*Number of high abuse 
prescriptions (1 month) 
A) 5.5 (2.1) to 2.0 (2.6)  
[-33.6%] 
B) 6.0 (2.8) to 3.1 (4.6)  
[-45.5%] 
[not reported] 
*23% of users whose 
physicians received 
letters did not show any 
change in dispensing 
patterns. 
*Authors attributed 
control group results to 
’regression toward the 
mean’.  
Katz22 
2010 
US 
(Jul 1995- Jun 
2006) 
 
Evaluate 
trends in 
schedule II 
opioid 
prescribing 
and  
dispensing. 
 
 
A) Cohort 
(N=562,592): ≥1 
opioid dispensings in 
2006. Excluded if: 
entry missing 
prescriber number, 
date filled, 
prescription number, 
quantity, national 
drug code, days of 
supply, valid date of 
birth or customer ID.  
 
 
1) Questionable activity: ≥3 
prescribers and ≥3 dispensing 
pharmacies (12 months) 
% persons; % prescriptions; % dosage 
units 
A) 1.6% (n=8,797); 7.7% (n=112,381); 
8.5% (n=7,622,840) 
2) Preferred indicator: Questionable 
activity: ≥4 prescribers and ≥4 
dispensing pharmacies (12 months) 
A) 0.5% (n=2,748); 3.1% (n=45,102); 
3.1% (n=2,805,613) 
3) Questionable activity: ≥5 
prescribers and ≥5 dispensing 
pharmacies (12 months) 
A) 0.2% (n=1,149); 1.5% (n=22,075); 
1.4% (n=1,247,666) 
4) ≥1 early refills: two consecutive 
*Number of prescribers 
(12 months) 
A) Mean (SD): 1.4 (0.93) 
1 prescriber: 78.9% 
(n=443,956) 
2 prescribers: 13.4% 
(n=75,191) 
3 prescribers: 4.4% 
(n=24,919) 
4 prescribers: 1.8% 
(n=9,980) 
5 prescribers: 0.8% 
(n=4,274) 
6 prescribers: 0.3% 
(n=1,887) 
7 prescribers: 0.2% 
(n=1,025) 
8 prescribers: 0.1% 
*Number of dispensing 
pharmacies (12 months) 
A) Mean (SD): 1.1 (0.52) 
1 pharmacy: 90.6% 
(n=509,818) 
2 pharmacies: 6.9% 
(n=38,865) 
3 pharmacies: 1.6% 
(n=8,870) 
4 pharmacies: 0.5% 
(n=2,917) 
5 pharmacies: 0.2% 
(n=1,138) 
6 pharmacies: 0.1% 
(n=464) 
7 pharmacies: 0.04% 
(n=248) 
8 pharmacies: 0.02% 
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prescriptions for same drug with 
number of days between prescriptions 
being >10% lower than number of 
days of supply in first prescription, i.e. 
if prescription for 30 days, second 
prescription filled <27 days after first 
dispensing) (time period varied based 
on length of prescription) 
Mean (SD): 0.1 (0.67) 
A) 6.9% (n=38,819) 
 
(n=543) 
9 prescribers: 0.1% 
(n=296) 
≥10 prescribers: 0.1% 
(n=520) 
*76.9% of users with one 
prescriber accessed one 
pharmacy; 0.1% of users 
with one prescriber 
accessed ≥4 dispensing 
pharmacies. 
*Among persons using ≥5 
prescribers, 14.1% used ≥4 
dispensing pharmacies. 
*Among persons using ≥10 
prescribers, 69.2% used ≥4 
dispensing pharmacies. 
*11% of total population 
received ≥1 schedule II 
opioid in 2006.  
(n=108) 
9 pharmacies: 0.01% 
(n=76) 
≥10 pharmacies: 0.02% 
(n=87) 
*Rate of questionable 
activity increased 
between 1996-2002 and 
decreased between 
2002-2006, despite an 
increase in opioid 
prescribing.  
*SA oxycodone was the 
opioid most associated 
with questionable 
activity. 
Logan23 
2013 
US 
(2009) 
Determine 
prevalence of 
opioid misuse 
and the 
inappropriate 
prescription 
practices by 
emergency 
department 
(ED) 
A) Cohort 
(N=400,288): aged 18-
64; ≥1 opioids 
dispensed same day 
as ED visit that was 
not part of a hospital 
admission. Excluded 
if: incomplete 
information; claims 
for services which 
1) ≥2 overlapping ED opioid 
prescriptions: overlapping by ≥7 days 
(12 months) 
A) 2.1% (n=8,229) 
2) Overlapping ED opioid and BZD 
prescriptions: overlapping by ≥7 days 
(12 months) 
A) 1.0% (n=3,867) 
3) ≥1 incidents of LA/ER opioid 
dispensed for acute pain condition (12 
*Prescriptions overlapped 
with another LA opioid 
prescriptions: overlapping 
by ≥7 days (12 months) 
A) 14.6% 
*≥2 opioid-related ED 
presentations (12 months) 
A) 8% (n=32,024) 
*Number of ED opioid 
prescriptions (12 months) 
*A higher proportion of 
females (11.5%) had at 
least one indicator of 
potentially inappropriate 
prescribing or misuse, 
compared to males 
(9.0%). 
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providers. 
 
could not render 
opioids; tests not 
confirming diagnostic 
information; not 
continuously enrolled 
in health plan for 
2009; or treatment for 
cancer pain 
determined by ICD-9 
diagnosis for cancer. 
months) 
A) 0.1% (n=565) 
4) Dispensed high opioid doses from 
ED: daily dose of ≥100 morphine 
milligram equivalent (12 months) 
A) 7.8% (n=31,117) 
 
A) 1 prescription: 91.0% 
2 prescriptions: 7.0% 
≥3 prescriptions: 2.0% 
Mailloux24 
2010 
US 
(Jul 1998– 
Aug 1999) 
Identify 
persons 
abusing 
controlled 
substances 
(opioids, 
BZDs, and 
CNS 
stimulants) 
through a 
decision 
support tool. 
Abuse 
determinatio
n based on 
number of 
prescribers, 
pharmacies, 
volume of 
drug 
A) Intermediate 
abusers (N=85): letter 
sent to physician to 
alert them to their 
patients’ behaviour 
B) Abusers (N=39): no 
change from 
‘intermediate abuser’ 
behaviour within 6 
months, individual is 
‘locked-in,’ i.e. for 2 
years one prescriber 
and one dispensing 
pharmacy. Excluded if: 
‘lock-in’ required 
informed consent, 
part of mental health 
commitment or 
condition of 
probation/parole. 
1) Shopping behaviour: drug obtained 
by ‘multiple providers and 
pharmacies’ (6 and 2 months) 
i) Mean (SD) days of overlapping 
prescriptions (6 months) 
A) 155.8 (103.1) 
B) 768.2 (609.2) 
ii) Mean (SD) days of overlapping 
prescriptions (2 months) 
A) 70.8 (55.4) 
B) 350.8 (246.1) 
2) Early refill: one drug obtained from 
one physician and multiple 
pharmacies within 50% of the days’ 
supply of the first prescription (6 and 
2 months) 
i) Mean (SD) episodes (6 months) 
A) 1.9 (2.5) 
B) 5.9 (13.4) 
ii) Mean (SD) episodes (2 months) 
*Mean (SD) duplicate 
prescription score: number 
of duplicate prescriptions 
(controlled substance 
obtained from different 
prescribers/pharmacies on 
the same day) (time period 
not reported)  
A) 0.3 (0.6) 
B) 1.2 (1.5) 
*Mean (SD) dispensing 
pharmacies (time period 
not reported) 
A) 4.2 (1.8) 
B) 9.9 (4.3) 
*Mean (SD) prescribers 
(time period not reported) 
A) 4.8 (2.7) 
B) 12.2 (6.5) 
 
*Mean controlled 
substances claims (time 
period not reported) 
A) 22.3 (10.4) 
B) 48.7 (18.6) 
*Overall the classification 
rate is 95.3%. (Sensitivity: 
87.2%, specificity: 
96.5%.) 
*Number of dispensing 
pharmacies was the best 
predictor of abuse of 
controlled substances. 
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dispensed 
and medical 
diagnosis. 
 A) 0.6 (1.0) 
B) 3.1 (6.6) 
Martin25 
2011 
US 
(2000-2005) 
Report rates 
of opioid 
misuse, 
discontinuati
on (≥182 days 
of no opioid 
use), and 
identify 
factors 
associated 
with 
discontinuati
on. 
 
A) Commercially 
insured (N=23,41): ≥1 
chronic opioid use 
episode, i.e. >90 days 
of opioids supplied in 
any 6 month period 
between Mar 2001-
Dec 2004, continuous 
enrolment for 12 
months pre-and post-
index date (first opioid 
dispensing), identified 
in HealthCore dataset.  
B) Publically insured 
(N=6,848): A) but 
identified in Arkansas 
Medicaid.  
1) Opioid misuse score: based on 
excess days supplied short- and long-
acting opioids, number of dispensing 
pharmacies, and number of 
prescribers (6 months) 
Score 0-1: no misuse 
A) 83.2% (n=19,474) 
B) 87.7% (n=6,003) 
Score 2-3: possible misuse 
A) 14.5% (n=3,399) 
B) 10.9% (n=747) 
Score ≥4: probable misuse 
A) 2.2% (n=523) 
B) 1.4% (n=98) 
 
*Prevalence of opioid 
abuse disorder (time 
period not reported) 
A) 0.6% (n=130) 
B) 0.5% (n=36) 
*Approximately 1/7 
persons potentially misuse 
opioids. 
*Commercially insured 
cohort: persons with 
possible or probable 
opioid misuse were 20% 
less likely to discontinue 
opioids than those with no 
indication of opioid 
misuse. 
 
McDonald26 
2013 
US 
(2008) 
Estimate 
prevalence of 
users 
obtaining 
opioid 
prescriptions 
from 
different 
physicians. 
A) Cohort (N=’13.6 
million’): ≥1 opioid 
dispenings in first 60 
days of 2008.  
 
1) Extreme outlying population: 
determined by latent class analysis 
based on method of payment, gender, 
age (10 months) 
A) 0.7% (n≈95,200), accounting for 
1.9% of dispensed drug. 
 
*Number of prescribers for 
57% of users dispensed an 
opioid after first 60 days of 
2008 (10 months) 
1 prescriber: 31%  
2 prescribers: 14% 
3-4 prescribers: 8.6% 
(inferred)  
5-9 prescribers: 3% 
10-19 prescribers: 0.4% 
*Users ’aged mid to late 
20s were 10 times more 
likely to fit the extreme 
profile than users double 
their age’. 
*In the extreme 
population, the average 
number of prescribers 
increased with age until 
age 40, after which it 
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≥20 prescribers: 0.04% 
*Mean number of 
prescribers for extreme 
population (10 months): 
10.4 
declined. 
Nordmann27 
2013 
France 
(2008) 
Describe and 
compare 
opioid abuse 
using doctor 
shopping to 
estimate 
abuse in 
three French 
regions. 
 
A) PACA (N=885,941): 
≥1 opioid dispensings;  
resident of Provence-
Alpes-cote d’Azur 
(PACA) 
B) RA (N=945,102): A) 
except resident of 
Rhone Alps (RA). 
C) MP (N=386,834): A) 
except resident of 
Midi-Pyrenees (MP). 
D) Entire cohort (N= 
2,217,877): A) + B) + 
C) 
1) Doctor shopping quantity (DSQ): 
amount of excess drug dispensed by 
overlapping prescriptions written by 
≥2 prescribers (12 months) 
A) 213.3 DDD/1000 population 
B) 115.1 DDD/1000 population 
C) 106.2 DDD/1000 population 
D) 150.5 DDD/1000 population 
Drug class: DSQ (DDD/1000 
population) (% of all dispensed drug) 
Weak opioid analgesics: 75.5 (50.2%) 
OMT opioids: 55.3 (36.7%) 
Strong opioid analgesics: 19.7 (13.1%) 
2) Doctor shopping indicator (DSI): 
proportion of total drug dispensed 
obtained by overlapping prescriptions 
from ≥2 prescribers (12 months). DSI 
<1% is not a signal for abuse. 
Drug class: DSI 
OMT: 6.2% 
Strong opioid analgesics: 5.0% 
Weak opioid analgesics: 1.1% 
*DSQ by opioid (12 
months) 
Drug: DSQ (DDD/1000 
population)  
D) Buprenorphine (OMT): 
50.3 
Dextropropoxyphene: 27.6 
Codeine: 24.1 
Tramadol: 23.3 
Morphine: 17.8 
Methadone: 4.9 
Oxycodone: 1.5 
Dihydrocodeine: 0.5 
Buprenorphine (analgesic): 
0.2 
Hydromorphone: 0.2 
 
*Specific opioids with 
DSI≥1% (12 months) 
D) Buprenorphine (OMT): 
8.0% 
Morphine: 5.5% 
Dihydrocodeine: 3.7% 
Buprenorphine 
(analgesic): 2.9% 
Oxycodone: 2.7% 
Codeine: 2% 
Methadone: 1.9% 
Hydromorphone: 1.8% 
Tramadol: 1.1% 
*DSQ was 2-fold higher 
in PACA than RA and MP. 
*Tramadol and 
dextropropoxyphene DSI 
show a very low signal of 
abuse. 
Parente28 
2004 
US 
Develop 
indicators of 
controlled 
A) Cohort 1 
(N=2,927,237).  
B) Cohort 2 
1) ≥6 prescribers of same drug (time 
period not reported) 
A) 0.2% (n=6,148) 
*These measures are not a 
direct measure of misuse, 
but direct attention to 
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(2000) substance 
misuse for 
general 
population 
(excluding 
persons with 
≥3 
prescriptions 
for injectable 
opioid 
without a 
cancer 
diagnosis in 
12 months 
and persons 
dispensed a 
BZD or opioid 
with a 
substance 
abuse 
diagnosis) 
 
(N=782,800). 
Inclusion/exclusion 
criteria not specified. 
 
 
B) 0.3% (n=1,957) 
2) ≥4 dispensing pharmacies for same 
drug (time period not reported) 
A) 0.1% (n=3,806) 
B) 0.1% (n=1,096) 
3) ≥4 prescriptions of carisoprodol (6 
months) 
A) 0.1% (n=3,805) 
B) 0.1% (n=862) 
4) Continuous overlap of ≥2 different 
BZDs for ≥90 days (time period not 
reported)  
i) when 1 BZD is alprazolam 
A) 0.1% (n=1,757) 
B) 0.1% (n=548) 
ii) when 1 BZD is clonazepam 
A) 0.01% (n=147) 
B) 0.01% (n=58) 
iii) when 1 BZD is diazepam 
A) 0.003% (n=88) 
B) 0.004% (n=32) 
5) ≥4 grams/day of acetaminophen 
(time period not reported) 
A) 0.03% (n=878) 
B) 0.01% (n=79) 
6) ≥2 prescriptions for meperidine 
hydrochloride with >2 days’ supply 
(time period not reported) 
A) 0.02% (n=585) 
B) 0.02% (n=157) 
potential problems to 
determine if intervention 
is needed. 
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7) ≥4 prescriptions of butorphanol (6 
months) 
A) 0.02% (n=585) 
B) 0.02% (n=157) 
8) Overlap of ≥2 different sustained 
release or LA opioids for ≥90 
consecutive days (time period not 
reported) 
A) 0.001% (n=30) 
B) 0.001% (n=8) 
Pauly29 
2011 
France 
(2006) 
Compare two 
methods to 
measure 
deviant 
behaviour 
when 
obtaining 
high dosage 
buprenorphin
e (HDB) 
(opioid). 
 
A) Cohort (N=6,519): 
≥1 dispensing of HDB. 
1) Deviant persons: defined by cluster 
analysis profiling individuals by 
number of: dispensing pharmacies; 
prescribers; dispensings, and total 
quantity dispensed (9 months).  
A) 6.0% (n=390) 
‘More deviant’ persons: 0.3% (n=21) 
2) Proportion of dispensed HDB 
obtained by DSI: 
Deviant: 40% (i.e. 60% not obtained 
by DSI) 
More deviant: 72% (i.e. 18% not 
obtained by DSI) 
Entire cohort: 13.2% 
*Mean (SD) prescribers (9 
months) 
Deviant: 6.5 (2.2) 
More deviant: 16.4 (5.7) 
*Mean (SD) dispensing 
pharmacies (9 months) 
Deviant: 8.2 (3.3) 
More deviant: 27.5 (9.5) 
*Mean (SD) dispensings (9 
months) 
Deviant: 36.9 (16.7) 
More deviant: 90.0 (32.0) 
* Mean (SD) total 
quantity dispensed (mg) 
(9 months) 
Deviant: 6,815 (4,462) 
More deviant: 33,720 
(14,432) 
*Deviant group are: 
younger, male, dispensed 
a higher proportion of 
flunitrazepam, 
bromazepam, 
clonazepam and ADs. 
Pauly30 
2011 
France 
(2008) 
Analyze and 
compare 
diversion and 
abuse of 14 
BZDs through 
a multi-
A) Cohort (N not 
reported): ≥1 BZD 
dispensings. 
 
1) Deviant persons: defined by cluster 
analysis profiling individuals by 
number of: dispensing pharmacies; 
prescribers; dispensings, and total 
quantity dispensed (9 months). 
BZD with highest % of deviant users:  
*Proportion of deviant 
users per BZD: 
Oxazepam: 0.4% 
Clonazepam: 0.3% 
Diazepam: 0.3% 
Zolpidem: 0.3% 
*BZDs with DSI≥1%: rate 
of <1% does not 
constitute a signal for 
abuse (12 months) 
Clonazepam: 2.6% 
Zolpidem: 2.5% 
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indicator 
approach. 
 
Flunitrazepam: 9.1% 
2) Doctor shopping indicator (DSI): 
proportion of total drug dispensed 
obtained by DSQ: amount of excess 
drug obtained by overlapping 
prescriptions and ≥2 prescribers (12 
months).  
BZD with highest DSI: 
Flunitrazepam: 27.0% 
Bromazepam: 0.3% 
Lormetazepam: 0.2% 
Clorazepate: 0.2% 
Alprazolam: 0.2% 
Lorazepam: 0.2% 
Zopiclone: 0.1% 
Prazepam: 0.04% 
Tetrazepam: 0.03% 
Nordazepam: 0.03% 
Oxazepam: 2.3% 
Diazepam: 2.2% 
Alprazolam: 1.7%  
Bromazepam: 1.7% 
Lormetazepam: 1.5% 
Lorazepam: 1.3% 
Clorazepate: 1.1% 
Zopiclone: 1.1% 
Pauly31 
2012 
France 
(2006-2008) 
Compare 
doctor 
shopping 
indicator 
(DSI) across 
14 BZDs and 
10 opioids 
[prescribed 
for analgesic 
or opioid 
maintenance 
treatment 
(OMT)]. 
A) Cohort (N not 
reported): 
inclusion/exclusion 
criteria not specified. 
1) DSI: proportion of total drug 
dispensed obtained by DSQ (DSQ: 
amount of excess drug obtained by 
overlapping prescriptions from ≥2 
prescribers) (time period not 
reported).  
DSI <1% is not a signal for abuse. 
Drug with highest DSI: 
Buprenorphine (OMT): 12.5% 
*Other drugs with DSI≥1% 
(time period not reported) 
Opioid (OMT): 7.2% 
Morphine: 6.2% 
Buprenorphine (analgesic): 
3.9% 
Methadone: 3.3% 
BZD: 1.9% 
Oxycodone: 1.9% 
*BZDs are prescribed at a 
high rate but have a low 
rate of abuse/diversion.  
*Opioids (OMT) 
prescribed at low rate 
but have a high level of 
abuse/diversion. 
Pearson32 
2006 
US 
(1988-1995) 
Examine 
impact of the 
triplicate 
prescription 
program 
(TPP) on 
potentially 
problematic 
A) Entire cohort 
(N=124,867): ≥19 
years; Medicaid 
enrollee for ≥10 out of 
12 months prior to 
TPP; dispensed ≥1 
BZDs. (B+C+D+E) 
Cohort stratified by 
1) Pharmacy hoppers: dispensed same 
BZD from ≥2 pharmacies (7 days)  
A) 1.6% (n=1,955) 
B) 1.3% (n=588) 
C) 1.7% (n=740) 
D) 1.4% (n=169) 
E) 1.9% (n=458) 
2) Problematic use of BZD: BZD use 
*After introduction of TPP 
there was a sudden and 
sustained reduction in BZD 
use and potentially 
problematic use in all New 
York neighborhoods. 
*Across all practices and 
pharmacy locations black 
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BZD use by 
race. 
 
predominant racial 
neighborhood 
composition  
B) White (N=45,222) 
C) Mixed (N=43,520) 
D) Black (N=12,054) 
E) Hispanic 
(N=24,071) 
 
 
was >2 times MRDD OR duration of 
BZD treatment >120 days 
A) 40.2% (n=50,197) 
3) Any potentially problematic BZD 
use: (1 or 2) pharmacy hopper or 
problematic use of BZD  
A) 42.8% (n=53,444) 
B) 51.6% (n=23,335) 
C) 41.1% (n=17,887) 
D) 34.5% (n=4,159) 
E) 33.7% (n=8,112) 
enrollees were most likely, 
white enrollees least likely, 
to experience reductions 
in access to BZDs. 
*’>83%’ of baseline 
pharmacy hoppers 
discontinued post-TPP.  
 
Peirce33 
2012 
US 
(Jul 2005-
2007) 
Compare 
doctor and 
pharmacy 
shopping 
behaviours 
between 
deceased and 
living 
persons, and 
identify 
factors that 
predict a 
drug-related 
death 
(controlled 
substances). 
 
A) “Living” persons 
cohort (N=1,049,205): 
≥18 years; dispensed 
≥1 schedule II-IV 
controlled substance 
between Jul 2005-Dec 
2007.  
B) Decedent cohort 
(N=698): A) and death 
recorded as drug-
related by the medical 
examiner in the 
Forensic Drug 
Database. 
C) Entire cohort 
(N=1,049,903): A) + B) 
1) Pharmacy shopper: ≥4 dispensing 
pharmacies (6 months) 
A) 1.3% (n=13,619) 
B) 17.5% (n=122) 
C) 1.3% (n=13,741) 
•In pharmacy shoppers (entire 
cohort), proportion of doctor shoppers 
(6 months) 
55.6% (n=7,640)  
2) Doctor shopper: ≥4 prescribers (6 
months) 
A) 3.6% (n=37,594) 
B) 25.2% (n=176) 
C) 3.6% (n=37,770) 
•In doctor shoppers (entire cohort), 
proportion of pharmacy shoppers (6 
months) 
20.2% (n=7,640) 
*Pharmacy shoppers 
(entire cohort) with ≥4 
prescriptions dispensed (6 
months) 
90.0% (n=12,361) 
*Pharmacy shoppers 
(entire cohort) with ≥3 
controlled substances 
dispensed (6 months) 
50.3% (n=6,918) 
*Doctor shoppers with ≥4 
prescriptions dispensed (6 
months) 
82.6% (n=31,180) 
*Doctor shoppers (entire 
cohort) with ≥3 controlled 
substances dispensed (6 
months) 
Doctor shopper: 49.2% 
*86% of decedent cohort 
deaths were due to a 
controlled substance. 
*Predictors of drug-
related death: greater 
number of prescriptions 
dispensed (not defined, 
OR 1.14); dispensed an 
opioid (OR 3.40); 
dispensed a BZD (OR 
7.21); dispensed both 
BZD and opioid (OR 
14.92); pharmacy and 
doctor shopper (OR 
3.59); pharmacy shopper 
alone (OR 3.8); doctor 
shopper alone (OR 2.03). 
*Older age (not defined) 
was less associated with 
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(n=18,566) drug-related death (OR 
0.96). 
Pradel34 
2004 
France 
(Sep 1999-
Dec 2000) 
 
Assess rates 
of doctor 
shopping for 
high dosage 
buprenorphin
e (HDB) 
maintenance 
therapy 
(opioid) 
A) Cohort (N=2,587): 
≥1 HDB dispensings; 
>31 days of follow up. 
Excluded if: 
insufficient number of 
prescriptions. 
1) Doctor shopper: overlapping 
prescriptions and ≥2 prescribers (16 
months) 
A) 39.5% (n=1,023) 
•In doctor shoppers: persons 
dispensed ≥16 mg per day of HDB (16 
months)  
8.5% (n=87) 
*Quantity HDB obtained 
by doctor shoppers:  
18.7% (1,802,806 mg) 
*Delivered doses of HDB 
for doctor shoppers 
(mg/day):  
2.2 mg 
 
Pradel35 
2009 
France 
(2000, 2002, 
2004, 2005) 
Assess the 
prevalence of 
doctor 
shopping for 
HDB (opioid) 
and evaluate 
the impact of 
the 
prescription 
monitoring 
program 
(PMP) for 
maintenance 
treatment. 
A) Cohort (N=21,911): 
≥2 HDB dispensings in 
35 days. 
1) Doctor shopping quantity (DSQ): 
amount of excess drug dispensed by 
overlapping prescriptions written by 
≥2 prescribers (12 months). 
Range: 631 (2000) to 1151 (2004) 
grams  
2) Doctor shopping indicator (DSI): 
proportion of total drug dispensed 
obtained by DSQ (12 months)  
Range: 14.9% (2000) to 21.7% (2004) 
*Impact of PMP (last 6 
months of 2004 to last 6 
months of 2005):  
DSQ: 1151 grams to 858 
grams. 
DSI: 21.7% to 16.9%. 
*At any given time period, 
approximately 200 
patients (‘<8%’) obtained 
80% of HDB. 
*75% of users did not have 
a DSQ. 
 
Pradel36 
2010 
France 
(2003) 
Assess abuse 
potential of 
eight BZDs 
(14 
formulations) 
A) Cohort 
(N=128,230): ≥1 BZD 
dispensings.  
 
1) Doctor shopping quantity (DSQ): 
amount of excess drug dispensed by 
overlapping prescriptions written by 
≥2 prescribers (12 months).  
Total BZD DSQ: 361,428 DDD 
*Volume of drug obtained 
by DSQ (DDD) (12 months) 
Bromazepam 6 mg: 56,913  
Clorazepate 50 mg: 36,335  
Alprazolam 0.5 mg: 14,852  
*For BZDs with multiple 
formulations, highest 
doses always had higher 
DSI/DSQ than lower 
doses. 
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via doctor 
shopping. 
 
BZD with highest DSQ:  
Flunitrazepam 1 mg: 108,727 DDD 
2) Doctor shopping indicator (DSI): 
proportion of total drug dispensed 
obtained by DSQ. DSI<1% does not 
constitute a signal for abuse (12 
months)  
BZD with highest DSI: 
Flunitrazepam 1 mg: 42.8% 
 
Diazepam 10 mg: 11,125  
Lorazepam 2.5 mg: 10,360  
Clonazepam 2 mg: 7,752  
Lorazepam 1 mg: 4,222  
Tetrazepam 50 mg: 2,910  
Clorazepate 10 mg: 2,645  
Alprazolam 0.25 mg: 1,308  
Diazepam 5 mg: 1,110  
Clorazepate 5 mg: 401  
Diazepam 1 mg: 200  
*Drugs with DSI ≥1% (12 
months)  
Diazepam 10 mg: 3.2% 
Clorazepate 50 mg: 2.7% 
Alprazolam 0.5 mg: 1.9% 
Bromazepam 6 mg: 1.9% 
Clonazepam 2 mg: 1.8% 
Lorazepam 2.5 mg: 1.1% 
*BZDs by abuse 
potential:  
Very high: flunitrazepam 
1 mg;  
High: diazepam 10 mg, 
clorazepate 50 mg;  
Intermediate: alprazolam 
0.5 mg, bromazepam 6 
mg, clonazepam 2 mg; 
Low: alprazolam 0.25 mg; 
clorazepate 5-10 mg; 
diazepam 1-5 mg; 
lorazepam 1-2.5 mg; 
tetrazepam 50 mg. 
 
Rice37 
2012 
US 
(2007-2009) 
Identify user 
characteristic
s and 
behaviour 
associated 
with 
diagnosed 
opioid abuse. 
 
Cohort (N=821,916): 
aged 12-64 years; ≥1 
opioid dispensings; 
continuously eligible 
in 12 months prior to 
index date.  
Cohort stratified by 
opioid abuse 
diagnosis. 
A) Abusers (N=6,380): 
ICD-9-CM code 
related to opioid 
1) ≥1 early refills: prescription opioid 
refill occurred with >25% of the days’ 
supply remaining on the previous 
prescription for the same active 
ingredient (12 months) 
A) 38.4% (n=2,449) 
B) 4.1% (n=33,343) 
 
*Mean (SD) dispensing 
pharmacies (12 months) 
A) 2.4 (2.3) 
B) 0.7 (0.9) 
*Mean (SD) prescribers (12 
months) 
A) 3.2 (3.5) 
B) 0.8 (1.3) 
*Mean (SD) prescriptions 
(12 months) 
A) 13.3 (13.1) 
B) 1.9 (4.5) 
*Abusers more likely to 
have filled opioid 
prescriptions previously 
(IR or ER). 
*Predictors of ‘abusers’: 
1-5 prior opioid 
prescriptions (OR 2.23); 6 
prior opioid prescriptions 
(OR 6.85); ≥1 prior 
prescription for 
buprenorphine (OR 
51.75) or methadone (OR 
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dependence or 
poisoning in patient 
history 
B) All other 
individuals 
(N=815,536) 
 
*Mean (SD) opioids 
prescribed (12 months) 
A) 3.7 (3.7) 
B) 0.9 (1.4) 
*Mean (SD) active 
ingredients consumed in 
opioid prescriptions (12 
months) 
A) 1.9 (1.3) 
B) 0.7 (0.9) 
*Prior use of 
propoxyphene (OR 0.73) 
or hydrocodone (OR 0.70) 
associated with a reduced 
probability of abuse when 
controlling for other 
factors.  
2.97); ≥1 diagnosis of 
non-opioid drug abuse 
(OR 9.89), mental illness 
(OR 2.45) or hepatitis (OR 
2.36); family member 
diagnosis with opioid 
abuse (OR 3.01).  
*The finding that abusers 
were more likely to 
receive prescriptions 
from multiple providers 
was not significant when 
controlling for other 
factors. 
Ross-
Degnan38 
2004 
US 
(1988-1990) 
 
Evaluate the 
impact of a 
triplicate 
prescription 
program 
(TPP) on 
problematic 
and non-
problematic 
BZD use and 
on use of 
potential 
substitute 
Cohort: ≥19 years; 
reside in New York or 
New Jersey; 
continuously enrolled 
in Medicaid for ≥10 
out of 12 months for 
1988-1990; ≥1 BZD 
dispensings. Excluded 
if: reside in nursing 
home for >1 month. 
A) Baseline New York 
(N=25,399) 
B) Baseline New 
1) BZD treatment (>120 days) 
A) 40.3% (n=10,236) C) 41.9% 
(n=4,579) 
B) 37.5% (n=10,073) D) 40.1% 
(n=10,793) 
2) Excessive dose: average daily dose 
>2 times MRDD (Various) 
A) 6.7% (n=1,702) C) 9.2% (n=1,006) 
B) 7.2% (n=1,934) D) 6.2% (n=1,669) 
3) Concurrent use of 2 LA BZD in same 
class (120 days)  
A) 1.8% (n=458) C) 1.1% (n=121) 
B) 1.2% (n=323) D) 1.0% (n=270) 
*Continuous use (>330 
days) and no seizure or 
panic diagnosis (Various) 
A) 16.2% (n=41,15) C) 
15.7% (n=1,716)  
B) 13.7% (n=3,680) D) 
16.9% (n=4,549) 
*Existence of any 
‘problematic’ behaviour: 
outcome measures 1-6 
and continuous use (>330 
days) and no seizure or 
panic diagnoses (Various) 
*Pharmacy hopping 
greatly reduced in New 
York with a similar 
reduction for both 
potentially problematic 
and non-problematic BZD 
use. 
*The TPP appears to 
have encouraged 
deliberate 
discontinuation of BZD 
therapy rather than 
reducing problems in 
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drugs. 
 
Jersey (N=26,860) 
C) Post-TPP 
implementation New 
York (N=10,928) 
D) Post-TPP New 
Jersey (N=26,914): 
TPP was not 
implemented in New 
Jersey. 
 
MRDD: 10 DME/day 
>65 years; 20 
DME/day for <65 
years. 
4) Concurrent use of 2 SA BZD in same 
class (120 days ) 
A) 3.7% (n=940) C) 2.5% (n=274) 
B) 4.2% (n=1,129) D) 4.5% (n=1,212) 
5) Receipt of ≥4 different BZDs (120 
days) 
A) 1.7% (n=432) C) 0.6% (n=66) 
B) 1.9% (n=511) D) 1.9% (n=512) 
6) Pharmacy hopping: dispensed same 
BZD from ≥2 pharmacies (7 days) 
A) 7.7% (n=1,956) C) 3.7% (n=405) 
B) 3.8% (n=1,090) D) 3.9% (n=1,050) 
7) Receipt of a long half-life BZD for 
person aged >65 years (Various) 
A) 56.1% (n unclear) C) 51.3% (n 
unclear) 
B) 52.6% (n unclear) D) 48.6% (n 
unclear) 
A) 42.8% (n=10,871) C) 
45.1% (n=4,929) 
B) 40.1% (n=10,771) D) 
42.0% (n=11,304) 
*After TPP, there was a 
sudden and sustained 
reduction in BZD use in 
New York (-54.8%), with 
no changes in New Jersey.  
 
use. 
*More people in New 
York who used BZDs 
appropriately were 
affected by the policy, 
i.e. young AFDC women 
(Aid to Families with 
Dependent Children), 
living in low-income 
areas or high minority 
areas.  
 
Rouby39 
2012 
France 
(2005) 
Assess the 
extent of 
tianeptine 
abuse 
compared to 
other 
antidepressa
nts (ADs) and 
BZDs/Z-
drugs. 
 
A) AD cohort 
(N=410,525): ≥1 AD 
dispensings.  
B) BZD/Z-drug cohort 
(N=663,107): ≥1 
BZD/Z-drug 
dispensings. 
1) Doctor shopping quantity (DSQ): 
amount of excess drug dispensed by 
overlapping prescriptions written by 
≥2 prescribers (12 months). 
Drug with highest DSQ: 
A) Tianeptine: 96,183 DDD 
B) Zolpidem: 499,010 DDD 
2) Doctor shopping indicator (DSI): 
proportion of total drug dispensed, 
obtained by DSQ (12 months). DSI 
≥1% is a signal for abuse. 
Drug with highest DSI: 
*Volume of drug obtained 
via DSQ (DDD) (12 months) 
A) Paroxetine: 58,738  
Fluoxetine: 52,383  
Venlafaxine: 36,483  
Mianserin: 15,344  
Amitriptyline: 12,102  
Mirtazapine: 10,285  
Milnacipran: 4,417  
B) Flunitrazepam: 436,647 
Bromazepam: 379,785 
Oxazepam: 109,239 
*Drugs with DSI≥1% (12 
months) 
A) Mianserin 1.0% 
B) Clonazepam: 3.0% 
Zolpidem: 2.2%  
Oxazepam: 2.1% 
Diazepam: 2.0%  
Bromazepam: 2.0% 
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A) Tianeptine: 2.0%  
B) Flunitrazepam: 30.2% 
Clonazepam: 59,996 
Diazepam: 47,339 
Seal40 
2012 
US 
(Oct 2005-
Dec 2010) 
Investigate 
the effect of 
mental health 
disorders on 
risk of 
adverse 
clinical 
outcomes 
associated 
with high use 
of 
prescription 
opioids. 
Cohort (N=141,209): 
Iraq or Afghanistan 
veteran who entered 
VA database between 
Oct 2005-Dec 2008; 
within 12 months of 
entry received a non-
cancer pain diagnosis 
(ICD-9-CM code); ≥1 
opioid dispensings for 
≥20 consecutive days.  
Stratified by mental 
health diagnosis (ICD-
9-CM code). 
A) No mental health 
diagnosis (n=4,488)  
B) Mental health 
diagnosis including 
PTSD (n=7,983) 
C) Mental health 
diagnosis excluding 
PTSD (n=3,205) 
D) Entire cohort  
(N=15,676): A) + B) + 
C)  
1) ≥1 early refill: obtaining the same 
opioid prescription >7 days before the 
end of the previous prescription (12 
months) 
A) 20.4% (n=914) 
B) 33.8% (n=2,701) 
C) 30.6% (n=980) 
D) 29.3% (n=4,595) 
2) Highest quintile for opioid dose (12 
months) 
A) 15.9% (n=712) 
B) 22.7% (n=1,813) 
C) 19.2% (n=615) 
D) 20.0% (n=3,140) 
3) Concurrent use of ≥2 types of 
opioids: >7 days of overlap (30 days) 
A) 10.7% (n=478) 
B) 19.8% (n=1,581) 
C) 17.3% (n=553) 
D) 16.7% (n=2,612) 
4) Concurrent use of ≥2 types of 
sedative hypnotics: >7 days of overlap 
(30 days) 
A) 7.6% (n=343) 
B) 40.7% (n=3,251) 
C) 25.0% (n=802) 
D) 28.0% (n=4,396) 
5) Median duration of opioid use ≥2 
*Adverse clinical outcomes 
for opioid users (12 
months) 
i) Opioid-related accidents 
and overdoses: 
A) 0.02% (n=1) 
B) 0.4% (n=29) 
C) 0.2% (n=7) 
D) 0.2% (n=37) 
*Prevalence of all adverse 
clinical outcomes 
(wounding, alcohol injury, 
self-inflicted injury or 
violence) was greater for 
those prescribed an 
opioid. 
*Veterans with a mental 
health diagnosis were 
more likely to receive an 
opioid for pain than 
persons without a mental 
health diagnosis, and 
likelihood increased if the 
diagnosis included PTSD. 
*Veterans with PTSD were 
more likely to receive a 
sedative. 
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months (12 months) 
A) 42.7% (n=1,916) 
B) 63.2% (n=5,047) 
C) 57.0% (n=1,828) 
D) 56.1% (n=8,791) 
Simoni-
Wastila41 
2004 
US 
(1988-1990, 
1995) 
 
Assess the 
effect of New 
York triplicate 
prescription 
program 
(TPP) on 
changes in 
BZD and 
other 
psychoactive 
drug use 
compared to 
New Jersey 
(no TPP). 
A) New York 
(N=6,054): reside in 
New York; ≥19 years; 
continuously enrolled 
in Medicaid for ≥10 
out of 12 months for 
1988-1990 and 1995; 
≥1 inpatient or ≥2 
outpatient diagnoses 
of a specified mood 
disorder in 1988.  
B) New Jersey 
(N=6,875): A) but 
reside in New Jersey. 
1) Probably problematic behaviour: 
dispensed same BZD from ≥2 
pharmacies (7 days) OR  
BZD use >2 times MRDD (time period 
not reported) 
Rate in 1988 to 1990 rates [% change] 
A) 7.1 to 2.4 [-4.7%] 
B) 4.0 to 3.4 [-0.6%] 
 
*Probably non-
problematic BZD use (BZD 
use of ≤120 days, no 
pharmacy hopping or high 
daily dose) was affected to 
a greater extent by TPP 
then problematic BZD use. 
*The implementation of 
the TPP resulted in abrupt, 
large and sustained 
reductions in BZD use 
among chronically ill users 
in New York relative to 
identically defined users in 
New Jersey who were not 
exposed to TPP. 
*6 months post-TPP, 
anxiolytic use increased 
85.7% in New York, 
sedative-hypnotic use 
increased 35.0%. There 
were no changes in 
utilisation for BZDs in 
New Jersey. 
*Reduction in BZD use 
was sustained 7 years 
after TPP. 
 
Skurtveit42 
2011 
Norway 
(2005-2008) 
 
Determine 
prevalence of 
persistent/ 
problematic 
opioid use. 
A) Cohort 
(N=245,006):  
≥1 dispensings of a 
weak opioid (codeine, 
tramadol or 
dextropropoxyphene). 
Excluded if: received 
any opioid for 
palliative treatment of 
1) Persistent user: dispensed ≥1 opioid 
(not further specified) each year from 
2005 to 2008; in 2008 dispensed >365 
DDD of opioids in 2008 (48 months) 
A) 0.3% (n=686) 
2) Milder probable problematic user 
indicator: dispensed ≥1 opioid (weak 
or strong) in each year from 2005 to 
2008; in 2008 dispensed >365 DDD of 
*9.5% of codeine users, 
21.0% of tramadol users, 
and 22.3% of 
dextropropoxyphene users 
(in 2008) were dispensed a 
LA opioid as their first 
opioid in 2005.  
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malignant disease. 
 
Strong opioids: 
buprenorphine, 
fentanyl, 
hydromorphone, 
ketobemidone, 
morphine, oxycodone, 
pentazocine and 
pethidine. 
opioids and ≥4 prescribers (48 
months) 
A) 0.2% (n=421) 
3) Probable problematic user: 
dispensed ≥1 opioid (weak or strong) 
in each year from 2005 to 2008; in 
2008 dispensed >365 DDD of opioids; 
≥4 prescribers and >100 DDD of BZDs 
(48 months) 
A) 0.08%  (n=191) 
4) Stricter probable problematic user 
indicator: dispensed ≥1 opioid (weak 
or strong) in each year from 2005 to 
2008; in 2008 dispensed >365 DDD of 
opioids; ≥4 prescribers and >300 DDD 
of BZDs (48 months) 
A) 0.06% (n=139) 
5) Strictest probable problematic user 
indicator: dispensed ≥1 opioid (weak 
or strong) in each year from 2005 to 
2008; in 2008 dispensed >365 DDD of 
opioids; ≥7 prescribers and >100 DDD 
of BZDs (48 months) 
A) 0.05% (n=126) 
Soumerai43 
2003 
US 
(1987-1990) 
Determine if 
pharmacy 
hopping is 
associated 
with dose 
escalation in 
A) Entire cohort 
(N=2,440): ≥2 years of 
BZD use; enrolled in 
Medicaid for ≥10 out 
of 12 months per year 
1987-1990. (B + C) 
1) Pharmacy hoppers: dispensed same 
BZD from ≥2 pharmacies (7 days) 
A) 7.4% (n=180) 
B) 7.0% (n=139) 
C) 8.9% (n=41) 
2) Users escalated to 'high' dosages: 
*Predictors of dose 
escalation: 
B+C) regular use of SA, 
high potency BZD 
lorazepam; or young users 
(<45 years).  
 
 323 
 
long term 
BZD users (≥2 
years) and 
identify 
predictors of 
dose 
escalation. 
 
B) Continuing BZD 
user (N=1,980) A) but 
≥2 years of BZD use 
between 1988-1990. 
C) Incident BZD user 
(N=460): A) but no 
BZD use before Dec 
1987. 
20 (elderly patients) or 40 (younger 
patients) diazepam milligram 
equivalents per day (24 months) 
A) 1.6% (n=40) 
B) 1.3% (n=26) 
C) 3.0% (n=14) 
 
B) Use of antidepressants 
and pharmacy hopping 
(OR 5.2). 
*Long-term use of BZDs is 
not associated with 
notable dose escalation. 
Sullivan44 
2010 
US 
(2000-2005) 
Validate an 
indicator of 
opioid misuse 
and 
determine 
the 
demographic, 
clinical, and 
pharmacologi
cal risks 
associated 
with opioid 
misuse. 
 
A) Commercially 
insured (N=21,685): 
≥18 years; chronic 
opioid user, i.e. ≥90 
days of opioid use in 
any 6 month period 
between Jan 2001-
Dec 2004; continuous 
enrolment 12 months 
prior to and post 
index date (first opioid 
dispensing); identified 
in HealthCore dataset. 
Excluded if: ≥32 day 
gap in opioid use; 
cancer diagnosis 
within 12 months of 
index date (pre- or 
post-); resident of 
nursing home or 
hospice user. 
B) Publically insured 
1) Opioid misuse score: based on 
excess days supplied short- and long-
acting opioids, number of dispensing 
pharmacies and prescribers (6 
months). 
Score 0-1: no misuse 
A) 70.0% (n=15,180) 
B) 76.0% (n=7,721) 
Score 2-4: possible misuse 
A) 24.0% (n=5,205) 
B) 20.0% (n=2,032) 
Score ≥5: probable misuse 
A) 6.0% (n=1,302) 
B) 3.0% (n=305) 
*For commercially insured 
cohort, risk of diagnosis of 
opioid abuse increased 
41% for every 1 point 
increase in opioid misuse 
score.  
*For publically insured 
cohort, risk of diagnosis of 
opioid abuse increased 
51% for every 1 point 
increase in opioid misuse 
score. 
*Factors that increase risk 
of opioid misuse: younger 
age, back pain, multiple 
pain complaints, 
substance abuse disorder, 
high daily dose of opioids 
(>120 mg MED/day) and 
shorting acting schedule II 
opioids. 
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(N=10,159): A) but 
identified in Arkansas 
Medicaid. 
Thirion45 
2002 
France 
(Sep-Dec 
1999) 
Identify and 
profile 
deviant users 
dispensed 
buprenorphin
e (opioid). 
A) Cohort (N=2,078): 
≥1 buprenorphine 
dispensings. 
1) Deviant: ≥3 prescribers or 
dispensed >20 mg/day of 
buprenorphine (4 months) 
A) 18.1% (n=377) 
 
*Number of prescribers (4 
months) 
1 prescriber: 66% 
(n=1,371) 
2 prescribers: 22% (n=457) 
3-5 prescribers: 11% 
(n=229) 
≥6 prescribers: 1% (n=21) 
*Deviant group profile: 
younger, male and higher 
consumption of BZDs. 
*Mean (SD) prescriptions 
(4 months) 
Deviant user: 10.1 (5.9) 
Victorri-
Vigneau46 
2006 
France 
(second half 
of years 
2001, 2002 
and 2003) 
Demonstrate 
impact of 
intervention 
program to 
reduce 
excessive 
doses of 
psychotropic 
drugs (drug 
class not 
further 
specified). 
A) Intervention cohort 
(N=1,390) reside in 
Pays de Loire; 
dispensed >2 times 
maximum 
recommended daily 
dose (MRDD) for ≥3 
consecutive months 
for one psychotropic 
drug. (Includes but is 
not limited to cohorts 
B and C.) 
B) No action cohort 
(N=422): A) and 
reimbursement code 
related to “serious 
problems of behaviour 
and personality”. 
C) Action cohort 
Proportion of cohort pre-intervention 
to post-intervention 
1) >2 times MRDD (3 consecutive 
months) 
A) 100% (n=1,390) to 89.5% (n=1,244) 
B) Figures not reported (reduction of 
58.5% of patients meeting this 
criteria) 
C) Figures not reported (reduction of 
66% of patients meeting this criteria) 
D) Figures not reported (reduction of 
46.2% of patients meeting this 
criteria) 
2) Excess consumption: average daily 
consumption exceeds MRDD specified 
in drug monograph (change from pre- 
to post-intervention)  (12 months) 
A) Not reported 
B) 2.5 to 2.1 [-15%] 
*Mean number of 
prescribers  (12 months) 
[% change] 
B) Mean not reported [-
4%] 
C) 2.67 to 2.28 [-15%] 
D) Mean not reported 
[2%] (direction of change 
not reported) 
*R ratio: number of 
patients receiving >2 
MRDD of psychotropic 
drug to number of patients 
receiving psychotropic 
drug 
C) 100% (n=840) to 33.4% 
(n=281). 
*When considering all 
persons dispensed 
*Health professionals 
involved with ‘action 
cohort’ filed 116 drug 
addiction reports. The 
prevalence of drugs 
mentioned in these 
reports: 
Zopiclone: 19% 
Zolpidem: 17% 
Oxazepam: 16% 
BZD (other): 13% 
Meprobamate: 11% 
Clorazepate: 9% 
Buprenorphine: 8% 
Bromazepam: 7% 
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(N=840): A); doctors 
and pharmacists of 
identified users 
received a letter to 
review their patients’ 
medical prescriptions. 
Excluded if: assigned 
to B); refusal to have 
data included in study; 
death, or moved 
residence. 
D) Comparison cohort 
(N not reported): A) 
but reside in Vendee. 
C) 2.6 to 1.9 [-27%]  
D) 2.3 to 2.1 [-9%] 
 
 
psychotropic drug, the R 
ratio decreased by 14.1% 
over the study period. 
 
 
Victorri-
Vigneau47 
2011 
France 
(Jul-Dec 
2005) 
Characterise 
AD over-
consumption. 
 
A) Tianeptine 
(N=7,264): ≥2 
tianeptine 
dispensings. [MRDD = 
37.5 mg] 
B) Milnacipran 
(N=1,918): ≥2 
milnacipran 
dispensings. [MRDD = 
100 mg] 
 
1) Overconsumer: dispensed more 
drug than medically required (6 
months) 
A) Dispensed 1.7 times the MRDD: 
0.4% (n=29) 
B) Dispensed 2 times the MRDD: 2.4% 
(n=46)  
2) Pharmacy shoppers: ≥4 dispensing 
pharmacies (6 months)  
•In tianeptine overconsumers (n=29): 
20.7% (n=6) 
•Other tianeptine users (n=7,235): 
1.0% (n=72) 
•Milnacipran overconsumers (n=46): 
4.3% (n=2) 
•Other milnacipran users (n=1,872): 
*Median (range) 
prescribing physicians (6 
months) 
A) 1 (1-6) 
B) 1 (1-5) 
*Median (range) 
dispensing pharmacies (6 
months) 
A) 1 (1-13) 
B) 1 (1-6) 
*Median (range) 
dispensings (6 months) 
A) 5 (2-40) 
B) 4 (2-17) 
*Consumption factor >1: 
estimate of average daily 
*The consumption factor 
reached higher values for 
tianeptine (up to 11 
times higher) but 
occurred less frequently 
compared to 
milnacipran.  
*Pharmacy shopping 
increased risk of 
overconsumption for 
tianeptine (OR 10.78). 
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1.4% (n=26) 
3) % R ratio>1: observed number of 
dispensings delivered to the user is 
greater than the amount actually 
required (6 months) 
•Tianeptine overconsumers: 89.7% 
(n=26) 
•Other tianeptine user: 27.9% 
(n=2,015) 
•Milnacipran overconsumers: 93.5% 
(n=43) 
•Other milnacipran users: 29.9% 
(n=560) 
consumption of a 
psychotropic drug divided 
by the MRDD (6 months) 
A) 17.2% (n=125) 
B) 32.3% (n=620) 
Victorri-
Vigneau48 
2013 
France 
(Feb-Jul 
2010) 
Identify and 
characterise 
zolpidem and 
zopiclone (Z-
drugs) users. 
 
A) Zopiclone 
(N=21,860): ≥1 
zopiclone dispensings; 
number of dispensings 
are equal to or higher 
than medically 
required rate (3.75 
mg).  
B) Zolpidem 
(N=25,168): ≥1 
zolpidem dispensings; 
number of dispensings 
are equal to or higher 
than medically 
required rate (5 mg). 
1) Problematic user: latent class 
analysis based on: prescribing 
physician type, doctor shopping, 
pharmacy shopping, excess use, 
agreement with practice guidelines 
and associated psychiatric disorders (6 
months) 
A) 0% (n=0) 
B) 1.0% (n=252) 
2) Doctor shopper: ≥4 prescribers (6 
months) 
A) 1.1% (n=241) 
•In problematic zopiclone users: 0% 
(n=0) 
B) 1.0% (n=252) 
•In problematic zolpidem users: 47.2% 
(n=119) 
*Problematic users mean 
(SD) daily dose (mg/day) (6 
months) 
A) 0 (0) 
B) 20.9 (2.4) 
*Zolpidem ‘problematic’ 
users were younger, 
average daily dose was 
higher and the number of 
dispensings is 2-fold 
higher.  
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3) Pharmacy shopper: ≥4 dispensing 
pharmacies (6 months) 
A) 1.7% (n=372) 
•In problematic zopiclone users: 0% 
(n=0) 
B) 2.1% (n=529) 
•In problematic zolpidem users: 84.1% 
(n=212) 
4) Excess use: medication possession 
ratio (MPR) >1: number of drug supply 
days excluding last refill divided by the 
number of days between the first and 
last dispensing (6 months) 
A) 32.8% (n=7,171) 
•In problematic zopiclone users: 0% 
(n=0) 
B) 31.2% (n=7,853) 
•In problematic zolpidem users: 75.0% 
(n=189) 
Wainstein49 
2011 
France 
(Jan-Jun 
2008) 
Characterise 
consumption 
behaviour 
related to 
three 
psychotropic 
drugs (BZD, Z-
drugs and 
AD).  
 
A) Bromazepam 
(N=40,644): ≥18 years; 
≥2 bromazepam 
dispensings.  
[MRDD = 18 mg]. 
B) Zolpidem 
(N=36,264) ≥18 years; 
≥2 zolpidem 
dispensings.  
[MRDD = 10 mg]. 
C) Paroxetine 
1) Problematic user: latent class 
analysis based on excessive drug use, 
prescribing physician specialty, ‘doctor 
shopping’ behaviour, ‘pharmacy 
shopping’ behaviour, prescription in 
agreement with practice guidelines (6 
months) 
A) 1.0% (n=407) 
B) 1.0% (n=363) 
C) 0% (n=0) 
2) Pharmacy shoppers: ≥4 dispensing 
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(N=31,235): ≥18 years; 
≥2 paroxetine 
dispensings.  
[MRDD = 40 mg]. 
 
Excluded if: 2 
dispensings received 
on the same day. 
 
pharmacies (6 months) 
A) 1.2%  (n=488) 
•In problematic bromazepam users: 
93.1% (n=379) 
B) Not reported 
• In problematic zolpidem users: 
65.0% (inferred from graph) (n=236) 
C) Not reported 
• In problematic paroxetine users: 0%  
3) Doctor shoppers: ≥4 prescribers 
doctors (6 months)  
A) 0.4% (n=163) 
• In problematic bromazepam users: 
41.0% (n=167) 
B) Not reported 
• In problematic zolpidem users: 32% 
(inferred from graph) (n=117) 
C) Not reported 
• In problematic paroxetine users: 0% 
4) Estimate of average daily 
consumption of a psychotropic drug 
greater than MRDD (6 months) 
A) 1.1% (n=448) 
• In problematic bromazepam users: 
56.0% (n=228) 
B) 17.8% (n=6,455) 
•In problematic zolpidem users: 89.0% 
(inferred from graph) (n=324) 
C) 0.3% (n=94) 
•In problematic paroxetine users: 0% 
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(n=0) 
White50  
2009 
US  
(2005-2006) 
 
Assess 
feasibility of 
using medical 
and 
prescription 
drug claims 
to develop 
models that 
identify 
prescription 
opioid abuse 
or misuse. 
 
Model A cohort 
details. 
A) Cohort 
(N=116,382): aged 12-
64, ≥1 opioid claim 
and ≥1 medical claim. 
(B + C) 
B) Abusers (N=875): 
A) ICD-9-CM code of 
opioid dependence or 
poisoning.  
C) All other 
individuals 
(N=115,507): A) not B) 
 
Model B cohort details 
D) Cohort (subset of 
A) (N=8,592): A) 
claims occurred Sep-
Dec 2006.  
(E + F) 
E) Abusers (N=303): B) 
between Sep-Dec 
2006. 
F) All other 
individuals (N=8,289): 
C) not E). 
1) Number of prescribers: ≥2 
prescribers (3 months) 
A) not analysed: D) 26.1% (n=2,242) 
B) not analysed: E) 40.9% (n=124) 
C) not analysed: F) 25.6% (n=2,118) 
2) Pharmacy shopper: ≥2 dispensing 
pharmacies (3 months) 
A) 7.9% (n=9,213): D) 19.9% (n=1,708) 
B) 39.4% (n=345): E) 38.0% (n=115) 
C) 7.7% (n=8,868): F) 19.2% (n=1,593) 
3) ≥4 opioid prescriptions (3 months) 
A) 10.1% (n=11,740): D) not analysed 
B) 60.1% (n=526): E) not analysed 
C) 9.7% (n=11,214): F) not analysed 
4) ≥1 early refills of opioid 
prescriptions: two consecutive opioid 
prescriptions where days of supply of 
first prescription was >10% higher 
than the number of days between 
prescriptions (3 months) 
A) 4.0% (n=4,615): D) 16.5% (n=1,414) 
B) 36.0% (n=315): E) 40.9% (n=124) 
C) 3.7% (n=4,300): F) 15.6% (n=1,290) 
5) Dose escalation: 50% increase in 
the mean milligrams of morphine per 
month for 2 consecutive months (3 
months) 
A) 0.4% (n=509): D) not analysed 
B) 4.7% (n=41): E) not analysed 
*Factors associated with 
ICD-9-CM code of opioid 
abuse, dependence or 
poisoning (not related to 
an outcome measure 
defining misuse): male (OR 
2.19), ≥3 dispensing 
pharmacies (OR 1.96), ≥1 
early refills of opioid 
prescriptions (OR 6.52), ≥2 
consecutive months of 
dose escalation (OR 1.59), 
≥12 opioid prescriptions 
(OR 2.12), ≥1 non-opioid 
substance abuse diagnosis 
(OR 5.83).  
 
 
 330 
 
C) 0.4% (n=468): F) not analysed 
Wilsey51 
2010 
US 
(2007) 
 
Determine 
prevalence 
and 
predictors of 
multiple 
provider 
episodes 
(MPEs) for 
different 
controlled 
substances. 
 
A) Cohort (N not 
reported): 
prescription for 
schedule II-IV 
controlled substances. 
Excluded if: missing or 
incomplete user or 
provider 
identification; 
implausible 
prescriptions; use of 
drugs not suggestive 
of standard delivery 
systems employed by 
most users. 
Prescription level data 
(N=27,773,347) 
1) Prescriptions obtained by multiple 
provider episodes (MPEs): ≥2 
prescribers and ≥2 dispensing 
pharmacies (30 days) 
A) 8.4% (n prescriptions=2,332,962) 
2) Proportion of prescription obtained 
by MPEs by drug class: 
Opioids: 12.8% 
BZDs: 4.2% 
Stimulants: 1.4% 
Anorectics: 0.9% 
 
*Risk of simultaneous 
MPEs for different 
controlled substances: 
i) Opioids and: 
BZD: OR 15.54 
Stimulants/anorectics: OR 
10.56 
BZD and 
stimulants/anorectics: OR 
21.40 
ii) BZD and: 
Opioids: OR 13.04 
Stimulants/anorectics: OR 
20.60 
Stimulants/anorectics and 
opioids: OR 3.64 
iii) Stimulant and: 
BZD: OR 19.62 
Opioids: OR 9.23 
BZD and opioids: OR 26.83 
iv) Anorectic and: 
BZD: OR 9.95 
Opioids: OR 11.06 
BZD and opioids: OR 27.16 
*For opioids: 
hydromorphone and 
controlled release 
oxycodone were most 
associated with MPEs. 
*Younger age predictor 
of MPEs associated with 
opioid and BZDs. 
*Older age associated 
with MPE use to obtain 
stimulants and 
anorectics.  
*Males were more likely 
to use MPE for BZD; less 
likely for stimulants; no 
gender relationship 
between anorectics or 
opioids.  
*Strongest predictor was 
simultaneously receiving 
prescriptions for 
different controlled 
substances and 
concurrent use of 
multiple prescribers to 
obtain other controlled 
substances. 
Wilsey52 
2011 
Determine if 
persons 
A) Cohort 
(N=12,870,831)  
1) Multiple prescribers: 2-5 prescribers 
(12 months) 
*Single prescriber (12 
months) 
*Persons accessing 2-5 
prescribers are different 
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US 
(1999-2007) 
accessing 2-5 
prescribers 
were 
distinguishabl
e from 
persons 
accessing one 
prescriber in 
demographic 
characteristic
s or opioid 
utilisation 
(opioid). 
 
Prescribed same 
schedule II or III opioid 
in 12 months. 
Excluded if: 
missing/incomplete 
prescription, 
pharmacy or 
prescriber 
information; 
implausible 
prescription; use of 
opioids not suggestive 
of chronic pain. 
A) 22.1% (n=2,849,464) 
2) Frequency of use of multiple 
prescribers per drug (12 months) 
Hydrocodone (schedule III): 68.3% 
Codeine (schedule III): 9.8% 
Oxycodone IR (schedule II): 7.8% 
Oxycodone ER (schedule II): 3.0% 
Fentanyl (transcutaneous) (schedule 
II): 4.0% 
Morphine ER (schedule II): 3.2% 
Methadone (schedule II): 1.5% 
Hydromorphone (schedule II): 1.5% 
Morphine IR (schedule II): 0.6% 
Fentanyl (oral transbuccal): 0.1% 
Meperidine (schedule II): 0.1% 
Levorphanol (schedule II): 0.02% 
A) 77.9% (n=10,021,367) 
*Persons accessing 2-5 
prescribers were more 
likely to use LA opioids 
than hydrocodone 
(ranging from 7.8% 
[fentanyl patch] to 38.8% 
[methadone]) and less 
likely to use SA opioids. 
*Likelihood of MPEs 
increased with age. 
*Persons with multiple 
prescribers were more 
likely to: be female; reside 
in a small geographic area.  
 
 
from those using one 
prescriber, but 
differences do not 
suggest abuse. 
 
a See Electronic Supplementary Material 6 for reference list. 
bPeriod of observation covers the entire year, unless otherwise stated. 
cReported aim(s) and cohort(s) may differ from original article as we only report aspects of paper related to prescription drug misuse. 
dWe renamed/redefined some measures from the original manuscript for clarity and due to space constraints. If either a rate or the number of people 
identified by a measure was not reported, where possible we calculated it. All reported rates were derived from drug-user or misuse cohorts unless 
otherwise stated. 
 
ACRONYMS: 
AD(s): antidepressant(s) 
AP: antiparkinson 
BMT: buprenorphine maintenance therapy 
BZD(s): benzodiazepine(s) 
DDD: defined daily dose 
DSI: doctor shopping indicator 
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DSQ: doctor shopping quantity 
DME: diazepam milligram equivalent 
ED: emergency department 
ER: extended release 
GP(s): general practitioner(s) 
HDB: high dosage buprenorphine 
ICD: International Classification of Diseases 
IR: immediate release 
LA: long-acting 
MPE(s): multiple provider/prescriber episode(s) 
MRDD: maximum recommended daily dose 
OMT: opioid maintenance therapy 
OR: odds ratio 
PMP: prescription monitoring program 
PTSD: Post-Traumatic Stress Disorder 
SA: short-acting
 333 
 
 
Supplementary Material 2.8 The reported extent of prescription drug misuse based on indicators 
with a defined threshold 
Supplementary Material 2.8.1 Proportion of cohort identified as ‘misusers’ based on indicators with 
a defined threshold 
A. Stand-alone measures of misuse (drug-users only) 
Stand-alone measure details 
(A single behaviour of misuse measured in drug-users: 
persons dispensed the drug of interest) 
Time 
period 
(days)a 
Drug-user 
cohortb 
Reference
c 
Number of prescribers 
≥2 prescribers 90 26.1 50 
2-5 prescribers  365 22.1 52 
≥3 prescribers  365 NM 16 
≥4 prescribers  180 0.9 2 
≥4 prescribers NR 0.5 3 
≥4 prescribers 180 3.6 33 
≥4 prescribers 180 1.1 48 
≥4 prescribers 180 0.4 49 
Number of dispensing pharmacies 
≥2 dispensing pharmacies  7 1.9 32 
≥2 dispensing pharmacies  7 3.9 38 
≥2 dispensing pharmacies  7 8.9 43 
≥2 dispensing pharmacies 90 19.9 50 
≥4 dispensing pharmacies  180 1.3 2 
≥4 dispensing pharmacies 180 1.3 33 
≥4 dispensing pharmacies 180 1.4 47 
≥4 dispensing pharmacies 180 2.1 48 
≥4 dispensing pharmacies 180 1.2 49 
Volume of drug dispensed 
≥1 benzodiazepine dispensings per year for 4 consecutive 
years 
1440 2.2 20 
≥4 dispensings 90 10.1 50  
>15 defined daily doses of carisoprodol 365 32.2 3 
≥100 defined daily doses of opioids 365 13.6 3 
>365 defined daily doses of codeine 365 5.8 14 
>1000 defined daily doses of carisoprodol  365 0.2 4 
Daily dose ≥100 morphine milligram equivalent 365 7.8 23 
Daily consumption of drug greater than maximum 
recommended daily dose  
180 17.8 49 
>2 times maximum recommended dose Various 9.2 38 
≥2 times maximum daily dose 180 2.4 47 
Number of dispensings greater than medically required 180 29.9 47 
Overlapping prescriptions or early refills 
≥1 early refills: two consecutive prescriptions for same drug 365 6.9 22 
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with number of days between prescriptions being >10% 
lower than number of days’ supply in first prescription  
1 early refill: prescription filled >7 days before the end of 
previous prescription 
365 33.8 40 
≥1 early refills: two consecutive opioid prescriptions where 
days of supply was >10% higher than number of days 
between prescriptions 
90 16.5 50 
≥1 early refills: prescription opioid refill that occurred with 
>25% of the days’ supply remaining on the previous 
prescription for the same active ingredient  
365 4.1 37 
≥4 days of overlapping prescriptions 540 11.1 5 
≥7 days of overlapping prescriptions 365 2.1 23 
Use of specific prescribed drug 
Long-acting or extended release opioids prescribed for acute 
pain conditions  
365 0.1 23 
Use of ≥4 different benzodiazepines Various 1.9 38 
Receipt of long half-life benzodiazepines (persons aged ≥65 
years) 
NR 51.3 38 
Duration of treatment 
Median duration of opioid use ≥2 months  365 63.2 40 
>120 days of benzodiazepine treatment Various 41.9 38 
Dose escalation 
Users escalating to ‘high’ dosages: 20 (elderly patients) or 40 
(younger patients) diazepam milligram equivalents per day 
NR 3.0 43 
50% increase in mean milligrams of morphine per month for 2 
consecutive months 
90 0.4 50 
a All time periods have been converted to days, i.e. 30 days = 1 month; 90 days = 3 months; 180 days = 6 
months; 365 days = 12 months etc. NR = not recorded in original manuscript. 
b If study reported rates for >1 drug-user cohort or drug, we record the highest reported rate alone. 
c See Electronic Supplementary Material 6 for reference list. 
NM = no meaningful result was obtained. 
NR = not recorded in original manuscript. 
 
B. Composite measures: a single measure of misuse reported in a misuse cohort 
(where possible, we also record the extent of misuse in the drug-user cohort) 
Composite measure of misuse details  
 (A single behaviour of misuse measured in a 
defined misuse cohort) 
Misuse cohort definition 
Time 
period 
(days)a 
Drug-user 
cohortb 
Misuse 
cohortb 
Reference
c 
Number of prescribers 
≥2 prescribers 
Misuse cohort definition: ICD-9 code of opioid 
abuse, dependence or poisoning 
90 26.1 40.9 50 
≥3 prescribers 
≥1 days of overlapping prescriptions 
540 (0.7) 5.4 5 
≥4 prescribers  
2 defined daily doses (DDD)/day of carisoprodol; 
NR 0.6 4.5 3 
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dispensed <100 DDD of opioids, and dispensed <100 
DDD of benzodiazepines in 365 days 
≥4 prescribers  
Drug-related death 
180 3.6 25.2 33 
≥4 prescribers  
≥4 dispensing pharmacies 
180 (0.7) 55.6 33 
≥4 prescribers 
Highest 1% zolpidem users determined by latent 
class analysis 
180 (0.5) 47.2 48 
≥4 prescribers 
Highest 1% bromazepam users determined by latent 
class analysis 
180 (0.4) 41.0 49 
 ≥5 prescribers 
Pharmaceutical overdose death 
365 N/A 21.4 18 
Number of dispensing pharmacies 
≥2 dispensing pharmacies 
Misuse cohort definition: ≥1 days of overlapping 
prescriptions 
540 (2.8) 21.3 5 
≥2 dispensing pharmacies  
ICD-9 code of opioid abuse, dependence or 
poisoning 
90 19.9 39.4 50 
≥3 dispensing pharmacies 
≥1 days of overlapping prescriptions 
540 (0.2) 1.3 5 
≥4 dispensing pharmacies 
Drug-related death 
180 1.3 17.5 33 
≥4 dispensing pharmacies 
≥4 prescribers 
180 (0.7) 20.2 33 
≥4 dispensing pharmacies 
Dispensed 1.7 or 2 times more drug than medically 
required 
180 1.4 20.7 47 
≥4 dispensing pharmacies 
Highest 1% zolpidem users determined by latent 
class analysis 
180 (0.8) 84.1 48 
≥4 dispensing pharmacies 
Highest 1% bromazepam users determined by latent 
class analysis 
180 (0.9) 93.1 49 
Volume of drug dispensed 
>2 times maximum recommended daily dose (post-
intervention) 
Misuse cohort definition: Pre-intervention dispensed 
>2 times maximum recommended daily dose 
90 N/A 89.5 46 
≥4 prescriptions 
ICD-9 code of opioid abuse, dependence or 
poisoning 
90 10.1 60.1 50 
>15 defined daily dose (DDD) of carisoprodol 
>365 DDD of codeine 
365 (1.7) 30.2 14 
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≥16 mg per day of high dosage buprenorphine 
≥2 overlapping prescriptions and ≥2 prescribers 
480 (3.4) 8.5 34 
>100 defined daily dose (DDD) of benzodiazepines 
Dispensed >365 DDD of codeine 
365 (2.9) 50.5 14 
>730 defined daily dose (DDD) of codeine 
Dispensed >365 DDD of codeine 
365 (1.1) 19.0 14 
Medication possession ratio >1: number of drug 
supply days excluding last refill divided by the 
number of days between the first and last 
dispensing. 
Number of dispensings greater than medically 
required 
180 N/A 32.8 48 
Number of dispensings greater than medically 
required 
Dispensed 1.7 or 2 times more drug than medically 
required 
180 29.9 93.5 47 
Amount of drug dispensed greater than medically 
required 
Highest 1% zolpidem users determined by latent 
class analysis 
180 (0.8) 75.0 48 
Daily consumption of drug greater than medically 
required 
Highest 1% zolpidem users determined by latent 
class analysis 
180 (0.9) 89.0 49 
Overlapping prescriptions or early refills 
≥1 early refills: two consecutive opioid prescriptions 
where days of supply was >10% higher than number 
of days between prescriptions 
Misuse cohort definition: ICD-9 code of opioid 
dependence or poisoning 
90 16.5 40.9 50 
≥1 early refills: any prescription opioid refill that 
occurred with >25% of the days’ supply remaining 
on the previous prescription for the same active 
ingredient  
ICD-9 code of opioid dependence or poisoning 
365 4.1 38.4 37 
Dose escalation 
50% increase in the mean milligrams of morphine in 
2 consecutive months  
Misuse cohort definition: ICD-9 code of opioid 
dependence or poisoning 
90 0.4 4.7 50 
a All time periods have been converted to days, i.e. 30 days = 1 month; 90 days = 3 months; 180 days = 6 
months; 365 days = 12 months etc. N/A = not applicable as study investigated measure in misuse cohort 
alone 
b Where studies report multiple results across drug or user cohorts we record the highest reported rate. We 
calculated all bracketed and italicised values. Values were not reported in original manuscript. 
c See Electronic Supplementary Material 6 for reference list. 
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C. Composite measures: measure of misuse with two or more behaviours or characteristics 
reported in drug-user and/or misuse cohort(s) 
Composite measure details 
 (≥2 behaviours/characteristics of misuse measured 
in drug-user and/or misuse cohorts) 
Misuse cohort definition (where applicable) 
Time 
period 
(days)a 
Drug-user 
cohortb 
Misuse 
cohortb 
Referencec 
Composite measures of misuse including number of prescribers and/or number of dispensing 
pharmacies 
≥2 prescribers and ≥1 days overlapping prescriptions 540 13.9  5 
≥2 prescribers and ≥1 days overlapping prescriptions 480 39.5  34 
≥2 dispensing pharmacies in 7 days or 
benzodiazepine treatment duration >120 days or 
dispensed >2 times maximum recommended daily 
dose 
Various 42.8  32 
≥2 prescribers, ≥3 dispensing pharmacies and ≥1 
days overlapping prescriptions  
540 NR  6 
≥2 prescribers, ≥3 dispensing pharmacies and ≥1 
days overlapping prescriptions 
365 0.9  8 
≥2 prescribers, ≥3 dispensing pharmacies and ≥1 
days overlapping prescriptions 
540 0.7  9 
≥2 prescribers, ≥3 dispensing pharmacies and ≥1 
days overlapping prescriptions 
540 0.3  7 
≥2 dispensing pharmacies within 7 days OR 
dispensed >2 times maximum recommended daily 
dose 
Various 3.4  41 
≥3 dispensing pharmacies and ≥1 overlapping 
prescriptions 
540 0.2  5 
≥3 prescribers and ≥3 dispensing pharmacies 365 1.6  22 
≥3 prescribers or dispensed >20 mg/day of 
buprenorphine 
120 18.1  45 
≥4 prescribers and ≥4 dispensing pharmacies 365 0.5  22 
≥4 prescribers, ≥1 opioid dispensings for 4 
consecutive years and in final year dispensed >365 
defined daily doses of opioids 
1460 0.2  42 
≥4 prescribers, ≥1 opioid dispensings for 4 
consecutive years, in final year dispensed >365 
defined daily doses (DDD) of opioids and >100 DDDs 
of benzodiazepines 
1460 0.08  42 
≥4 prescribers, ≥1 opioid dispensings for 4 
consecutive years, in final year dispensed >365 
defined daily doses (DDD) of opioids and >300 DDD 
of benzodiazepines 
1460 0.06  42 
≥5 prescribers and ≥5 dispensing pharmacies 365 0.2  22 
≥5 shopping episodes: ≥2 prescribers, ≥3 dispensing 
pharmacies and ≥1 days overlapping prescriptions (1 
365 0.07  8 
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shopping episode) 
≥5 shopping episodes: ≥2 prescribers, ≥3 dispensing 
pharmacies and ≥1 days overlapping prescriptions (1 
shopping episode) 
540 0.1  9 
≥6 shopping episodes: ≥2 prescribers, ≥3 dispensing 
pharmacies and ≥1 days overlapping prescriptions (1 
shopping episode) 
Misuse cohort definition: ≥2 prescribers, ≥3 
dispensing pharmacies and ≥1 days overlapping 
prescriptions 
540 (0.03) 9.5 7 
≥7 prescribers, ≥1 opioid dispensings for 4 
consecutive years, in final year dispensed >365 
defined daily doses (DDD) of opioids and >100 DDD 
of benzodiazepines 
1460 0.05  42 
Opioid misuse score: possible misuse score (score 2-
3): based on number of dispensing pharmacies, 
prescribers, and excess days supplied short- and 
long-acting opioids 
180 14.5  25 
Opioid misuse score: possible or probable misuse 
score (score 2-4). Score based on number of 
dispensing pharmacies, prescribers, and excess days 
supplied short- and long-acting opioids 
180 24.0  44 
Opioid misuse score: probable misuse score (score 
≥4) 
Score based on number of dispensing pharmacies, 
prescribers, and excess days supplied short- and 
long-acting opioids 
180 2.2  25 
Opioid misuse score: probable misuse score (score 
≥5) 
Score based on number of dispensing pharmacies, 
prescribers, and excess days supplied short- and 
long-acting opioids 
180 6.0  44 
≥2 letters sent out to physician informing them of 
patient’s problematic use of prescribed drug. Based 
on alerts of number of prescribers or dispensing 
pharmacies and/or amount of drug prescribed. 
Physician previously sent a letter describing patient’s 
problematic use of prescription drug(s) 
180 N/A 29.8 21 
Composite measures of misuse including volume of drug dispensed: none of the listed measures 
below include number of prescribers or dispensing pharmacies. 
≥1 opioid dispensings for 4 consecutive years; and in 
final year dispensed >365 defined daily doses of 
opioids 
1460 0.3  42 
2 defined daily doses (DDD) per day of carisoprodol, 
<100 DDD of benzodiazepines and <100 DDD of 
opioids 
365 1.0  3 
≥100 defined daily doses (DDD) of benzodiazepines 365 7.8  3 
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and <100 DDD of opioids 
≥2 dispensings of carisoprodol and dispensed: >15 
defined daily doses (DDD) of carisoprodol, >2 times 
recommended maximum daily dose for a period, 
<100 DDD of opioids and <100 DDD of 
benzodiazepines  
365 1.0  4 
Dispensed ≥100 defined daily doses (DDD) of 
benzodiazepines and/or ≥15 DDD of carisoprodol 
365 50.1  1 
Dispensed ≥100 defined daily doses (DDD) of 
benzodiazepines or ≥15 DDD of carisoprodol 
365 41.9  1 
Dispensed ≥100 defined daily doses (DDD) of 
benzodiazepines and ≥15 DDD of carisoprodol 
365 8.2  1 
Dispensed >2 times maximum recommended daily 
dose or benzodiazepine treatment duration >120 
days 
Various 40.2  32 
Composite measures of misuse including early refills or overlapping prescriptions: none of the 
measures listed below include number of prescribers, dispensing pharmacies or volume of drug 
dispensed 
Opioid and BZD prescription with ≥7 days overlap 365 1.0  23 
Concurrent use of 2 long-acting benzodiazepines Various 1.1  38 
Concurrent use of 2 short-acting benzodiazepines Various 4.5  38 
≥2 types of concurrent opioid use with >7 days 
overlap 
30 19.8  40 
≥2 types of concurrent sedative hypnotic use  30 40.7  40 
a All time periods have been converted to days, i.e. 30 days = 1 month; 90 days = 3 months; 180 days = 6 
months; 365 days = 12 months etc. N/A = not applicable as study investigated measure in misuse cohort 
alone. NR = not recorded in original manuscript. 
b Where studies report multiple results across drug or user cohorts we record the highest reported rate. We 
calculated all bracketed and italicised values. Values were not reported in original manuscript. 
c See Electronic Supplementary Material 6 for reference list. 
 
Electronic Supplementary Material 2.8. Proportion of misusers determined through empirical 
analysis. 
Empirical analysis details (empirically derived thresholds of 
misuse where relevant) 
Time 
period 
(days)a 
Drug-user 
cohortb 
Referencec 
Excessive use based on Peaks Over Threshold model 180 7.2 2 
Highest 1% of carisoprodol users based on Lorenz curve 
(dispensed ≥480 defined daily doses) 
365 1.1 4 
Highest 10% of codeine users (≥120 defined daily doses) 365 10.7 1 
Highest quintile (20%) of opioid users 365 22.7 40 
Cluster analysis based on number of: prescribers; dispensing 
pharmacies; dispensing episodes and sum of DDD dispensed 
270 1.1 12 
Cluster analysis based on number of: prescribers; dispensing 
pharmacies; dispensing episodes and sum of DDD dispensed 
270 1.1 13 
Cluster analysis based on number of: prescribers; dispensing 
pharmacies; dispensing episodes and sum of DDD dispensed 
270 6.0 29 
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Cluster analysis based on number of: prescribers; dispensing 
pharmacies; dispensing episodes and sum of DDD dispensed 
270 9.1 30 
Latent class analysis based on gender; age and method of 
payment 
300 0.7 26 
Highest 1% of drug-users based on latent class analysis including 
consumption factor; prescriber specialty; number of prescribers; 
number of dispensing pharmacies; consistent with practice 
guidelines 
180 1.0 49 
Highest 1% of drug-users based on latent class analysis including 
prescriber specialty; number of prescribers; number of 
dispensing pharmacies; excess use; consistent with practice 
guidelines; associated psychiatric disorders 
180 1.0 48 
a All time periods have been converted to days, i.e. 180 days = 6 months; 365 days = 12 months etc. 
b Where studies report multiple results across drug or user cohorts we record the highest reported rate. 
c See Electronic Supplementary Material 6 for reference list.
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Supplementary Material 2.9 The proportion of prescription drugs dispensed to a misuse 
cohort: determined by a measure of misuse with a defined threshold 
A. Stand-alone and composite measures of misuse reporting the proportion of drugs 
dispensed to misuser cohorts 
Drug class of interest 
(Misuse cohort definition) 
Time 
period 
(days)a 
Proportion of 
drug class 
dispensed to a 
misuse cohort 
Reference
b 
Anorectics 
Misuser cohort definition: ≥2 prescribers and ≥2 
dispensing pharmacies 
30 0.9 51 
Benzodiazepines 
≥2 prescribers and ≥2 dispensing pharmacies 
7 1.2 10 
Benzodiazepines  
≥2 prescribers and ≥2 dispensing pharmacies 
30 4.2 51 
Opioids 
≥2 prescribers and ≥2 dispensing pharmacies 
7 3.2 10 
Opioids 
≥2 prescribers and ≥2 dispensing pharmacies 
30 9.6 15 
Opioids 
≥2 prescribers and ≥2 dispensing pharmacies 
30 12.8 51 
Opioids 
≥3 prescribers and ≥3 dispensing pharmacies 
365 7.7 22 
Opioids  
≥4 prescribers and ≥4 dispensing pharmacies  
365 3.1 22 
Opioids  
≥5 prescribers and ≥5 dispensing pharmacies 
365 1.5 22 
Stimulants 
≥2 prescribers and ≥2 dispensing pharmacies 
30 1.4 51 
Prescription drug of interest 
(Misuse cohort definition) 
Time 
period 
(days)a 
Proportion of 
drug dispensed 
to a misuse 
cohortc 
Reference
b 
Buprenorphine 
Misuse cohort definition: Doctor shopping quantity: 
amount of excess drug obtained by misusers by 
overlapping prescriptions from ≥2 prescribers 
485 18.7 34 
Hydrocodone 
≥2 prescribers 
365 68.3 52 
Hydromorphone 
≥2 prescribers and ≥2 dispensing pharmacies 
30 15.2 15 
a All time periods have been converted to days, i.e. 30 days = 1 month; 365 days = 12 months etc. 
b See Electronic Supplementary Material 6 for reference list. 
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c Per drug class, we report the result of the drug with the highest DSI. 
 
B. Composite measures of misuse reporting the volume of drugs dispensed to misuse 
cohorts: specific measures of doctor shopping quantity (DSQ) and doctor shopping indicator 
(DSI) 
Drug class or drug of interest 
Time 
period 
(days)a 
Measure of 
misuse: 
DSQb 
Measure 
of misuse: 
DSI (%)b 
Reference
c 
Doctor shopping quantity (DSQ): amount of excess drug obtained by misusers by 
overlapping prescriptions from ≥2 prescribers 
Doctor shopping indicator (DSI) (%): amount of drug calculated by the DSQ, expressed as the 
proportion of total drug dispensed (i.e. DSQ/total drug volume dispensed). DSI >1% is a signal 
for drug abuse. 
Drug class 
Benzodiazepines NR d 1.9 31 
Benzodiazepines 365 361,428 DDD NR 36 
Opioids (opioid maintenance therapy) 
365 
55.3 
DDD/1000 
population  
6.2 
27 
Antidepressants 
Mianserin 365 15,344 DDD 1.0 39 
Benzodiazepine 
Flunitrazepam 365 d 27.0 30 
Flunitrazepam 365 108,727 DDD 42.8 36 
Flunitrazepam 365 436,647 DDD 30.2 39 
Opioids 
Buprenorphine 365 1151 grams 21.7 35 
Buprenorphine (opioid maintenance 
therapy) 
365 
50.3 
DDD/1000 
population 
8.0 
27 
Buprenorphine (opioid maintenance 
therapy) 
NR d 
12.5 31 
Z-drugs 
Zolpidem 365 d 2.5 30 
Zolpidem 365 499,010 DDD 2.2 39 
a All time periods have been converted to days, i.e. 365 days = 12 months etc. NR = not recorded in 
original manuscript. 
b Per drug class, we report the result of the drug with the highest DSI. 
c See Electronic Supplementary Material 6 for reference list. 
d DSQ not investigated in study 
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C. Proportion of drug dispensed to empirically defined misuse cohort 
Empirical analysis details 
Time 
period 
(days)a 
Proportion of 
drug of interest 
dispensed to 
misuse cohortb 
Reference
c 
Highest 1% of benzodiazepine drug-users based 
on Lorenz curve 
365 16.5 16 
Highest 1% of carisoprodol users 365 18.7 4 
Highest 1% of biperiden drug-users based on 
Lorenz curve 
365 6.2 16 
a All time periods have been converted to days, i.e. 365 days = 12 months etc. 
b Where studies report multiple results relating to one drug class we report the drug with the highest 
rate. 
c See Electronic Supplementary Material 6 for reference list. 
 
 
